

Supplementary Results

Table 1. High- and lower-confidence imprinted gene candidates.

Ensembl ID	Band	Pred.†	Ensembl ID	Band	Pred.†	Ensembl ID	Band	Pred.†
173447	1p36.33	S M	143921 (<i>ABCG8</i>)	2p21	E.S M	159674 (<i>SPON2</i>)	4p16.3	E.S P
184235	1p36.33	S M	138083 (<i>SIX3</i>)	2p21	S P	163945 (<i>NP_065945.1</i>)	4p16.3	E.S M
131591 (<i>NM_017891</i>)	1p36.33	S M	055813 (<i>Q96PX6</i>)	2p16.1	E.S P	174141 (<i>Q15270</i>)	4p16.3	S P
182839	1p36.33	E M	115507 (<i>OTX1</i>)	2p15	E.S M	068078 (<i>FGFR3</i>)	4p16.3	S M
184163 (<i>Q5EBL5</i>)	1p36.33	E.S M	116035 (<i>VAX2</i>)	2p13.3	E.S M	163956 (<i>LRPAP1</i>)	4p16.3	S M
131584 (<i>CENTB5</i>)	1p36.33	S M	178455	2p13.2	S P	183190	4p13	E M
127054 (<i>NM_017871</i>)	1p36.33	S M	003137 (<i>C26A</i>)	2p13.2	S P	182739 (<i>GRINL1B</i>)	4q13.2	S P
169962 (<i>TAS1R3</i>)	1p36.33	S M	144040 (<i>SFXN5</i>)	2p13.2	S P	153851 (<i>Q9NYI9</i>)	4q13.2	E.S P
107404 (<i>DVL1</i>)	1p36.33	E.S M	135637 (<i>MRPL53</i>)	2p13.1	S M	153852 (<i>Q9NYJ6</i>)	4q13.2	E.S P
162576 (<i>NM_032348</i>)	1p36.33	S M	115325 (<i>DOK1</i>)	2p13.1	S M	180769 (<i>Q8N507</i>)	4q21.23	S M
160075 (<i>NM_014188</i>)	1p36.33	S M	116119 (<i>KV2A</i>)	2p11.2	S P	138821 (<i>NM_022154</i>)	4q24	S P
178821 (<i>TMEM52</i>)	1p36.33	E.S P	115085 (<i>ZAP70</i>)	2q11.2	S P	168743 (<i>NP_001028219.1</i>)	4q24	E P
157916 (<i>RER1</i>)	1p36.33	S P	135951 (<i>TSGA10</i>)	2q11.2	E P	164093 (<i>PITX2</i>)	4q25	S P
157911 (<i>PEX10</i>)	1p36.32	E.S M	071082 (<i>RPL31</i>)	2q11.2	S P	177826	4q28.1	S P
157881 (<i>PANK4</i>)	1p36.32	S M	169636	2q12.3	E.S P	170153 (<i>Q9ULK6</i>)	4q31.21	S M
169797	1p36.32	S M	183998 (<i>RPL22</i>)	2q13	E P	180519	4q31.21	S P
157870 (<i>NM_152371</i>)	1p36.32	S M	015568 (<i>RANBP2L1</i>)	2q13	S P	151615 (<i>POU4F2</i>)	4q31.22	S M
177121 (<i>Q8N6L5</i>)	1p36.32	E.S P	184764 (<i>RPL22</i>)	2q13	E.S P	172799	4q31.3	S M
142611 (<i>PRDM16</i>)	1p36.32	E.S P	184538 (<i>RANBP2L1</i>)	2q13	S P	154531 (<i>PDGFC</i>)	4q32.1	E P
162591 (<i>EGFL3</i>)	1p36.32	S P	153094 (<i>BCL2L11</i>)	2q13	S P	038295 (<i>TLL1</i>)	4q32.3	S P
182956	1p36.32	S M	125618 (<i>PAX8</i>)	2q13	S M	056050 (<i>NM_017867</i>)	4q33	S M
116213 (<i>WDR8</i>)	1p36.32	E.S M	183300	2q14.3	S P	168322 (<i>NM_030970</i>)	4q34.3	S P
183509 (<i>Q8IYL3</i>)	1p36.32	S M	136720 (<i>HS6ST1</i>)	2q14.3	S P	177310 (<i>NM_153008</i>)	4q35.1	E M
131697 (<i>Q9UFQ2</i>)	1p36.31	S M	169822 (<i>NM_030970</i>)	2q14.3	S P	186158	4q35.2	E.S M
130940 (<i>NM_017766</i>)	1p36.22	S M	136698 (<i>NM_032545</i>)	2q11.1	S M	186147 (<i>DUX2</i>)	4q35.2	E.S P
117154 (<i>NM_032880</i>)	1p36.13	S P	179843 (<i>RAB6C</i>)	2q21.1	S M	066230 (<i>SLC9A3</i>)	5p15.33	S M
179002 (<i>TAS1R2</i>)	1p36.13	S P	183840 (<i>GPR39</i>)	2q21.2	E M	185486	5p15.33	S M
179163 (<i>FUCA1</i>)	1p36.11	E.S P	136539 (<i>NM_014880</i>)	2q24.2	S P	125063 (<i>NM_017808</i>)	5p15.33	S M
142698 (<i>NM_032884</i>)	1p35.1	E P	174470 (<i>Q96M44</i>)	2q24.2	S M	112877 (<i>NM_018140</i>)	5p15.33	S M
126070 (<i>EIF2C3</i>)	1p34.3	E M	128714 (<i>HOXD13</i>)	2q31.1	S M	145506 (<i>NKD2</i>)	5p15.33	S M
185668 (<i>POU3F1</i>)	1p34.3	S P	128713 (<i>HOXD11</i>)	2q31.1	S M	113504 (<i>SLC12A7</i>)	5p15.33	S M
183682 (<i>BMP8</i>)	1p34.3	E.S P	128709 (<i>HOXD9</i>)	2q31.1	S M	174358	5p15.33	S M
173935 (<i>NM_182518</i>)	1p34.2	E.S M	170166 (<i>HOXD4</i>)	2q31.1	E M	153395 (<i>Q8NF37</i>)	5p15.33	S M
178973 (<i>NM_024547</i>)	1p34.2	E.S M	171567 (<i>TIGD1</i>)	2q37.1	E.S P	113430 (<i>IRX4</i>)	5p15.33	S M
117410 (<i>ATP6V0B</i>)	1p34.1	S M	157985 (<i>CENTG2</i>)	2q37.2	E M	170561 (<i>IRX2</i>)	5p15.33	S P
118473 (<i>SGIP1</i>)	1p31.2	E P	144485 (<i>HES6</i>)	2q37.3	S M	170549 (<i>IRX1</i>)	5p15.33	S M
132489 (<i>NM_020948</i>)	1p31.2	E P	132326 (<i>PER2</i>)	2q37.3	S M	145536 (<i>ADAMTS16</i>)	5p15.32	E.S M
117069 (<i>SI7E</i>)	1p31.1	E P	186540 (<i>Q9Y419</i>)	2q37.3	E.S M	164236 (<i>XP_293937.5</i>)	5p15.2	E P
137944 (<i>NM_019610</i>)	1p22.2	E.S M	178580 (<i>Q8WXC7</i>)	2q37.3	S P	133357 (<i>NM_030970</i>)	5p15.2	E P
162676 (<i>GFI1</i>)	1p22.1	E.S P	172428 (<i>MYEOV2</i>)	2q37.3	E.S P	145526 (<i>CDH18</i>)	5p14.3	E.S P
182166	1p21.2	S P	178602 (<i>NM_148961</i>)	2q37.3	S P	132404	5p14.1	S P
186371 (<i>NDUFA4</i>)	1p13.3	E.S P	063660 (<i>GPCI1</i>)	2q37.3	S M	113492 (<i>AGXT2</i>)	5p13.2	E P
121931 (<i>NM_018372</i>)	1p13.3	S P	142327 (<i>RNPEPL1</i>)	2q37.3	S M	168621 (<i>GDNF</i>)	5p13.2	S P
116455 (<i>ME50</i>)	1p13.2	S P	115687 (<i>PASK</i>)	2q37.3	E M	016082 (<i>ISL1</i>)	5q11.2	S P
179735 (<i>Q8NE92</i>)	1q21.1	S P	132170 (<i>PPARG</i>)	3p25.2	S P	164258 (<i>NDUFS4</i>)	5q11.2	S P
184458 (<i>Q86YZ3</i>)	1q21.3	S P	131374 (<i>TBC1D5</i>)	3p24.3	E M	164283 (<i>ESM1</i>)	5q11.2	S P
169474 (<i>SPRR1A</i>)	1q21.3	S M	060971 (<i>ACAA1</i>)	3p22.3	S P	152929 (<i>Q9BXE3</i>)	5q12.1	S M
160691 (<i>SHC1</i>)	1q22	S M	010282 (<i>KB73</i>)	3p22.1	S P	145645 (<i>Q9P193</i>)	5q12.1	S P
143620 (<i>EFNA4</i>)	1q22	S M	178055 (<i>NM_182702</i>)	3p21.31	S M	171540 (<i>OTP</i>)	5q14.1	S M
160856 (<i>NM_052939</i>)	1q23.1	S P	068028 (<i>RASSF1</i>)	3p21.31	S M	131730 (<i>CKMT2</i>)	5q14.1	S M
132704 (<i>FCRL2</i>)	1q23.1	E M	145050 (<i>ARMET</i>)	3p21.31	S P	131732 (<i>NM_032280</i>)	5q14.1	S M
132703 (<i>APCS</i>)	1q23.2	S P	114841 (<i>NM_015512</i>)	3p21.1	S M	153922 (<i>CHD1</i>)	5q15	E M
173110 (<i>HSPA6</i>)	1q23.3	E.S M	010322 (<i>NISCH</i>)	3p21.1	S M	174132 (<i>Q8TBP5</i>)	5q21.1	E.S P
143152 (<i>Q9C074</i>)	1q24.1	S M	168268 (<i>NM_022908</i>)	3p21.1	S M	181751 (<i>NM_033211</i>)	5q21.1	S M
117501 (<i>NM_025063</i>)	1q24.3	S P	144741 (<i>NM_173471</i>)	3p14.1	S P	176857	5q21.3	E M
116147 (<i>TNR</i>)	1q25.1	S P	183185 (<i>Q9UIV9</i>)	3q12.1	S P	080709 (<i>KCNN2</i>)	5q22.3	S M
116703 (<i>PDC</i>)	1q31.1	S P	184804	3q13.12	E M	113396 (<i>SLC27A6</i>)	5q23.3	S M
118194 (<i>TNNT2</i>)	1q32.1	S P	185565 (<i>LSAMP</i>)	3q13.31	S M	164400 (<i>CSF2</i>)	5q23.3	E.S M
152104 (<i>PTPN14</i>)	1q32.3	E.S M	144908 (<i>FTHFD</i>)	3q21.3	E.S M	069011 (<i>PITX1</i>)	5q31.1	S P
152120 (<i>Q9NQI3</i>)	1q41	S P	114626 (<i>ABTB1</i>)	3q21.3	S P	174313	5q31.1	E P
117791 (<i>NM_017898</i>)	1q41	S P	179348 (<i>GATA2</i>)	3q21.3	S M	081818 (<i>PCDHB4</i>)	5q31.3	S M
185495 (<i>Q9H5Q3</i>)	1q42.11	S M	004399 (<i>PLXND1</i>)	3q22.1	S P	177895 (<i>PCDHB16</i>)	5q31.3	S P
173419 (<i>Q8IVP0</i>)	1q42.12	S P	174640 (<i>SLC21A2</i>)	3q22.1	S P	120327 (<i>PCDHB14</i>)	5q31.3	E P
081692 (<i>NM_023007</i>)	1q42.13	S P	144872	3q22.2	S P	081853 (<i>PCDHGC5</i>)	5q31.3	S M
124860 (<i>OBSCN</i>)	1q42.13	E.S P	181882	3q22.3	E.S P	113580 (<i>NR3C1</i>)	5q31.3	E P
181203 (<i>HIST3H2BB</i>)	1q42.13	E.S M	168875 (<i>SOX14</i>)	3q22.3	S M	169302	5q32	S P
168159 (<i>Q5TA31</i>)	1q42.13	E M	114120 (<i>NM_018155</i>)	3q23	S M	113667 (<i>Y555</i>)	5q32	E M
182887	1q42.13	E P	175685 (<i>Q9BZ57</i>)	3q24	S P	145888 (<i>GLRA1</i>)	5q33.1	E P
162946 (<i>DISC1</i>)	1q42.2	S M	174963 (<i>ZIC4</i>)	3q24	S M	182344	5q35.2	S M
179397 (<i>NM_173807</i>)	1q44	S M	152977 (<i>ZIC1</i>)	3q24	E.S M	185548	5q35.3	S M
177356 (<i>Q8NGX0</i>)	1q44	E.S P	175726	3q25.1	S M	178392	5q35.3	S M
035115 (<i>NM_015677</i>)	2p25.3	S M	174948 (<i>Q86SP6</i>)	3q25.2	S M	185784 (<i>Q8TAJ0</i>)	5q35.3	E M
172554 (<i>SNTG2</i>)	2p25.3	S P	151967 (<i>SCHIP1</i>)	3q25.32	S P	168903 (<i>BTNL3</i>)	5q35.3	S P
186170 (<i>TMSL2</i>)	2p25.3	S M	181501	3q26.33	E M	137273 (<i>FOXF2</i>)	6p25.3	S P
182551 (<i>NM_018269</i>)	2p25.2	S P	163882 (<i>POLR2H</i>)	3q27.1	S M	184250 (<i>Q86WA7</i>)	6p25.2	S M
134321 (<i>NM_080657</i>)	2p25.2	S P	114315 (<i>HES1</i>)	3q29	E.S P	145945 (<i>FAM50B</i>)	6p25.2	E.S M
115738 (<i>ID2</i>)	2p25.1	E M	169020 (<i>ATP5I</i>)	4p16.3	S M	124785 (<i>NRN1</i>)	6p25.1	S M
138061 (<i>CYP11B1</i>)	2p22.2	E.S P	145214 (<i>DGKQ</i>)	4p16.3	S M	137203 (<i>TFAP2A</i>)	6p24.3	S M
152154 (<i>NM_152390</i>)	2p22.1	S P	127418 (<i>FGFRL1</i>)	4p16.3	E.S M	176078 (<i>Q8NAN4</i>)	6p24.3	S M
152518 (<i>ZFP36L2</i>)	2p21	E.S M	176836	4p16.3	S P	185694	6p22.1	E P

181573 (<i>Q96MM2</i>)	6p22.1	S	P	120896 (<i>VINE</i>)	8p21.3	S	M	180740 (<i>Q9H6Z8</i>)	10q23.31	E,S	P
112498 (<i>PPP1R11</i>)	6p22.1	S	M	179388 (<i>EGR3</i>)	8p21.3	S	M	095585 (<i>BLNK</i>)	10q24.1	S	P
161871 (<i>C6orf10</i>)	6p21.32	S	M	172733 (<i>PURG</i>)	8p12	E,S	P	148820 (<i>LDB1</i>)	10q24.32	E,S	M
168426 (<i>BTNL2</i>)	6p21.32	E,S	M	167912 (<i>Q96QE0</i>)	8q12.1	E,S	M	166275 (<i>NM_144591</i>)	10q24.32	S	P
168383 (<i>HLA-DPB1</i>)	6p21.32	E	P	183226	8q12.3	E	P	176584	10q26.13	S	M
161896 (<i>IHPK3</i>)	6p21.31	S	M	185942 (<i>FAM77D</i>)	8q12.3	E,S	P	119965 (<i>C10orf88</i>)	10q26.13	E	M
156582	6p21.2	S	M	165084 (<i>NM_052958</i>)	8q13.2	E	M	108001 (<i>EBF3</i>)	10q26.3	S	M
137252 (<i>HCRT2</i>)	6p12.1	S	P	184234 (<i>NM_172239</i>)	8q21.2	S	M	165752 (<i>NM_173575</i>)	10q26.3	S	P
146151 (<i>HMGCLL1</i>)	6p12.1	S	P	180694 (<i>Q8N3G6</i>)	8q21.3	S	P	171813 (<i>Q96F43</i>)	10q26.3	S	P
179713 (<i>Q8N480</i>)	6q14.1	S	P	156486 (<i>KCNS2</i>)	8q22.2	S	P	180066 (<i>C10orf91</i>)	10q26.3	E,S	M
135324 (<i>C6orf117</i>)	6q14.2	E,S	P	164796 (<i>CSMD3</i>)	8q23.3	S	M	148826 (<i>NKX6-2</i>)	10q26.3	E,S	M
135315 (<i>C6orf84</i>)	6q14.2	S	P	104406 (<i>NM_032205</i>)	8q24.22	E	P	171811 (<i>C10orf93</i>)	10q26.3	E,S	M
184486 (<i>POU3F4</i>)	6q16.1	S	M	169427 (<i>KCNK9</i>)	8q24.3	E,S	M	151646 (<i>GPR123</i>)	10q26.3	S	M
183075	6q21	S	P	184489 (<i>PTP4A3</i>)	8q24.3	S	P	171798 (<i>Q8TEE5</i>)	10q26.3	S	M
153989 (<i>C6orf68</i>)	6q22.1	S	P	181790 (<i>BAI1</i>)	8q24.3	S	M	165824 (<i>NM_152643</i>)	10q26.3	S	M
146350 (<i>C6orf170</i>)	6q22.31	E	P	180838 (<i>Q8NAM3</i>)	8q24.3	E	M	171794 (<i>UTTF1</i>)	10q26.3	S	P
184362 (<i>Q9BZ63</i>)	6q22.31	S	P	167656 (<i>LY6D</i>)	8q24.3	E,S	P	151650 (<i>VENTX2</i>)	10q26.3	E,S	M
175211 (<i>Q9BXE6</i>)	6q23.2	S	P	179142 (<i>CYP11B2</i>)	8q24.3	S	M	178592 (<i>Q8N377</i>)	10q26.3	E,S	M
135521 (<i>C6orf93</i>)	6q24.2	S	M	182851 (<i>NM_178172</i>)	8q24.3	E	P	148832 (<i>PAOX</i>)	10q26.3	E,S	M
118508 (<i>RAB32</i>)	6q24.3	S	P	158106 (<i>RHPN1</i>)	8q24.3	S	M	186730 (<i>DUX4</i>)	10q26.3	S	P
112499 (<i>SLC22A2</i>)	6q25.3	E,S	P	181528	8q24.3	S	M	184243	10q26.3	S	P
146477 (<i>SLC22A3</i>)	6q25.3	S	P	179950 (<i>NM_078480</i>)	8q24.3	S	P	179882 (<i>DUX2</i>)	10q26.3	S	P
060762 (<i>BRP44L</i>)	6q27	E,S	P	185189 (<i>NM_178564</i>)	8q24.3	S	M	177947 (<i>ODF3</i>)	11p15.5	S	M
153471 (<i>TCP10</i>)	6q27	S	P	186574 (<i>Q8ND02</i>)	8q24.3	S	M	174885 (<i>PYA5</i>)	11p15.5	S	M
186340 (<i>THBS2</i>)	6q27	S	P	178719 (<i>GRINA</i>)	8q24.3	E	P	185885 (<i>IFITM1</i>)	11p15.5	E,S	M
164493 (<i>Q96N37</i>)	6q27	S	P	167701 (<i>GPT</i>)	8q24.3	E,S	M	182272 (<i>B4GALNT4</i>)	11p15.5	E,S	M
170767 (<i>C6orf208</i>)	6q27	E	M	160959 (<i>Y014</i>)	8q24.3	S	P	184363 (<i>PKP3</i>)	11p15.5	E,S	M
177706 (<i>FAM20C</i>)	7p22.3	S	P	177742 (<i>NM_178535</i>)	8q24.3	E	M	176828 (<i>Q8N9U2</i>)	11p15.5	E,S	M
184773 (<i>Q96GH9</i>)	7p22.3	E	M	120215 (<i>MLANA</i>)	9p24.1	S	M	177700 (<i>POLR2L</i>)	11p15.5	S	M
122691 (<i>TWIST2</i>)	7p21.1	S	M	186758 (<i>Q8N710</i>)	9p21.1	E,S	M	184956 (<i>MUC6</i>)	11p15.5	S	M
105855 (<i>ITGB8</i>)	7p21.1	E	M	174994 (<i>Q96M55</i>)	9p12	S	P	183116	11p15.5	S	M
105996 (<i>HOXA2</i>)	7p15.2	E,S	M	170152	9p11.2	S	M	184545 (<i>DUSP8</i>)	11p15.5	S	P
105997 (<i>HOXA3</i>)	7p15.2	E,S	M	154537 (<i>Q8NCQ8</i>)	9p11.2	S	M	130598 (<i>TNNI2</i>)	11p15.5	S	P
164519 (<i>Q96MZ3</i>)	7p15.2	S	M	178784 (<i>Q96F02</i>)	9q12	S	P	184682	11p15.5	E,S	M
160601 (<i>HOXA4</i>)	7p15.2	E,S	M	184879	9q13	S	M	183680 (<i>Q8N2L8</i>)	11p15.5	S	P
106004 (<i>HOXA5</i>)	7p15.2	E,S	M	182368 (<i>Q8NCQ8</i>)	9q13	S	M	181963 (<i>Q8NGK3</i>)	11p15.4	S	P
106006 (<i>HOXA6</i>)	7p15.2	S	M	170215 (<i>Q8NCQ8</i>)	9q13	S	M	180785 (<i>NM_152430</i>)	11p15.4	S	M
005073 (<i>HOXA11</i>)	7p15.2	E,S	M	170217	9q13	S	M	176904 (<i>Q8NH63</i>)	11p15.4	S	P
106038 (<i>EVX1</i>)	7p15.2	E,S	P	107282 (<i>APBA1</i>)	9q21.11	E,S	P	180974 (<i>Q8NGH9</i>)	11p15.4	S	P
106483 (<i>SFRP4</i>)	7p14.1	S	P	155621 (<i>NM_182505</i>)	9q21.12	E,S	P	051009 (<i>NM_032127</i>)	11p15.4	S	M
106571 (<i>GLI3</i>)	7p14.1	E,S	M	186788 (<i>NP_001001670</i>)	9q21.32	E,S	M	166337 (<i>TAF10</i>)	11p15.4	S	P
164543 (<i>TKF17A</i>)	7p13	E	P	177992 (<i>NM_178828</i>)	9q22.1	S	P	170748 (<i>NM_014469</i>)	11p15.4	S	P
058404 (<i>CAMK2B</i>)	7p13	S	P	186359 (<i>Q8NDS1</i>)	9q22.1	S	P	170688 (<i>OR5E1P</i>)	11p15.4	E	P
164742 (<i>ADCY1</i>)	7p13	S	M	130222 (<i>GADD45G</i>)	9q22.2	S	P	129152 (<i>MYOD1</i>)	11p15.1	S	M
185292	7p13	S	M	169027 (<i>NM_030970</i>)	9q22.31	S	P	184193 (<i>Q8N7V1</i>)	11p14.3	E,S	M
179869 (<i>NM_152701</i>)	7p12.3	S	P	131662 (<i>PHF2</i>)	9q22.31	S	P	129151 (<i>BBOX1</i>)	11p14.2	E	P
042813 (<i>ZPBP</i>)	7p12.2	S	P	119523 (<i>NM_033087</i>)	9q22.33	S	P	007372 (<i>PAX6</i>)	11p13	S	M
185037	7q11.21	E,S	M	177945 (<i>NM_016158</i>)	9q33.3	E,S	P	183242 (<i>WTT1</i>)	11p13	S	M
185947 (<i>Q8IVV5</i>)	7q11.21	E,S	P	136944 (<i>LMX1B</i>)	9q33.3	E,S	M	182565	11p11.12	S	P
135211 (<i>C7orf35</i>)	7q11.23	E,S	P	123454 (<i>DBH</i>)	9q34.2	S	M	185927	11q11	S	P
187391 (<i>MAGI2</i>)	7q21.11	E,S	M	186459	9q34.3	S	P	186660 (<i>ZFP91</i>)	11q12.1	S	P
185191	7q21.12	S	P	160345 (<i>NM_144654</i>)	9q34.3	E,S	P	172289 (<i>Q8NGI7</i>)	11q12.1	S	P
182348 (<i>NM_181646</i>)	7q21.13	S	P	148411 (<i>NM_144653</i>)	9q34.3	S	M	134824 (<i>FADS2</i>)	11q12.2	S	M
105810 (<i>CDK6</i>)	7q21.2	S	M	160360 (<i>Q9UF58</i>)	9q34.3	S	M	174903 (<i>RAB1B</i>)	11q13.2	E,S	M
006377 (<i>DLX6</i>)	7q21.3	S	P	148400 (<i>NOTCH1</i>)	9q34.3	S	M	174851 (<i>YIF1</i>)	11q13.2	S	M
121716 (<i>PILRB</i>)	7q22.1	S	M	172889 (<i>EGFL7</i>)	9q34.3	E,S	P	173621 (<i>NM_024036</i>)	11q13.2	S	P
128594 (<i>NM_022143</i>)	7q32.1	S	P	169692 (<i>AGPAT2</i>)	9q34.3	S	M	172932	11q13.2	S	P
106028 (<i>SSBP1</i>)	7q34	S	M	054148 (<i>PHPT1</i>)	9q34.3	E,S	M	162105 (<i>SHANK2</i>)	11q13.3	S	M
181551	7q34	S	P	184709	9q34.3	S	M	175534 (<i>Q8TB74</i>)	11q13.4	S	M
184412	7q34	S	P	185863	9q34.3	S	M	137474 (<i>MYO7A</i>)	11q13.5	S	P
133624 (<i>NM_024910</i>)	7q36.1	S	P	176248 (<i>NM_013366</i>)	9q34.3	S	M	168959 (<i>GRM5</i>)	11q14.2	S	P
164889 (<i>SLC4A2</i>)	7q36.1	E,S	M	176058 (<i>NM_073691</i>)	9q34.3	S	M	182359 (<i>KBTBD3</i>)	11q22.3	E,S	P
164896 (<i>FASTK</i>)	7q36.1	E,S	M	182569 (<i>NM_053045</i>)	9q34.3	S	M	150750 (<i>C11orf53</i>)	11q23.1	E	M
164690 (<i>SHH</i>)	7q36.3	S	P	186909	10p15.3	E,S	P	184824 (<i>C1QTNF5</i>)	11q23.3	S	M
187177	7q36.3	E	M	151632 (<i>AKRIC2</i>)	10p15.1	S	P	154146 (<i>NRGN</i>)	11q24.2	S	P
146909 (<i>C7orf3</i>)	7q36.3	E	P	178462 (<i>NM_024803</i>)	10p15.1	S	M	182657	11q24.3	E,S	M
130675 (<i>HLXB9</i>)	7q36.3	S	M	178372 (<i>CLSP</i>)	10p15.1	S	P	120462 (<i>Q9P195</i>)	11q24.3	S	M
178158 (<i>Q8N7D3</i>)	7q36.3	S	M	176730 (<i>Q8N218</i>)	10p15.1	E	M	182667 (<i>NTRI</i>)	11q25	E,S	P
155093 (<i>PTPRN2</i>)	7q36.3	S	M	107485 (<i>GATA3</i>)	10p14	E,S	P	170257 (<i>NM_030970</i>)	11q25	S	P
180204 (<i>NM_181648</i>)	8p23.3	E,S	P	182077 (<i>NP_001030014.1</i>)	10p12.1	E	M	080854 (<i>Q9UPX0</i>)	11q25	S	M
104284 (<i>DLGAP2</i>)	8p23.3	E,S	P	099250 (<i>NRP1</i>)	10p11.22	E	P	151503 (<i>Y056</i>)	11q25	S	M
036448 (<i>MYOM2</i>)	8p23.3	S	M	175395 (<i>ZNF25</i>)	10p11.21	E	M	149328 (<i>NM_138342</i>)	11q25	S	M
186550	8p23.1	E	M	165511 (<i>NM_145022</i>)	10q11.21	S	M	109956 (<i>B3GAT1</i>)	11q25	S	M
186553	8p23.1	E	M	165406 (<i>MARCH8</i>)	10q11.21	E	P	139194 (<i>RBP5</i>)	12p13.31	E,S	P
186555	8p23.1	E	P	148611 (<i>SYT15</i>)	10q11.22	S	M	150045 (<i>KLRF1</i>)	12p13.31	S	P
186558	8p23.1	E	P	165606	10q11.23	S	M	121374 (<i>KLRC3</i>)	12p13.2	S	P
186560	8p23.1	E	M	107671 (<i>NM_018245</i>)	10q11.23	S	M	171681 (<i>ATF7IP</i>)	12p13.1	S	M
186647	8p23.1	E	M	165443 (<i>NM_032439</i>)	10q21.1	S	M	111404 (<i>NM_024730</i>)	12p12.3	S	P
185161 (<i>Q8N9I4</i>)	8p23.1	E,S	P	148575 (<i>NM_178505</i>)	10q21.2	S	M	172572 (<i>PDE3A</i>)	12p12.2	S	M
158815 (<i>FGF17</i>)	8p21.3	S	M	182771 (<i>GRID1</i>)	10q23.2	E	M	111700 (<i>SLC21A8</i>)	12p12.2	S	P
168487 (<i>BMP1</i>)	8p21.3	S	P	138135 (<i>CH25H</i>)	10q23.31	S	P	069431 (<i>ABCC9</i>)	12p12.1	E,S	M

013573 (<i>DDX11</i>)	12p11.21	S	M	183643 (<i>C15orf32</i>)	15q26.1	E	M	130876 (<i>SLC7A10</i>)	19q13.11	S	M
177627 (<i>NM_152319</i>)	12q13.11	E	P	184254 (<i>ALDH1A3</i>)	15q26.3	S	M	124302 (<i>CHST8</i>)	19q13.11	E,S	M
123364 (<i>HOXC13</i>)	12q13.13	S	M	140479 (<i>PACE4</i>)	15q26.3	S	M	105698 (<i>USF2</i>)	19q13.12	S	M
123388 (<i>HOXC11</i>)	12q13.13	S	M	103326 (<i>SOLH</i>)	16p13.3	S	M	126266 (<i>GPR40</i>)	19q13.12	S	M
180818 (<i>HOXC10</i>)	12q13.13	S	M	127585 (<i>NM_153350</i>)	16p13.3	S	M	105663 (<i>TRX2</i>)	19q13.12	E	M
180806 (<i>HOXC9</i>)	12q13.13	E,S	M	127586 (<i>CHTF18</i>)	16p13.3	S	M	180458 (<i>Q8N3U1</i>)	19q13.13	E,S	P
186426 (<i>HOXC4</i>)	12q13.13	E,S	M	005513 (<i>SOX8</i>)	16p13.3	E,S	P	105737 (<i>GRIK5</i>)	19q13.2	S	M
170338 (<i>HOXC6</i>)	12q13.13	S	M	172268 (<i>Q96S05</i>)	16p13.3	E,S	P	159904 (<i>ZNF225</i>)	19q13.31	E,S	P
172789 (<i>HOXC5</i>)	12q13.13	E	M	172257 (<i>Q96S03</i>)	16p13.3	S	P	167383 (<i>ZNF229</i>)	19q13.31	E,S	M
174604 (<i>Q9BXE6</i>)	12q13.2	S	P	184471	16p13.3	S	M	176499 (<i>Q9Y4U5</i>)	19q13.33	E	M
135502 (<i>SLC26A10</i>)	12q13.3	E,S	M	073761 (<i>CACNA1H</i>)	16p13.3	S	M	175856 (<i>Q8NB48</i>)	19q13.41	E	M
135446 (<i>CDK4</i>)	12q14.1	E,S	M	140650 (<i>PMM2</i>)	16p13.2	S	P	186818 (<i>LILRB4</i>)	19q13.42	E,S	M
079081 (<i>SRGAP1</i>)	12q14.2	S	M	182375	16p11.2	S	P	105132 (<i>ZN550</i>)	19q13.43	E,S	M
173401 (<i>NM_152779</i>)	12q21.1	E	M	185836	16p11.2	S	P	130724 (<i>CHMP2A</i>)	19q13.43	E,S	M
165891 (<i>Q96AV8</i>)	12q21.2	E,S	M	102924 (<i>CBLN1</i>)	16q12.1	S	M	099326 (<i>ZNF42</i>)	19q13.43	E,S	M
111046 (<i>MYF6</i>)	12q21.31	S	P	103449 (<i>SALL1</i>)	16q12.1	E,S	M	175487 (<i>Q9BPX8</i>)	19q13.43	S	P
151572 (<i>NM_178826</i>)	12q23.1	S	P	183022	16q12.2	S	M	178591 (<i>DEFB125</i>)	20p13	S	M
089116 (<i>LHX5</i>)	12q24.13	S	M	103005 (<i>C16orf57</i>)	16q13	E,S	M	088782 (<i>DEFB127</i>)	20p13	S	P
175727 (<i>NM_014938</i>)	12q24.31	S	P	102890 (<i>ELMO3</i>)	16q22.1	S	P	125906 (<i>Q9H410</i>)	20p13	E	P
184967 (<i>NM_024078</i>)	12q24.33	S	M	102977 (<i>ACD</i>)	16q22.1	E,S	M	125861 (<i>GFRA4</i>)	20p13	S	P
112787 (<i>Q9HCM7</i>)	12q24.33	E,S	M	103056 (<i>SMPD3</i>)	16q22.1	S	M	101230 (<i>C20orf82</i>)	20p12.1	E,S	P
139495 (<i>NM_153023</i>)	13q12.12	S	P	103241 (<i>FOXF1</i>)	16q24.1	E,S	M	172264 (<i>C20orf133</i>)	20p12.1	S	M
169840 (<i>GSH1</i>)	13q12.2	S	M	179588 (<i>ZFPM1</i>)	16q24.2	S	M	125798 (<i>FOXA2</i>)	20p11.21	S	M
102760 (<i>NM_014059</i>)	13q14.11	S	M	051523 (<i>CYBA</i>)	16q24.2	S	M	125810 (<i>C1QR1</i>)	20p11.21	S	M
152207 (<i>CYSLTR2</i>)	13q14.2	S	P	183788 (<i>Q8N206</i>)	16q24.3	E,S	M	125831 (<i>CST11</i>)	20p11.21	S	M
171945 (<i>NM_030970</i>)	13q14.3	S	P	183518	17p13.3	E,S	M	154930 (<i>ACAS2L</i>)	20p11.21	E	P
178215 (<i>Q8N7V5</i>)	13q21.1	E,S	M	183688 (<i>NM_182705</i>)	17p13.3	S	M	183029 (<i>Q8NCY9</i>)	20q11.21	S	P
178205 (<i>Q8N7V5</i>)	13q21.1	S	M	167874 (<i>TMEM88</i>)	17p13.1	E,S	M	026559 (<i>KCNJ1</i>)	20q13.13	S	P
178200 (<i>Q8N7V5</i>)	13q21.1	S	P	190961 (<i>MYH1</i>)	17p13.1	S	P	124222 (<i>STX16</i>)	20q13.32	E	P
177527 (<i>Q8N7F4</i>)	13q21.31	E,S	P	108448 (<i>TRIM16</i>)	17p12	E	M	179242 (<i>CDH4</i>)	20q13.33	S	M
185498	13q21.32	E,S	P	160516 (<i>RPS28</i>)	17p11.2	S	M	101180 (<i>HRH3</i>)	20q13.33	S	M
152192 (<i>POU4F1</i>)	13q31.1	S	M	181977 (<i>PYY2</i>)	17q11.2	E,S	P	130702 (<i>LAMA5</i>)	20q13.33	S	M
171650 (<i>PTMA</i>)	13q31.1	S	P	184142 (<i>TIAF1</i>)	17q11.2	E	M	174407 (<i>C20orf166</i>)	20q13.33	S	M
184052	13q31.1	E	P	108587 (<i>GOSR1</i>)	17q11.2	S	P	101188 (<i>NTSR1</i>)	20q13.33	S	M
165300 (<i>Y918</i>)	13q31.2	S	P	172716 (<i>NM_152270</i>)	17q12	S	M	101189 (<i>C20orf20</i>)	20q13.33	E,S	M
139800 (<i>ZIC5</i>)	13q32.3	S	M	171532 (<i>NEUROD2</i>)	17q12	S	P	060491 (<i>OGFR</i>)	20q13.33	S	M
102466 (<i>FGF14</i>)	13q33.1	E	M	173917 (<i>HOXB2</i>)	17q21.32	E,S	M	092758 (<i>COL9A3</i>)	20q13.33	E,S	M
185950 (<i>IRS2</i>)	13q34	S	M	120093 (<i>HOXB3</i>)	17q21.32	E,S	M	101204 (<i>CHRNA4</i>)	20q13.33	E	M
153481 (<i>NM_018210</i>)	13q34	S	M	182742 (<i>HOXB4</i>)	17q21.32	S	M	075043 (<i>KCNQ2</i>)	20q13.33	S	M
126218 (<i>F10</i>)	13q34	S	M	108511 (<i>HOXB6</i>)	17q21.32	S	M	130589 (<i>P285</i>)	20q13.33	E	M
186009 (<i>ATP4B</i>)	13q34	S	M	120068 (<i>HOXB8</i>)	17q21.32	S	M	125520 (<i>SLC2A4RG</i>)	20q13.33	S	M
184497 (<i>FAM70B</i>)	13q34	E,S	M	141378 (<i>YCE7</i>)	17q23.2	E,S	M	171700 (<i>RGS19</i>)	20q13.33	S	M
185989 (<i>RASA3</i>)	13q34	S	M	121068 (<i>TBX2</i>)	17q23.2	S	M	171695 (<i>Q8TD35</i>)	20q13.33	S	P
176294 (<i>QRAN2</i>)	14q11.2	E	P	187013 (<i>C17orf82</i>)	17q23.2	E	M	181872	20q13.33	S	P
136367 (<i>ZFHX2</i>)	14q11.2	S	M	136492 (<i>BRIP1</i>)	17q23.2	S	P	175302 (<i>Q9NSI9</i>)	21q11.2	S	P
176165 (<i>FOXG1C</i>)	14q12	E,S	P	125398 (<i>SOX9</i>)	17q24.3	S	P	184856 (<i>C21orf74</i>)	21q21.1	E	P
136352 (<i>TITF1</i>)	14q13.3	S	M	161547 (<i>SFRS2</i>)	17q25.1	E	M	186930 (<i>KRTAP6-2</i>)	21q22.11	S	P
186215 (<i>Q86SZ3</i>)	14q13.3	S	P	167281	17q25.3	S	P	185569 (<i>OLIG2</i>)	21q22.11	S	M
136327 (<i>NKX2-8</i>)	14q13.3	S	P	141570 (<i>CBX8</i>)	17q25.3	S	M	159263 (<i>SIM2</i>)	21q22.13	E,S	P
151338 (<i>MIPOL1</i>)	14q13.3	E	M	141582 (<i>CBX4</i>)	17q25.3	S	M	183067 (<i>Q9NSI5</i>)	21q22.2	E	P
151748 (<i>SAVI</i>)	14q22.1	E	M	175901 (<i>Q8NBT7</i>)	17q25.3	S	M	141956 (<i>PRDM15</i>)	21q22.3	S	M
073712 (<i>PLEKHC1</i>)	14q22.1	E,S	P	181428 (<i>Q8N8L1</i>)	17q25.3	E,S	P	014442 (<i>ADARB1</i>)	21q22.3	E	M
125378 (<i>BMP4</i>)	14q22.2	S	M	181409 (<i>AATK</i>)	17q25.3	S	M	182586 (<i>C21orf89</i>)	21q22.3	E	P
184302 (<i>SIX6</i>)	14q23.1	S	P	187207	17q25.3	S	M	186866 (<i>C21orf80</i>)	21q22.3	S	P
177126 (<i>C14orf141</i>)	14q24.3	S	P	186765 (<i>FSCN2</i>)	17q25.3	S	P	187153	21q22.3	S	M
183992	14q31.1	E,S	M	184703 (<i>SIRT7</i>)	17q25.3	S	M	142156 (<i>COL6A1</i>)	21q22.3	S	M
140093 (<i>SERPINA10</i>)	14q32.13	E	P	184715 (<i>NM_032711</i>)	17q25.3	S	M	160294 (<i>MCM3AP</i>)	21q22.3	E	M
036530 (<i>CYP46A1</i>)	14q32.2	S	P	169750 (<i>RAC3</i>)	17q25.3	S	P	160305 (<i>DIP2</i>)	21q22.3	S	M
140107 (<i>Q8MU14</i>)	14q32.2	E	M	169727 (<i>GPS1</i>)	17q25.3	S	M	160307 (<i>S100B</i>)	21q22.3	E	P
185469 (<i>RTL1</i>)	14q32.31	E,S	M	154655 (<i>NM_173464</i>)	18p11.31	S	P	160310 (<i>HRMT1L1</i>)	21q22.3	E	P
066735 (<i>KIF26A</i>)	14q32.33	E	M	067900 (<i>ROCK1</i>)	18q11.1	S	M	183628 (<i>DGCR6</i>)	22q11.21	E,S	P
184601 (<i>Q8N912</i>)	14q32.33	S	M	141448 (<i>GATA6</i>)	18q11.2	E	M	100075 (<i>SLC25A1</i>)	22q11.21	S	M
130235 (<i>NM_032714</i>)	14q32.33	S	M	141441 (<i>FAM59A</i>)	18q12.1	E,S	P	183099	22q11.21	E,S	M
184916 (<i>JAG2</i>)	14q32.33	S	M	101746 (<i>NOLA</i>)	18q12.1	S	M	100208 (<i>IGLC1</i>)	22q11.22	S	P
184552 (<i>Q8NAF8</i>)	14q32.33	S	M	101489 (<i>BRUNOL4</i>)	18q12.2	E,S	M	186746	22q11.22	E	M
182351 (<i>CRIP1</i>)	14q32.33	S	M	152217 (<i>SETBP1</i>)	18q12.3	E	P	178803 (<i>Q8NAW6</i>)	22q11.23	S	P
177199 (<i>IGHA2</i>)	14q32.33	S	M	183677 (<i>ELA2</i>)	18q21.1	S	M	100104 (<i>SRR1</i>)	22q12.1	E	M
177154 (<i>IGHF</i>)	14q32.33	S	P	141644 (<i>MBD1</i>)	18q21.1	S	M	169184 (<i>MNT</i>)	22q12.1	S	P
177145 (<i>IGHG1</i>)	14q32.33	S	M	041353 (<i>RAB27B</i>)	18q21.2	E	P	184390 (<i>Q6ICM0</i>)	22q12.2	E,S	P
126309 (<i>HV1A</i>)	14q32.33	S	P	141668 (<i>NM_182511</i>)	18q22.3	S	P	166897 (<i>Q96PY3</i>)	22q13.1	S	P
126290 (<i>HV2A</i>)	14q32.33	E,S	P	141665 (<i>NM_152676</i>)	18q22.3	S	P	184687 (<i>Q8ND38</i>)	22q13.31	E,S	P
151802 (<i>Q9P168</i>)	15q13.1	E,S	P	101544 (<i>NM_014913</i>)	18q23	S	M	075275 (<i>CELSR1</i>)	22q13.31	E	M
103832 (<i>Q60374</i>)	15q13.2	E	P	178184 (<i>PARD6G</i>)	18q23	S	P	182858 (<i>NM_024105</i>)	22q13.33	S	M
134146 (<i>NM_080650</i>)	15q14	S	P	141934 (<i>PPAP2C</i>)	19p13.3	E,S	M	128159 (<i>TUBGCP6</i>)	22q13.33	S	M
179315	15q14	S	P	118050 (<i>NM_017914</i>)	19p13.3	S	M	185386 (<i>MAPK12</i>)	22q13.33	S	M
184263	15q21.2	S	P	180866 (<i>Q8NB05</i>)	19p13.2	E,S	P	100239 (<i>K685</i>)	22q13.33	S	P
169856 (<i>ONECUT1</i>)	15q21.3	S	M	105655 (<i>NM_016368</i>)	19p13.11	S	M	025770 (<i>NM_014551</i>)	22q13.33	S	M
069667 (<i>RORA</i>)	15q22.2	S	M	172684 (<i>Q8NE65</i>)	19p13.11	E,S	P	182786	22q13.33	S	P
138622 (<i>HCN4</i>)	15q24.1	S	M	172666	19p13.11	E,S	P				
186690	15q24.3	S	P	187135	19q12	S	M				
140557 (<i>SIAT8B</i>)	15q26.1	S	P	121297 (<i>TSH3</i>)	19q12	E,S	P				

Genes predicted to be imprinted by both the linear and RBF kernel classifiers learned by Equbits are denoted by E, and those predicted by both the linear and RBF kernel classifiers learned by SMLR by S. Genes predicted to be imprinted by both programs are denoted by E,S and represent the ‘high-confidence’ set presented in Table 1 of the article. Genes predicted to be expressed from the maternal or paternal allele are denoted by M or P, respectively. To enhance legibility, the common prefix “ENSG00000” has been dropped from the Ensembl ID.

Table 2. Chromosomal bands with high frequencies of genes proved or predicted with high confidence to be imprinted.

Band	Freq. (# known)	<i>P</i>	Novel candidates
11p15.5	10/82 (5)	$< 3 \times 10^{-16}$	<i>PKP3</i>, an oncogene involved in lung cancer (Furukawa et al., 2005), located distal to the <i>IGF2/H19</i> cluster. <i>PRDM16</i>, whose orthologue was also predicted to be imprinted in mouse (Luedi et al., 2005), and is associated with leukemia (Du et al., 2005). Several loci are involved in development and are susceptible to epigenetic regulation. <i>NKX6-2</i>, which was also predicted to be imprinted in the mouse (Luedi et al., 2005), is preferentially expressed in the brain (Lee et al., 2001). <i>NKX6-2</i>, along with five neighboring candidate genes, was predicted to show maternal expression. This region on 10q26 is near the marker D10S217, which has been found to be maternally linked to male sexual orientation (Mustanski et al., 2005). A germline differentially methylated region was found in this region (Strichman-Almashanu et al., 2002), lending further support to the prediction of imprinted genes within the immediate vicinity of this region. <i>RTL1</i>, imprinted in the mouse (Seitz et al., 2003) and sheep (Charlier et al., 2001).
1p36.32	5/24 (1)	$< 3 \times 10^{-16}$	
7p15.2	6/26 (0)	$< 3 \times 10^{-16}$	
10q26.3	6/44 (0)	9×10^{-16}	
14q32.31	2/5 (1)	1×10^{-11}	
15q12	2/6 (2)	7×10^{-10}	
7q21.3	4/35 (4)	2×10^{-8}	


P-values derived from a χ^2 -test with 1 degree of freedom.

Table 3. High-confidence imprinted gene candidates predicted in human and mouse.

Gene	Band	Expression		Description
		Human	Mouse	
<i>GFI1</i>	1p22	P	M	Oncogenic growth factor (Gilks et al., 1993), also involved in development (Moroy, 2005).
<i>PRDM16, MEL1</i>	1p36	P	P	Myeloid leukemia gene (Du et al., 2005).
<i>Q96PX6</i>	2p16	P	P	
<i>MAGI2, ACVRIP1, AIP1</i>	7q21	M	M	Specifically expressed in human brain and interacts specifically with atrophin-1 (Wood et al., 1998). A mutation in atrophin-1 causes dentatorubral and pallidolusian atrophy (DRPLA), a progressive neurodegenerative disorder (Li et al., 1993; Koide et al., 1994; Nagafuchi et al., 1994). <i>MAGI2</i> is also involved in zebrafish development (Wright et al., 2004)
<i>LY6D</i>	8q24	P	M	Expressed in head and neck squamous carcinoma (Kato et al., 1998; Brakenhoff et al., 1999)
<i>KCNK9</i>	8q24	M	M	K ⁺ channel protein involved in neuron apoptosis and cell tumorigenesis (Patel and Lazdunski, 2004).
<i>NKX6-2</i>	10q26	M	M	Shows tissue-specific regulation with highest expression in the brain (Lee et al., 2001) and is located near marker D10S217 that Mustanski et al. (2005) found was maternally linked to male sexual orientation.
<i>ENSG00000184682</i>	11p15	M	M	Contained within an intron of <i>LSP1</i> , both in human and in mouse.
<i>FOXG1C</i>	14q12	P	P	Shows haploinsufficiency in a patient with severe mental retardation, brain malformations and microcephaly (Shoichet et al., 2005). Mouse orthologue is essential for normal development of the telencephalon (Xuan et al., 1995).
<i>NM_024598</i>	16q13	M	M	

Genes predicted to be expressed from the maternal or paternal allele are denoted by M or P, respectively. For brevity, we did not include genes previously known to be imprinted.

Equbits



SMLR




Figure 1. Distributions of the weights of features characteristic of imprinted genes, as determined by two feature selection methods, those of Equbits and SMLR. Absolute weights are shown as box plots, the dotted line represents the overall mean of all selected features. (A) Distribution of feature type. (B) Distribution of different ways of quantifying repetitive elements. Ratios of $\pm$ counts carried the greatest weight ($P < 6 \times 10^{-11}$). (C) Distribution of different repetitive element locations. The 1 kb downstream window was of least importance ($P < 1 \times 10^{-3}$). (D) Distribution of different families of repetitive elements. Alus carried the lowest weight ($P < 4 \times 10^{-3}$), whereas endogenous retroviruses were of greatest importance ($P < 3 \times 10^{-3}$). (E) Distribution of counts of the highest scoring transcription factor binding sites.

Table 4. Relevant features for prediction of imprinting by Equibits classifiers.

Feature	Weight	Mean (Standard deviation)		Imprinted	P
		All Genes			
downstream 10:100 SINE _{Alu} ± ²	-16.96	4.11 (61.50)	1.68 (0.81)	4.76 × 10 ⁻⁹	
downstream 10:100 AluS± ²	11.28	16.89 (162.70)	161.12 (557.13)	5.70 × 10 ⁻²	
upstream 60:0 LTR _{ERV} L± ²	10.08	11.31 (21.28)	34.03 (55.48)	7.28 × 10 ⁻³	
upstream 9:8 Sp1 ¹	-9.75	0.34 (1.09)	0.15 (0.53)	1.64 × 10 ⁻²	
upstream 100:10 AluJ± ²	9.16	61.09 (228.98)	193.30 (372.53)	1.63 × 10 ⁻²	
upstream 5:4 NFuE1 ¹	9.14	0.04 (0.21)	0.13 (0.33)	6.88 × 10 ⁻²	
downstream 0:5 MIR3 ²	8.89	0.33 (0.99)	0.45 (1.34)	2.91 × 10 ⁻¹	
upstream 100:downstream 100 CCACGTGG within THE1B/B-int elements ³	8.86	0.13 (0.33)	0.30 (0.46)	1.31 × 10 ⁻²	
upstream 8:7 GTTC ¹	8.73	0.34 (0.61)	0.53 (0.78)	7.02 × 10 ⁻²	
upstream 3:2 Sp1 ¹	8.59	0.36 (1.13)	0.93 (1.40)	8.41 × 10 ⁻³	
upstream 5:0 LTR _{ERV} 1 ¹	8.58	0.36 (1.07)	0.58 (2.11)	2.68 × 10 ⁻¹	
downstream 5:10 LIME± ¹	-8.57	0.01 (0.99)	-0.28 (1.18)	6.79 × 10 ⁻²	
intron LTR _{ERV} 1± ²	8.39	173.80 (743.12)	617.58 (1711.93)	5.68 × 10 ⁻²	
upstream 100:downstream 100 CCACGTGG within THE1B/B-int elements ¹	8.27	0.15 (0.43)	0.43 (0.78)	1.70 × 10 ⁻²	
downstream 10:100 LIM4 ²	8.22	0.70 (1.11)	1.45 (1.77)	5.85 × 10 ⁻³	
intron CpGi ²	8.17	44.47 (86.92)	102.33 (186.25)	2.98 × 10 ⁻²	
upstream 10:9 Sp1 ¹	-8.15	0.34 (1.11)	0.30 (0.61)	3.46 × 10 ⁻¹	
downstream 10:100 LIP ²	-8.14	0.31 (1.06)	0.14 (0.58)	3.61 × 10 ⁻²	
downstream 10:100 SINE _{MIR} ± ¹	-8.13	0.11 (2.25)	-0.41 (2.31)	8.33 × 10 ⁻²	
upstream 50:0 L2± ¹	7.97	0.29 (2.90)	1.05 (4.42)	1.47 × 10 ⁻¹	
upstream 100:10 LIME± ¹	-7.94	0.29 (4.79)	-1.72 (3.94)	1.42 × 10 ⁻³	
upstream 2:1 PEA2 ¹	7.91	0.02 (0.15)	0.05 (0.22)	2.18 × 10 ⁻¹	
upstream 5:4 AP1 ¹ × downstream 0:100 MLT1C phase change ²	-7.89	0.77 (2.32)	0.03 (0.16)	0	
downstream 0:5 MIR3 ¹	7.84	0.14 (0.41)	0.18 (0.50)	3.43 × 10 ⁻¹	
downstream 5:10 LIPB ¹	7.79	0.04 (0.29)	0.13 (0.56)	1.75 × 10 ⁻¹	
upstream 100:10 DNA _{Tip} 100 ¹ × upstream 6:5 GTTC ³	-7.77	0.18 (0.72)	0.00 (0.00)	0	
downstream 0:5 MIR3± ¹	7.65	0.01 (0.41)	0.10 (0.44)	1.01 × 10 ⁻¹	
upstream 4:3 PEA1 ¹	7.6	0.10 (0.32)	0.13 (0.40)	3.50 × 10 ⁻¹	
upstream 100:10 AluJ± ¹	7.57	0.27 (2.37)	1.17 (2.83)	2.73 × 10 ⁻²	
intron LTR _{ERV} 1± ¹	-7.53	-0.49 (2.02)	-1.75 (4.90)	5.78 × 10 ⁻²	
downstream 5:10 LIMC± ²	7.5	71.64 (271.78)	129.05 (386.82)	1.80 × 10 ⁻¹	
upstream 100:10 LIMA± ¹	7.36	0.07 (2.70)	1.13 (3.64)	3.81 × 10 ⁻²	
upstream 6:5 SIF ³ × upstream 2:0 BPVE2 ³	-7.31	0.13 (0.33)	0.00 (0.00)	0	
upstream 9:8 CEBP ¹	7.29	0.04 (0.20)	0.10 (0.38)	1.64 × 10 ⁻¹	
downstream 40:100 LTR _{ERV} 1± ¹	7.26	0.59 (2.87)	1.95 (6.14)	8.60 × 10 ⁻²	
exon 0.225:0.41 nucleosome potential ²	-7.22	0.67 (0.92)	-0.10 (1.06)	2.65 × 10 ⁻⁵	
upstream 3:2 Sp1 ³	7.17	0.21 (0.41)	0.43 (0.50)	5.46 × 10 ⁻³	
downstream 5:10 Alu ²	7.08	0.01 (0.06)	0.01 (0.09)	3.05 × 10 ⁻¹	
upstream 100:10 MIR3± ¹	7.07	0.14 (1.84)	0.51 (1.74)	9.53 × 10 ⁻²	
upstream 3:2 BPVE2 ¹ × upstream 1:0 Pit1 ³	-7.06	0.14 (0.44)	0.00 (0.00)	0	
upstream 30:20 CpGi ^{2,10}	7.02	0.13 (0.28)	0.17 (0.35)	2.47 × 10 ⁻¹	
upstream 100:10 LTR _{ERV} 1± ²	-6.98	459.12 (1253.59)	183.25 (433.61)	1.56 × 10 ⁻⁴	
upstream 100:10 LIMC± ¹	6.96	0.24 (4.23)	1.23 (5.64)	1.40 × 10 ⁻¹	
upstream 8:7 EFC ¹	6.87	0.00 (0.04)	0.03 (0.16)	1.82 × 10 ⁻¹	
upstream 8:7 GT2B ¹ × upstream 9:8 Sp1 ³	-6.86	0.11 (0.44)	0.00 (0.00)	0	
upstream 9:8 Sp1 ³ × upstream 8:7 GT2B ³	-6.82	0.08 (0.27)	0.00 (0.00)	0	
downstream 5:10 LINE _L 2± ²	6.8	106.50 (243.27)	116.37 (272.10)	4.11 × 10 ⁻¹	
upstream distance to closest recomb. hotspot	-6.79	315.02 (1369.12)	122.40 (94.52)	0	
upstream 100:10 LIM4± ² × upstream 1:0 MLTF ³	-6.78	229.05 (605.18)	25.45 (91.09)	0	
upstream 8:7 SIF ³ × upstream 5:0 ETFA ³	-6.76	0.06 (0.24)	0.00 (0.00)	0	
upstream 5:0 LINE _{CR1} ± ²	6.75	12.41 (69.05)	38.48 (121.07)	9.33 × 10 ⁻²	
intron LIM2 ¹	-6.73	0.05 (0.37)	0.00 (0.00)	0	
upstream 5:4 AP1 ³ × downstream 0:100 MLT1C phase change ²	-6.71	0.34 (0.85)	0.03 (0.16)	5.55 × 10 ⁻¹⁶	
upstream 9:8 MLTF ³	6.62	0.57 (0.50)	0.70 (0.46)	4.03 × 10 ⁻²	
upstream 5:4 AP1 ¹ × downstream 0:100 MLT1C phase change ²	-6.59	0.23 (0.69)	0.01 (0.08)	0	
upstream 6:5 SIF ¹ × upstream 2:0 BPVE2 ³	-6.57	0.16 (0.50)	0.00 (0.00)	0	
upstream 0.83:0.61 nucleosome potential ¹	-6.55	182.33 (154.05)	102.79 (169.84)	2.87 × 10 ⁻³	
downstream 5:10 LIMC ²	6.54	0.78 (2.85)	1.29 (3.87)	2.06 × 10 ⁻¹	
downstream 5:10 DNA _{MER2} type± ²	6.52	46.30 (230.76)	190.05 (602.01)	7.20 × 10 ⁻²	
downstream 5:10 CpGi ¹ × upstream 10:9 NFuE5 ³	-6.51	0.12 (0.44)	0.00 (0.00)	0	
upstream 7:6 NFuE5 ³	6.47	0.28 (0.45)	0.35 (0.48)	1.73 × 10 ⁻¹	
upstream 8:7 SIF ¹ × upstream 8:7 BPVE2 ³	-6.45	0.10 (0.37)	0.00 (0.00)	0	
upstream 8:7 ICP4 ¹	-6.44	0.05 (0.24)	0.03 (0.16)	1.58 × 10 ⁻¹	
upstream 4:3 PEA2 ¹	6.43	0.02 (0.13)	0.10 (0.30)	4.92 × 10 ⁻²	
upstream 100:10 DNA _{Tip} 100 ¹ × upstream 3:2 Pit1 ³	-6.42	0.29 (0.89)	0.00 (0.00)	0	
downstream 0:100 MLT1A0 phase change ¹	6.37	0.40 (0.86)	0.83 (1.03)	7.45 × 10 ⁻³	
upstream 1:0 BPVE2 ¹ × upstream 10:9 NFuE5 ³	-6.32	0.12 (0.40)	0.00 (0.00)	0	
upstream 9:8 MLTF ¹	6.31	0.91 (1.13)	1.23 (1.10)	4.28 × 10 ⁻²	
upstream 7:6 NFuE4 ¹	6.29	0.04 (0.21)	0.05 (0.22)	3.85 × 10 ⁻¹	
upstream 100:10 DNA _{Tip} 100± ²	-6.24	90.37 (251.03)	69.05 (309.29)	3.35 × 10 ⁻¹	
upstream 9:8 CEBP ³	6.22	0.04 (0.19)	0.08 (0.27)	1.99 × 10 ⁻¹	
upstream 2:0 Oct1 ³	6.18	0.61 (0.49)	0.73 (0.45)	5.29 × 10 ⁻²	
upstream 10:9 GT2B ¹ × upstream 3:2 Pit1 ³	-6.17	0.17 (0.49)	0.00 (0.00)	0	
downstream 5:10 AluY± ²	6.12	80.80 (155.01)	145.40 (217.27)	3.55 × 10 ⁻²	
downstream 10:100 MIR± ¹	-6.11	0.12 (2.35)	-0.23 (2.46)	1.84 × 10 ⁻¹	
upstream 2:0 CpGi ¹ × upstream 9:8 E4F1 ³	-6.08	0.07 (0.26)	0.00 (0.00)	0	
upstream 8:7 GTTC ³	6.07	0.28 (0.45)	0.38 (0.49)	1.05 × 10 ⁻¹	

downstream 10:100 FLAM $\pm^2$ $\times$ upstream 10:9 ATF ¹	-6.06	34.06	(129.03)	0.22	(0.62)	0
upstream 40:30 CpGi ^{1,10}	6.05	0.36	(0.85)	0.45	(1.30)	3.28×10^{-1}
downstream 5:10 DNA_MER2_type ²	6.03	0.50	(2.39)	1.90	(6.02)	7.69×10^{-2}
upstream 6:5 ATF ³	6.01	0.36	(0.48)	0.48	(0.51)	7.39×10^{-2}
upstream 5:0 LINE_CR1 ²	6	0.26	(1.42)	0.77	(2.42)	9.71×10^{-2}
upstream 9:8 Sp1 ³ $\times$ upstream 1:0 ICSBP ³	-5.95	0.14	(0.35)	0.00	(0.00)	0
upstream 7:6 NFkB ³	5.92	0.08	(0.27)	0.15	(0.36)	1.14×10^{-1}
upstream 100:10 HAL1 $\pm^2$ $\times$ upstream 9:8 TFIIID ³	-5.86	141.37	(392.44)	13.28	(47.90)	0
upstream 2:0 MIR ² $\times$ upstream 8:7 GT2B ³	-5.85	0.79	(2.90)	0.00	(0.00)	0
downstream 10:100 DNA ¹ $\times$ upstream 10:9 PU1 ³	-5.83	0.23	(0.66)	0.00	(0.00)	0
exon LINE_L2 $\pm^1$	5.82	0.00	(0.23)	0.05	(0.22)	8.77×10^{-2}
upstream 100:10 DNA_Tip100 ¹ $\times$ upstream 8:7 ICSBP ³	-5.79	0.53	(1.14)	0.08	(0.27)	1.61×10^{-13}
upstream 100:10 DNA_Tip100 ² $\times$ upstream 8:7 ICSBP ³	-5.78	0.09	(0.27)	0.01	(0.04)	0
upstream 2:0 LIM2 $\pm^1$	5.74	0.00	(0.10)	0.03	(0.16)	1.82×10^{-1}
upstream 100:10 LIP ¹	-5.71	0.42	(0.96)	0.28	(0.55)	6.08×10^{-2}
downstream 5:10 LTR_ERVK $\pm^1$	-5.7	0.00	(0.26)	-0.15	(0.95)	1.64×10^{-1}
downstream 0:1 CpGi ¹	-5.68	0.04	(0.19)	0.03	(0.16)	2.86×10^{-1}
upstream 100:10 HAL1 ¹ $\times$ upstream 8:7 GT2B ¹	-5.66	0.49	(1.88)	0.03	(0.16)	0
downstream 10:100 MIR3 $\pm^2$ $\times$ upstream 4:3 GATA1 ¹	-5.65	48.09	(147.61)	1.72	(9.34)	0
downstream 5:10 LTR_ERVK ¹	5.64	0.03	(0.27)	0.15	(0.95)	2.23×10^{-1}
downstream 10:100 LIMB ²	5.61	1.24	(1.54)	1.67	(2.02)	9.54×10^{-2}
upstream 2:0 MIR ¹ $\times$ upstream 8:7 GT2B ³	-5.58	0.12	(0.45)	0.00	(0.00)	0
upstream 100:10 DNA $\pm^2$	5.57	45.51	(150.10)	99.38	(312.29)	1.44×10^{-1}
downstream 10:100 LTR_ERVK ²	5.55	0.38	(1.24)	0.83	(1.89)	7.35×10^{-2}
upstream 9:8 Sp1 ³ $\times$ upstream 10:0 CpGi ^{1,11}	-5.53	0.66	(1.70)	0.08	(0.27)	0
upstream 2:1 SIF ³	5.49	0.24	(0.43)	0.28	(0.45)	3.22×10^{-1}
downstream 0:100 LTR phase change ^{2,99}	5.48	0.29	(0.28)	0.40	(0.27)	1.09×10^{-2}
upstream 100:10 DNA_Tip100 ¹ $\times$ upstream 8:7 ICSBP ¹	-5.47	1.00	(2.50)	0.10	(0.38)	0
upstream 5:0 CpGi ¹ $\times$ upstream 9:8 E4F1 ³	-5.46	0.09	(0.32)	0.00	(0.00)	0
upstream 10:5 LIMC ²	-5.45	0.77	(2.82)	0.57	(2.26)	2.83×10^{-1}
upstream 4:3 E2F ¹	-5.43	0.01	(0.11)	0.00	(0.00)	0
upstream 2:0 SINE_MIR ² $\times$ upstream 8:7 GT2B ³	-5.42	0.93	(3.19)	0.00	(0.00)	0
upstream 1:0 CP1 ³	-5.41	0.07	(0.25)	0.03	(0.16)	5.73×10^{-2}
downstream 0:5 DNA_Tip100 ²	-5.4	0.10	(1.02)	0.00	(0.00)	0
downstream 10:100 LIMC ¹ $\times$ downstream 0:100 MLT1C phase change ²	-5.39	1.96	(5.89)	0.13	(0.40)	0
downstream 5:10 CpGi2 ¹	5.37	2.26	(2.27)	2.93	(2.55)	5.61×10^{-2}
intron CpGi ³	5.36	0.08	(0.27)	0.28	(0.45)	5.48×10^{-3}
intron CpGi ¹	5.35	0.47	(1.10)	1.05	(1.52)	1.10×10^{-2}
downstream 0:2 AluY ¹ $\times$ upstream 10:9 MLTF ³	-5.33	0.07	(0.30)	0.00	(0.00)	0
upstream 9:8 PEA2 ¹	-5.32	0.02	(0.14)	0.03	(0.16)	4.06×10^{-1}
upstream 350:350 downstream recomb ¹	5.28	4.84	(2.75)	6.15	(2.18)	2.96×10^{-4}
downstream 5:10 DNA_MER1_type ¹ $\times$ upstream 3:2 Pit1 ³	-5.27	0.15	(0.53)	0.00	(0.00)	0
upstream 10:5 LTR_MaLR $\pm^2$ $\times$ upstream 6:5 APF ³	-5.26	94.23	(233.79)	3.92	(23.86)	0
upstream 9:8 ATF ³ $\times$ upstream 5:4 NFUE5 ³	-5.25	0.11	(0.31)	0.00	(0.00)	0
upstream 100:10 LIPB ²	5.24	0.49	(1.48)	0.69	(1.89)	2.64×10^{-1}
downstream 5:10 LIMD $\pm^1$	5.23	0.00	(0.47)	0.00	(0.45)	5.00×10^{-1}
downstream 0:2 MIR ²	5.21	1.73	(3.99)	1.80	(4.79)	4.63×10^{-1}
upstream 5:0 PEA2 ³	5.2	0.12	(0.32)	0.25	(0.44)	3.12×10^{-2}
upstream 9:8 Sp1 ¹ $\times$ upstream 1:0 ICSBP ³	-5.19	0.24	(0.93)	0.00	(0.00)	0
downstream 5:10 LINE_L2 ²	5.18	1.52	(3.00)	1.65	(3.31)	3.99×10^{-1}
upstream 100:10 LIMB $\pm^2$ $\times$ upstream 5:4 ATF ³	-5.17	188.41	(642.54)	6.87	(40.74)	0
intron DNA $\pm^1$	-5.16	0.00	(0.50)	-0.15	(0.58)	5.62×10^{-2}
intron MIR3 ² $\times$ upstream 4:3 TFIIID ¹	-5.15	16.59	(66.36)	1.43	(6.31)	0
downstream 10:100 MIR3 $\pm^2$ $\times$ upstream 4:3 GATA1 ³	-5.12	33.26	(88.69)	1.62	(9.32)	0
upstream 2:0 LINE_L2 ¹ $\times$ upstream 5:4 GATA1 ³	-5.11	0.14	(0.48)	0.00	(0.00)	0
upstream 9:8 NFkB ¹	5.08	0.08	(0.29)	0.13	(0.40)	2.45×10^{-1}
upstream 10:9 NFUE5 ³ $\times$ upstream 1:0 BPVE2 ³	-5.07	0.10	(0.30)	0.00	(0.00)	0
downstream 10:100 LIM4 $\pm^1$	5.06	0.05	(2.87)	0.79	(3.97)	1.26×10^{-1}
I ⁵ $\times$ downstream 10:100 DNA_Mariner ¹	-5.05	0.17	(0.57)	0.00	(0.00)	0
upstream 2:0 LINE_L2 ²	5.04	2.88	(7.56)	3.35	(10.80)	3.93×10^{-1}
downstream 5:10 CpGi ¹ $\times$ upstream 10:9 NFUE5 ¹	-5.03	0.15	(0.63)	0.00	(0.00)	0
downstream 10:100 FLAM $\pm^2$ $\times$ upstream 10:9 ATF ³	-5.02	25.49	(84.33)	0.22	(0.62)	0
upstream 5:0 LINE_CR1 $\pm^1$	-5.01	0.01	(0.36)	-0.10	(0.50)	9.50×10^{-2}
upstream 7:6 NFkB ¹	4.98	0.08	(0.29)	0.15	(0.36)	1.27×10^{-1}
upstream 5:0 LIM2 $\pm^1$	4.97	0.00	(0.16)	0.03	(0.16)	1.94×10^{-1}
downstream 10:100 LTR_ERV1 ²	-4.96	2.65	(3.61)	2.50	(3.07)	3.82×10^{-1}
downstream 10:100 DNA_Mariner ¹ $\times$ upstream 3:2 MLTF ³	-4.95	0.23	(0.64)	0.00	(0.00)	0
downstream 50:90 LTR_ERVL $\pm^1$	4.94	0.43	(1.55)	1.19	(2.30)	2.34×10^{-2}
upstream 90:20 MIR $\pm^1$	4.93	0.21	(2.27)	0.85	(2.69)	7.48×10^{-2}
upstream 5:0 LINE_CR1 ¹	4.92	0.07	(0.36)	0.20	(0.46)	5.03×10^{-2}
upstream 6:5 PEA1 ³	4.91	0.10	(0.29)	0.18	(0.38)	1.01×10^{-1}
upstream 2:1 Oct1 ³	4.9	0.42	(0.49)	0.50	(0.51)	1.62×10^{-1}
upstream 8:7 E4F1 ¹	4.89	0.20	(0.49)	0.45	(1.45)	1.49×10^{-1}
downstream 10:100 DNA ²	-4.88	0.06	(0.17)	0.02	(0.05)	2.98×10^{-6}
downstream 10:100 LIMC ¹ $\times$ downstream 0:100 MLT1C phase change ²	-4.86	0.59	(1.67)	0.06	(0.20)	0
downstream 10:100 DNA $\pm^1$	4.85	0.02	(0.80)	0.10	(0.50)	1.56×10^{-1}
upstream 4:3 E4F1 ³	4.84	0.18	(0.38)	0.20	(0.41)	3.77×10^{-1}
upstream 10:5 LTR_ERV1 $\pm^1$	4.83	0.01	(1.05)	0.13	(1.02)	2.47×10^{-1}
upstream 2:0 LINE_L2 $\pm^1$	4.82	0.03	(0.68)	0.23	(0.58)	2.01×10^{-2}
downstream 5:10 MIR ¹	-4.81	0.77	(1.14)	0.40	(0.50)	2.14×10^{-5}
upstream 3:2 NFUE3 ¹	4.8	0.08	(0.29)	0.15	(0.43)	1.49×10^{-1}

downstream 0:2 SINE_MIR ²	4.78	2.06	(4.34)	2.02	(4.90)	4.80×10^{-1}
exon DNA_MER2_type ²	4.76	0.18	(2.98)	2.21	(10.17)	1.09×10^{-1}
upstream 1:0 NFKB ³	4.75	0.11	(0.31)	0.08	(0.27)	2.33×10^{-1}
I ⁵ × upstream 2:1 BPVE2 ³	-4.74	0.16	(0.37)	0.00	(0.00)	0
upstream 2:0 DNA_MER1_type ¹ × upstream 6:5 AP1 ³	-4.73	0.11	(0.40)	0.00	(0.00)	0
upstream 2:0 LTR_ERV1 ^{±2}	4.72	34.74	(150.24)	60.40	(234.23)	2.49×10^{-1}
upstream 5:4 SIF ³ × upstream 4:3 PU1 ³	-4.71	0.12	(0.32)	0.00	(0.00)	0
downstream 5:10 DNA_MER2_type ^{±1}	-4.7	0.00	(0.56)	-0.18	(0.78)	8.61×10^{-2}
downstream 5:10 L1PA ²	-4.68	2.70	(10.90)	2.43	(10.47)	4.37×10^{-1}
upstream 9:8 SIF ³ × m3m11	-4.67	0.09	(0.29)	0.00	(0.00)	0
upstream 2:0 CpGi ²	4.66	152.21	(161.47)	222.15	(212.49)	2.33×10^{-2}
downstream 10:100 DNA_MER1_type ² × upstream 10:5 LTR_MaLR ^{±2}	-4.63	128.89	(371.35)	6.60	(32.09)	0
downstream 5:10 L1PA ^{±2}	-4.62	231.39	(1001.15)	179.41	(978.02)	3.71×10^{-1}
upstream 100:10 HAL1 ¹ × upstream 8:7 GT2B ³	-4.61	0.37	(1.26)	0.03	(0.16)	0
downstream 0:5 LTR_ERV1 ¹	-4.59	0.28	(0.92)	0.10	(0.38)	3.00×10^{-3}
downstream 10:100 Other ²	-4.57	0.19	(0.60)	0.06	(0.27)	1.37×10^{-3}
upstream 6:5 NF1 ³	4.56	0.12	(0.33)	0.18	(0.38)	2.00×10^{-1}
downstream 0:1 CpGi ²	-4.55	47.19	(117.94)	54.10	(122.05)	3.63×10^{-1}
downstream 10:100 FLAM ^{±2} × upstream 100:10 MIR3 ^{±2}	-4.53	5099.30	(18824.72)	54.26	(133.79)	0
upstream 2:1 MLTF ¹	4.52	0.96	(1.06)	1.10	(1.22)	2.34×10^{-1}
upstream 100:10 LIM1 ^{±1}	-4.51	0.04	(0.87)	-0.23	(0.97)	4.79×10^{-2}
upstream 5:0 LTR_MaLR ^{±2}	-4.5	87.69	(215.92)	64.15	(132.75)	1.38×10^{-1}
upstream 10:5 LTR_MaLR ^{±2} × upstream 100:10 LINE_L2 ²	-4.49	315.39	(889.70)	25.95	(109.14)	0
downstream 10:100 L1MB ¹	4.48	3.62	(3.92)	4.08	(3.86)	2.31×10^{-1}
downstream 10:100 L1PB ^{±1}	-4.47	0.01	(1.37)	0.03	(1.05)	4.63×10^{-1}
upstream 80:70 CpGi ^{1,10}	-4.46	0.34	(0.81)	0.23	(0.62)	1.21×10^{-1}
upstream 10:0 ETFA ¹ × upstream 10:9 E4F1 ³	-4.45	0.14	(0.48)	0.00	(0.00)	0
upstream 5:0 LINE_L2 ^{±1}	4.44	0.05	(1.24)	0.30	(1.32)	1.23×10^{-1}
upstream 3:2 APF ¹ × downstream 0:100 MLT1C phase change ²	-4.43	1.01	(2.96)	0.05	(0.22)	0
upstream 10:5 LTR_MaLR ² × upstream 10:9 COUP ³	-4.42	1.26	(2.92)	0.12	(0.57)	7.77×10^{-16}
upstream 3:2 Oct1 ³ × downstream 0:100 MLT1C phase change ²	-4.41	0.05	(0.18)	0.00	(0.00)	0
downstream 0:5 FRAM ^{±1}	-4.4	0.00	(0.23)	-0.05	(0.22)	8.06×10^{-2}
downstream 10:100 CpGi ³ × upstream 100:10 L1MB ^{±2}	-4.39	286.48	(761.12)	22.01	(95.07)	0
downstream 10:100 DNA_Mariner ¹ × upstream 10:0 ETFA ³	-4.38	0.17	(0.55)	0.00	(0.00)	0
downstream 35:68 L2 ^{±1}	4.37	0.52	(2.58)	0.98	(2.07)	8.56×10^{-2}
upstream 7:6 E2F ¹	4.36	0.01	(0.10)	0.05	(0.22)	1.35×10^{-1}
upstream 5:4 NFue5 ¹ × upstream 9:8 ATF ³	-4.35	0.13	(0.43)	0.00	(0.00)	0
upstream 10:0 NFKB ¹	4.34	0.85	(0.98)	1.08	(1.02)	9.27×10^{-2}
exon L1 ²	4.33	0.03	(1.56)	0.17	(1.09)	2.13×10^{-1}
upstream 10:9 E4F1 ³ × upstream 3:2 MLTF ³	-4.32	0.10	(0.30)	0.00	(0.00)	0
upstream 6:5 MLTF ³	4.31	0.57	(0.50)	0.63	(0.49)	2.44×10^{-1}
upstream 5:0 CpGi ¹ × upstream 9:8 E4F1 ¹	-4.3	0.11	(0.43)	0.00	(0.00)	0
upstream 8:7 BPVE2 ³ × upstream 8:7 SIF ³	-4.29	0.09	(0.28)	0.00	(0.00)	0
upstream 8:7 MLTF ¹	4.28	0.90	(1.08)	1.20	(1.86)	1.60×10^{-1}
downstream 10:100 HAL1 ^{±1}	-4.27	-0.03	(1.92)	-0.44	(2.23)	1.29×10^{-1}
downstream 5:10 MIR ²	-4.26	1.02	(1.55)	0.58	(0.76)	4.61×10^{-4}
upstream 6:5 ATF ¹	4.25	0.49	(0.78)	0.63	(0.81)	1.43×10^{-1}
upstream 2:0 LINE_L2 ¹ × upstream 5:4 GATA1 ¹	-4.24	0.20	(0.75)	0.00	(0.00)	0
upstream 100:10 DNA_Mariner ¹	-4.23	0.41	(0.83)	0.23	(0.58)	2.43×10^{-2}
upstream 2:0 DNA_MER1_type ¹ × upstream 10:9 AP1 ³	-4.22	0.11	(0.40)	0.00	(0.00)	0
upstream 100:60 LTR_ERVL ^{±1}	-4.21	0.41	(1.56)	-0.11	(3.58)	1.84×10^{-1}
downstream 10:100 LIM1 ²	-4.2	0.12	(0.64)	0.18	(0.66)	2.84×10^{-1}
upstream 5:0 LINE_L2 ^{±2}	4.19	112.34	(241.50)	164.27	(305.43)	1.48×10^{-1}
intron DNA_Tip100 ¹	-4.18	0.19	(0.76)	0.10	(0.38)	7.26×10^{-2}
downstream 0:5 LTR_ERV1 ²	-4.17	2.52	(10.32)	0.41	(1.91)	1.65×10^{-8}
upstream 9:8 GATA1 ³ × downstream 0:100 MLT1C phase change ²	-4.15	0.06	(0.18)	0.00	(0.00)	0
upstream 6:5 APF ³ × upstream 5:4 E4F1 ³	-4.14	0.15	(0.35)	0.00	(0.00)	0
upstream 10:9 NFue5 ¹ × upstream 10:0 NFue3 ³	-4.13	0.17	(0.48)	0.00	(0.00)	0
upstream 10:9 E4F1 ¹ × upstream 9:8 PU1 ³	-4.12	0.12	(0.38)	0.00	(0.00)	0
downstream 5:10 L1PB ²	4.11	0.35	(3.49)	1.46	(6.49)	1.45×10^{-1}
upstream 10:5 SINE_MIR ^{±2} × upstream 7:6 BPVE2 ³	-4.1	23.93	(74.12)	0.02	(0.14)	0
intron DNA_Tip100 ^{±1}	-4.09	0.00	(0.59)	0.00	(0.39)	4.73×10^{-1}
upstream 10:5 LTR_ERVL ^{±1}	4.08	0.00	(0.66)	0.18	(0.75)	7.32×10^{-2}
upstream 100:10 HAL1 ^{±2} × upstream 9:8 TFIIID ¹	-4.07	264.58	(860.20)	17.11	(63.06)	0
upstream 10:9 E4F1 ¹ × upstream 10:0 ETFA ³	-4.06	0.11	(0.38)	0.00	(0.00)	0
upstream 2:0 DNA_MER1_type ^{±2}	-4.05	19.25	(74.01)	2.20	(13.91)	1.34×10^{-9}
upstream 10:9 NFue5 ¹ × upstream 1:0 BPVE2 ³	-4.04	0.12	(0.42)	0.00	(0.00)	0
upstream 100:10 L1MB ¹	4.03	3.70	(3.98)	4.38	(4.80)	1.93×10^{-1}
upstream 100:10 LTR_ERV1 ¹ × upstream 10:0 NFue4 ³	-4.02	2.12	(5.53)	0.18	(0.50)	0
upstream 7:6 CP1 ¹	4.01	0.05	(0.26)	0.08	(0.27)	2.84×10^{-1}
upstream 100:10 L1MD ^{±1}	-4	0.04	(2.40)	-0.06	(2.73)	4.09×10^{-1}
upstream 2:1 AP2 ¹	3.99	0.42	(0.82)	0.90	(1.46)	2.38×10^{-2}
downstream 10:100 DNA_Te2 ^{±1}	-3.98	-0.01	(0.63)	-0.03	(0.66)	4.34×10^{-1}
downstream 10:100 DNA_MER2_type ^{±1}	3.97	0.11	(2.47)	0.58	(1.90)	6.53×10^{-2}
upstream 9:8 ATF ¹ × upstream 5:4 NFue5 ¹	-3.96	0.19	(0.74)	0.00	(0.00)	0
upstream 6:5 GT2B ¹	3.95	0.44	(0.77)	0.70	(0.94)	4.81×10^{-2}
downstream 10:100 DNA_Mariner ¹ × upstream 1:0 ATF ¹	-3.94	0.35	(1.23)	0.00	(0.00)	0
upstream 100:10 DNA ²	3.93	0.06	(0.17)	0.10	(0.31)	2.08×10^{-1}
upstream 10:9 E4F1 ³ × upstream 3:2 GATA1 ³	-3.92	0.08	(0.27)	0.00	(0.00)	0
upstream 10:5 LTR_MaLR ^{±2} × upstream 3:2 AP1 ³	-3.9	91.79	(229.88)	0.15	(0.65)	0
upstream 4:3 NFue5 ³ × upstream 4:3 Pit1 ³	-3.89	0.10	(0.30)	0.00	(0.00)	0

upstream 10:9 GT2B ¹ × upstream 1:0 MLTF ¹	-3.88	0.58	(1.54)	0.08	(0.27)	5.88 × 10 ⁻¹⁵
downstream 10:100 DNA_Mariner ¹ × upstream 1:0 TFIID ³	-3.87	0.21	(0.62)	0.00	(0.00)	0
downstream 0:2 LTR_ERVL ¹	-3.86	0.06	(0.37)	0.00	(0.00)	0
exon LINE_L2 ¹	3.85	0.04	(0.24)	0.05	(0.22)	3.73 × 10 ⁻¹
upstream 1:0 NFUE3 ¹	-3.84	0.05	(0.24)	0.03	(0.16)	1.31 × 10 ⁻¹
upstream 10:9 GTIC ³ × upstream 4:3 BPVE2 ³	-3.83	0.10	(0.30)	0.00	(0.00)	0
upstream 7:6 COUP ³ × upstream 2:1 E4TF1 ³	-3.82	0.06	(0.25)	0.00	(0.00)	0
upstream 10:5 DNA_MER2type± ²	-3.81	32.24	(145.71)	13.18	(70.83)	5.09 × 10 ⁻²
upstream 5:4 GATA1 ³ × downstream 0:100 MLTIC phase change ²	-3.8	0.19	(0.65)	0.00	(0.00)	0
upstream 2:1 BPVE2 ³ × upstream 5:0 ETFA ³	-3.79	0.11	(0.31)	0.00	(0.00)	0
upstream 2:0 LINE_L2 ¹ × upstream 7:6 Pit1 ³	-3.78	0.13	(0.46)	0.00	(0.00)	0
upstream 2:1 TFIID ³ × downstream 0:100 MLTIC phase change ²	-3.77	0.24	(0.73)	0.00	(0.00)	0
upstream 7:6 Sp1 ³	3.76	0.20	(0.40)	0.35	(0.48)	2.81 × 10 ⁻²
downstream 5:10 L1PB± ¹	-3.75	0.00	(0.28)	-0.03	(0.58)	3.95 × 10 ⁻¹
upstream 7:6 GTIC ³ × upstream 5:0 CP1 ³	-3.73	0.06	(0.24)	0.00	(0.00)	0
upstream 2:0 DNA_MER1type ¹	-3.72	0.13	(0.44)	0.03	(0.16)	7.19 × 10 ⁻⁵
upstream 2:1 SRF ¹	-3.71	0.02	(0.13)	0.00	(0.00)	0
upstream 4:3 Pit1 ³ × downstream 0:100 MLTIC phase change ²	-3.7	0.18	(0.63)	0.00	(0.00)	0
upstream 2:0 E4TF1 ¹	3.69	0.21	(0.48)	0.13	(0.46)	1.32 × 10 ⁻¹
upstream 9:8 NFUE5 ¹ × upstream 6:5 Oct1 ³	-3.68	0.14	(0.42)	0.00	(0.00)	0
upstream 10:0 CpGi ^{1,11}	3.67	2.32	(2.09)	2.48	(1.97)	3.14 × 10 ⁻¹
downstream 0:2 SINE_MIR ¹	3.66	0.32	(0.66)	0.25	(0.59)	2.16 × 10 ⁻¹
upstream 7:6 SIF ³	3.65	0.22	(0.41)	0.30	(0.46)	1.31 × 10 ⁻¹
upstream 5:4 E4F1 ¹ × upstream 6:5 APF ³	-3.63	0.17	(0.50)	0.00	(0.00)	0
upstream 7:6 AP1 ³ × upstream 2:1 E4TF1 ³	-3.62	0.06	(0.25)	0.00	(0.00)	0
upstream 5:4 NFUE5 ³ × upstream 4:3 Pit1 ³	-3.61	0.11	(0.31)	0.00	(0.00)	0
downstream 10:100 L1PA ¹	-3.6	2.76	(3.56)	3.03	(3.09)	2.95 × 10 ⁻¹
upstream 4:3 CEBP ³	3.59	0.04	(0.19)	0.10	(0.30)	9.64 × 10 ⁻²
upstream 5:0 LIM ²	3.58	0.01	(0.21)	0.06	(0.36)	1.96 × 10 ⁻¹
upstream 10:5 MIR3 ¹	-3.57	0.14	(0.41)	0.08	(0.27)	6.80 × 10 ⁻²
downstream 0:5 FAM ¹	-3.56	0.01	(0.13)	0.00	(0.00)	0
downstream 5:10 LIMD± ²	-3.55	26.33	(197.25)	24.09	(152.26)	4.64 × 10 ⁻¹
upstream 3:2 Pit1 ¹ × upstream 7:6 BPVE2 ³	-3.54	0.25	(0.77)	0.00	(0.00)	0
downstream 0:2 FLAM± ¹	3.53	0.00	(0.22)	0.03	(0.16)	2.08 × 10 ⁻¹
upstream 2:0 SINE_MIR± ² × upstream 8:7 GT2B ³	-3.52	13.67	(50.16)	0.00	(0.00)	0
upstream 2:0 DNA_MER1type ¹ × upstream 8:7 ICSBP ³	-3.51	0.10	(0.39)	0.00	(0.00)	0
upstream 6:5 ETFA ³	3.5	0.06	(0.23)	0.10	(0.30)	1.85 × 10 ⁻¹
downstream 0:1 LIM± ¹	-3.49	0.00	(0.02)	-0.03	(0.16)	1.66 × 10 ⁻¹
downstream 0:1 CpGi ¹	-3.48	0.22	(0.47)	0.25	(0.49)	3.67 × 10 ⁻¹
downstream 0:100 MLTIC phase change ²	-3.47	0.12	(0.25)	0.06	(0.20)	3.07 × 10 ⁻²
upstream 10:0 GTIC ³ × upstream 10:0 Oct1 ³	3.46	0.92	(0.26)	1.00	(0.00)	0
upstream 9:8 Sp1 ³	-3.45	0.20	(0.40)	0.10	(0.30)	2.67 × 10 ⁻²
upstream 3:2 AP1 ¹ × downstream 0:100 MLTIC phase change ²	-3.44	0.78	(2.91)	0.03	(0.16)	0
upstream 10:5 LINE_L1 ²	-3.43	5.05	(8.09)	5.06	(8.30)	4.97 × 10 ⁻¹
upstream 10:5 Alu± ² × upstream 10:0 CP1 ³	-3.42	44.66	(129.92)	2.10	(13.28)	0
upstream 100:10 L1P± ²	-3.41	230.89	(832.85)	61.10	(160.04)	3.76 × 10 ⁻⁸
upstream 90:80 CpGi ^{1,10}	-3.4	0.35	(0.83)	0.28	(0.64)	2.33 × 10 ⁻¹
upstream 6:5 AP2 ³ × upstream 3:2 Pit1 ³	-3.39	0.09	(0.28)	0.00	(0.00)	0
upstream 100:10 L1MB± ¹	-3.38	0.14	(3.76)	-0.51	(3.60)	1.35 × 10 ⁻¹
downstream 10:100 LTR_ERV1 ¹	-3.37	6.24	(7.74)	6.30	(7.51)	4.80 × 10 ⁻¹
downstream 10:100 FRAM± ² × upstream 8:7 SIF ³	-3.36	18.57	(67.07)	0.07	(0.36)	0
upstream 4:3 ETFA ¹	3.35	0.06	(0.24)	0.10	(0.30)	1.96 × 10 ⁻¹
upstream 6:5 PU1 ¹	3.34	0.89	(1.05)	1.10	(1.19)	1.34 × 10 ⁻¹
downstream 0:5 LIMC± ²	-3.33	53.61	(230.70)	98.35	(454.18)	2.71 × 10 ⁻¹
upstream 1:0 L1MA ¹	-3.32	0.01	(0.12)	0.00	(0.00)	0
upstream 4:3 NFUE5 ³ × upstream 2:1 Pit1 ³	-3.31	0.10	(0.30)	0.00	(0.00)	0
upstream 2:1 NFIII ¹ × upstream 10:9 E4F1 ³	-3.3	0.36	(1.09)	0.00	(0.00)	0
ditan10kup	-3.29	23.10	(54.47)	15.50	(23.28)	2.46 × 10 ⁻²
upstream 2:0 NFkB ³	3.28	0.18	(0.38)	0.13	(0.33)	1.64 × 10 ⁻¹
upstream 10:0 IgPE2 ¹	3.27	0.20	(0.46)	0.25	(0.49)	2.73 × 10 ⁻¹
upstream 9:8 GATA1 ³ × upstream 2:0 NFkB ³	-3.26	0.08	(0.27)	0.00	(0.00)	0
upstream 9:8 NFUE5 ¹ × upstream 6:5 Oct1 ¹	-3.25	0.18	(0.64)	0.00	(0.00)	0
downstream 5:10 AluY ¹	3.24	0.37	(0.69)	0.50	(0.75)	1.44 × 10 ⁻¹
upstream 4:3 PU1 ¹	3.23	0.88	(1.04)	1.13	(1.20)	1.09 × 10 ⁻¹
upstream 10:5 LTR_MaLR± ² × upstream 1:0 MLTF ³	-3.22	68.32	(203.70)	0.08	(0.51)	0
upstream 2:1 E4TF1 ³ × upstream 10:0 NFUE5 ³	-3.21	0.07	(0.25)	0.00	(0.00)	0
upstream 10:5 LIM3 ¹	3.2	0.01	(0.14)	0.08	(0.47)	1.96 × 10 ⁻¹
upstream 10:9 E4F1 ³ × upstream 3:2 TFIID ³	-3.19	0.11	(0.31)	0.00	(0.00)	0
upstream 100:10 MIR± ¹	3.18	0.10	(2.33)	0.31	(3.55)	3.63 × 10 ⁻¹
upstream 9:8 GATA1 ¹	3.17	0.68	(0.89)	0.78	(1.07)	2.88 × 10 ⁻¹
upstream 10:9 SIF ¹	-3.16	0.27	(0.65)	0.28	(0.55)	4.59 × 10 ⁻¹
upstream 100:10 HAL1± ²	-3.15	221.71	(473.89)	119.00	(233.60)	4.63 × 10 ⁻³
upstream 100:10 LTR_ERVL ²	3.14	1.06	(1.45)	1.89	(2.96)	4.46 × 10 ⁻²
upstream 2:0 LINE_L2 ¹ × upstream 6:5 Oct1 ³	-3.13	0.13	(0.47)	0.00	(0.00)	0
upstream 9:8 APF ¹	-3.12	2.42	(1.99)	1.65	(1.48)	1.18 × 10 ⁻³
downstream 0:2 AluY± ¹	-3.11	0.01	(0.37)	-0.08	(0.27)	3.23 × 10 ⁻²
upstream 10:5 DNA_AcHobo ²	3.1	0.06	(0.51)	0.22	(1.24)	2.09 × 10 ⁻¹
upstream 3:2 SIF ³ × upstream 5:0 NFkB ³	-3.09	0.08	(0.27)	0.00	(0.00)	0
upstream 100:10 MIR3± ²	-3.08	71.24	(118.59)	35.53	(72.54)	1.95 × 10 ⁻³
downstream 5:10 L1MB± ²	-3.07	60.96	(281.86)	84.80	(423.47)	3.64 × 10 ⁻¹
upstream 10:0 IgPE2 ³	3.06	0.18	(0.38)	0.23	(0.42)	2.59 × 10 ⁻¹

downstream 10:100 LINE_CR1 ¹ × upstream 3:2 Pit1 ³	-3.05	0.58	(1.31)	0.10	(0.30)	1.47 × 10 ⁻¹²
upstream 2:0 NFkB ¹ × upstream 5:4 TFIID ³	-3.04	0.12	(0.37)	0.00	(0.00)	0
upstream 1:0 SRF ¹	-3.03	0.01	(0.12)	0.00	(0.00)	0
upstream 10:5 LINE_L1 ¹ × downstream 0:100 MLT1C phase change ²	-3.02	0.61	(2.34)	0.00	(0.00)	0
upstream 5:0 CpGi ²	3.01	91.87	(92.76)	126.55	(121.01)	4.07 × 10 ⁻²
upstream 4:3 SIF ¹	-3	0.27	(0.68)	0.13	(0.33)	5.44 × 10 ⁻³
upstream 100:10 LINE_CR1± ¹	-2.99	0.07	(1.61)	-0.11	(1.11)	1.52 × 10 ⁻¹
downstream 0:2 LIMB± ¹	-2.98	0.00	(0.26)	-0.05	(0.22)	8.95 × 10 ⁻²
downstream 5:10 DNA_AcHobo± ¹	2.97	0.00	(0.22)	0.03	(0.16)	1.73 × 10 ⁻¹
downstream 0:2 LINE_L2 ¹ × upstream 8:7 ICSBP ¹	-2.96	0.32	(1.07)	0.00	(0.00)	0
upstream 9:8 SIF ¹ × upstream 1:0 ATF ³	-2.95	0.15	(0.49)	0.00	(0.00)	0
upstream 8:7 NFkB ³	-2.94	0.07	(0.26)	0.05	(0.22)	2.54 × 10 ⁻¹
upstream 4:3 IgPE2 ¹	2.93	0.02	(0.14)	0.03	(0.16)	4.22 × 10 ⁻¹
Motif ₇ ⁹	-2.92	0.00	(0.17)	-0.05	(0.22)	7.52 × 10 ⁻²
upstream 2:0 ETFA ³ × downstream 0:100 MIR phase change ²	-2.91	0.06	(0.16)	0.00	(0.00)	0
upstream 9:8 NFuE5 ¹	-2.9	0.34	(0.63)	0.25	(0.54)	1.49 × 10 ⁻¹
downstream 10:100 LTR_ERV ¹	-2.89	0.03	(0.24)	0.03	(0.16)	3.57 × 10 ⁻¹
upstream 6:5 AP2 ¹	2.88	0.38	(0.79)	0.65	(1.00)	5.07 × 10 ⁻²
upstream 5:4 TFIID ¹ × upstream 2:0 NFkB ³	-2.87	0.20	(0.72)	0.00	(0.00)	0
downstream 10:100 FRAM± ² × upstream 5:0 GATA1 ¹	-2.86	235.74	(440.52)	35.12	(90.45)	0
downstream 10:100 LINE_CR1 ² × upstream 100:10 MIR3 ¹	-2.85	0.77	(1.91)	0.06	(0.19)	0
upstream 4:3 BPVE2 ³ × downstream 0:100 MLT1C phase change ²	-2.84	0.04	(0.16)	0.00	(0.00)	0
upstream 60:50 CpGi ^{1,10}	2.83	0.35	(0.80)	0.53	(1.13)	1.71 × 10 ⁻¹
downstream 5:10 MIR3 ¹	2.82	0.14	(0.41)	0.20	(0.41)	1.88 × 10 ⁻¹
upstream 5:0 LIPA± ¹	2.81	0.01	(0.35)	0.05	(0.22)	1.12 × 10 ⁻¹
upstream 100:10 LTR_ERV1 ²	2.8	2.85	(3.93)	3.68	(6.61)	2.19 × 10 ⁻¹
upstream 10:9 NFuE5 ¹ × upstream 10:9 Oct1 ¹	-2.79	0.17	(2.41)	0.00	(0.00)	0
upstream 10:5 DNA_MER1.type ² × upstream 5:4 Pit1 ³	-2.78	0.28	(1.09)	0.00	(0.00)	0
downstream 10:100 AluJ± ¹	2.77	-0.08	(2.42)	0.05	(2.65)	3.78 × 10 ⁻¹
downstream 10:100 LINE_CR1 ¹ × upstream 9:8 TFIID ³	-2.76	0.84	(1.50)	0.10	(0.30)	0
upstream 2:0 SINE_MIR ² × upstream 10:9 BPVE2 ³	-2.75	1.03	(3.37)	0.00	(0.00)	0
upstream 9:8 TFIID ³ × upstream 2:0 ICP4 ³	-2.74	0.08	(0.27)	0.00	(0.00)	0
upstream 2:1 BPVE2 ¹ × upstream 6:5 Pit1 ³	-2.73	0.21	(0.52)	0.00	(0.00)	0
exon CpGi ²	2.72	161.59	(186.01)	272.77	(250.19)	4.22 × 10 ⁻³
upstream 100:10 FAM ² × upstream 6:5 Pit1 ³	-2.71	0.02	(0.06)	0.00	(0.00)	0
downstream 5:10 AluS ² × upstream 1:0 MLTF ³	-2.7	3.47	(5.11)	0.34	(0.92)	0
upstream 2:0 PEA2 ¹	2.69	0.07	(0.28)	0.08	(0.27)	4.77 × 10 ⁻¹
upstream 3:2 ICP4 ³	2.68	0.05	(0.22)	0.03	(0.16)	1.59 × 10 ⁻¹
upstream 100:10 SINE_MIR± ¹	2.67	0.10	(2.22)	0.33	(3.43)	3.36 × 10 ⁻¹
upstream 10:5 FAM± ¹	-2.66	0.00	(0.13)	-0.03	(0.16)	1.61 × 10 ⁻¹
upstream 10:5 LIPB ²	-2.65	0.15	(1.51)	0.00	(0.00)	0
upstream 5:0 LTR_ERV1± ² × upstream 4:3 TFIID ³	-2.64	58.25	(241.18)	1.42	(8.07)	0
upstream 100:10 CpGi ¹ × upstream 100:10 AluS ²	-2.63	37.02	(53.50)	12.01	(11.29)	0
downstream 0:5 SINE_MIR ¹	2.62	0.86	(1.21)	0.65	(0.83)	6.03 × 10 ⁻²
upstream 2:0 Sp1 ³	2.61	0.62	(0.49)	0.73	(0.45)	7.79 × 10 ⁻²
upstream 8:7 AP1 ³ × upstream 7:6 NF1 ³	-2.6	0.10	(0.29)	0.00	(0.00)	0
upstream 8:7 GT2B ¹ × upstream 5:4 NFuE5 ³	-2.59	0.13	(0.45)	0.00	(0.00)	0
downstream 0:1 LINE_CR1 ²	2.58	0.19	(2.17)	0.47	(2.97)	2.78 × 10 ⁻¹
downstream 0:5 AluS ¹ × upstream 3:2 TFIID ¹	-2.57	1.83	(3.74)	0.28	(0.82)	4.77 × 10 ⁻¹⁵
upstream 100:10 AluJ ² × upstream 10:9 NFuE5 ³	-2.56	1.11	(2.27)	0.12	(0.37)	0
upstream 2:0 NFuE3 ³	-2.55	0.11	(0.31)	0.10	(0.30)	4.15 × 10 ⁻¹
upstream 10:5 DNA_MER1.type ¹ × upstream 5:4 Pit1 ¹	-2.54	0.26	(1.08)	0.00	(0.00)	0
upstream 1:0 PU1 ¹	-2.53	1.00	(1.09)	0.73	(0.85)	2.39 × 10 ⁻²
downstream 0:5 FLAM± ¹	-2.52	0.01	(0.38)	-0.08	(0.35)	7.23 × 10 ⁻²
upstream 100:10 CpGi ¹ × upstream 100:10 SINE_Alu ²	-2.51	60.28	(85.57)	22.82	(21.91)	1.48 × 10 ⁻¹³
upstream 10:5 Alu ¹	-2.5	0.02	(0.16)	0.00	(0.00)	0
downstream 10:100 CpGi ³ × upstream 2:0 PEA1 ¹	-2.49	0.08	(0.32)	0.00	(0.00)	0
upstream 2:0 NFuE3 ¹	-2.48	0.12	(0.38)	0.10	(0.30)	3.18 × 10 ⁻¹
upstream 8:7 SRF ¹	2.47	0.01	(0.12)	0.03	(0.16)	3.27 × 10 ⁻¹
upstream 7:6 APF ³	2.46	0.83	(0.37)	0.88	(0.33)	2.22 × 10 ⁻¹
upstream 1:0 MLTF ¹	-2.45	1.23	(1.32)	0.63	(0.90)	6.82 × 10 ⁻⁵
upstream 10:0 CpGi ^{1,10}	2.44	0.38	(0.86)	0.63	(0.95)	5.63 × 10 ⁻²
downstream 10:100 DNA_Mariner ¹ × upstream 9:8 Pit1 ¹	-2.43	0.33	(1.34)	0.00	(0.00)	0
downstream 0:5 LTR_MaLR ¹ × upstream 2:0 BPVE2 ¹	-2.42	0.37	(1.23)	0.00	(0.00)	0
upstream 100:10 DNA_Tc2 ²	2.41	0.04	(0.13)	0.11	(0.43)	1.47 × 10 ⁻¹
upstream 100:10 AluJ ² × upstream 10:9 E4F1 ¹	-2.4	0.72	(2.14)	0.04	(0.14)	0
upstream 7:6 NF1 ¹ × upstream 7:6 AP1 ³	-2.39	0.11	(0.36)	0.00	(0.00)	0
upstream 100:10 CpGi ² × upstream 100:10 AluS ²	-2.38	601.34	(769.54)	185.70	(151.99)	0
upstream 5:4 E4F1 ³ × upstream 1:0 MLTF ³	-2.37	0.12	(0.32)	0.00	(0.00)	0
upstream 4:3 TFIID ³ × downstream 0:100 MLT1C phase change ²	-2.36	0.25	(0.72)	0.00	(0.00)	0
downstream 10:100 LINE_CR1 ² × upstream 100:10 DNA_MER1.type ¹	-2.35	1.70	(3.44)	0.31	(0.63)	0
upstream 10:5 LTR_MaLR± ² × upstream 1:0 MLTF ¹	-2.34	129.34	(473.41)	0.08	(0.51)	0
upstream 4:3 AP1 ¹ × upstream 5:4 E4F1 ³	-2.33	0.33	(0.91)	0.00	(0.00)	0
upstream 9:8 ICSBP ¹	2.32	1.50	(1.21)	1.35	(1.05)	1.89 × 10 ⁻¹
upstream 2:0 ETFA ¹ × upstream 10:9 MLTF ³	-2.31	0.10	(0.34)	0.00	(0.00)	0
upstream 10:5 LIPA ¹	-2.3	0.12	(0.45)	0.13	(0.46)	4.87 × 10 ⁻¹
upstream 10:5 FRAM± ²	2.29	8.63	(36.14)	7.60	(33.59)	4.25 × 10 ⁻¹
upstream 100:10 DNA_Tc2± ¹	-2.28	0.00	(0.63)	0.07	(0.77)	2.86 × 10 ⁻¹
upstream 1:0 NFuE5 ³	2.27	0.20	(0.40)	0.15	(0.36)	1.96 × 10 ⁻¹
upstream 2:0 MIR ² × upstream 10:9 BPVE2 ³	-2.26	0.88	(3.06)	0.00	(0.00)	0

upstream 100:10 MIR3 $\pm^2$ $\times$ upstream 1:0 MLTF ¹	-2.25	87.83	(235.51)	11.73	(37.57)	3.33×10^{-16}
upstream 100:10 DNA_MER1_type ²	2.24	1.12	(0.84)	1.23	(0.97)	2.45×10^{-1}
downstream 10:100 FAM ¹ $\times$ upstream 4:3 TFIIID ¹	-2.23	0.30	(1.03)	0.00	(0.00)	0
upstream 10:5 LTR_MaLR $\pm^2$ $\times$ upstream 2:0 BPVE2 ³	-2.22	62.93	(194.19)	0.00	(0.00)	0
downstream 10:100 LINE_CRI ² $\times$ upstream 100:10 SINE_MIR ²	-2.21	0.60	(1.19)	0.07	(0.17)	0
upstream 2:0 DNA_MER1_type ¹ $\times$ upstream 5:0 Pit1 ¹	-2.2	0.45	(2.01)	0.00	(0.00)	0
downstream 0:2 LINE_CRI ²	2.19	0.20	(1.82)	0.83	(5.23)	2.31×10^{-1}
upstream 10:100 LINE_CRI ² $\times$ upstream 9:8 APF ³	-2.18	0.20	(0.34)	0.04	(0.10)	2.76×10^{-13}
downstream 10:100 LINE_CRI ² $\times$ downstream 5:10 SINE_MIR ¹	-2.17	0.26	(0.72)	0.03	(0.07)	0
intron LIP ¹	-2.16	0.13	(0.61)	0.03	(0.16)	1.61×10^{-4}
upstream 8:7 GT2B ³ $\times$ upstream 2:0 NFkB ³	-2.15	0.06	(0.24)	0.00	(0.00)	0
upstream 5:0 LIMA $\pm^2$	-2.14	30.55	(188.23)	0.00	(0.00)	0
downstream 0:5 DNA_MER2_type $\pm^2$	-2.13	40.07	(209.05)	7.73	(48.86)	1.02×10^{-4}
exon LTR_ERV1 ¹	-2.12	0.01	(0.16)	0.00	(0.00)	0
upstream 5:0 AluY ² $\times$ upstream 9:8 Pit1 ³	-2.11	0.75	(2.43)	0.00	(0.00)	0
downstream 10:100 FRAM $\pm^2$ $\times$ upstream 5:0 TFIIID ¹	-2.1	411.51	(770.95)	93.55	(208.60)	4.38×10^{-12}
intron LINE_L1 $\pm^1$	-2.09	-1.28	(3.60)	-1.64	(3.66)	2.68×10^{-1}
downstream 0:5 AluJ ¹ $\times$ upstream 4:3 GTIIIC ³	-2.08	0.17	(0.59)	0.00	(0.00)	0
downstream 10:100 LTR_MaLR ¹	-2.07	8.71	(7.00)	7.75	(5.15)	1.26×10^{-1}
downstream 0:2 MIR ¹ $\times$ upstream 1:0 ATF ³	-2.06	0.14	(0.45)	0.00	(0.00)	0
upstream 5:0 DNA_AcHobo ¹	2.05	0.04	(0.24)	0.03	(0.16)	3.17×10^{-1}
upstream 100:10 Other ¹ $\times$ upstream 100:0 MIR phase change ²	-2.04	0.07	(0.23)	0.00	(0.00)	0
intron MIR $\pm^2$ $\times$ upstream 6:5 APF ³	-2.03	36.15	(112.42)	0.72	(1.16)	0
upstream 100:10 Other ¹ $\times$ upstream 5:4 ICSBP ³	-2.02	0.14	(0.48)	0.00	(0.00)	0
downstream 0:2 DNA ²	-2.01	0.06	(1.08)	0.00	(0.00)	0
upstream 2:1 BPVE2 ¹ $\times$ upstream 4:3 ATF ³	-2	0.18	(0.49)	0.00	(0.00)	0
upstream 7:6 NF1 ¹ $\times$ upstream 2:0 ATF ³	-1.99	0.09	(0.33)	0.00	(0.00)	0
upstream 5:0 DNA_MER2_type ²	-1.98	0.60	(2.74)	0.36	(2.27)	2.56×10^{-1}
upstream 4:3 Pit1 ¹	-1.97	0.70	(1.20)	0.50	(0.88)	7.67×10^{-2}
downstream 10:100 LIM3 $\pm^1$	1.96	0.00	(0.71)	0.13	(1.22)	2.66×10^{-1}
upstream 2:0 NFue4 ¹ $\times$ upstream 5:0 GATA1 ³	-1.95	0.07	(0.28)	0.00	(0.00)	0
upstream 5:0 E2F ¹	-1.94	0.09	(0.31)	0.10	(0.30)	4.17×10^{-1}
downstream 0:2 SINE_MIR ¹ $\times$ upstream 1:0 ATF ³	-1.93	0.17	(0.51)	0.00	(0.00)	0
upstream 8:7 SIF ³	-1.92	0.21	(0.41)	0.13	(0.33)	5.63×10^{-2}
upstream 5:4 PEA1 ¹ $\times$ upstream 3:2 APF ³	-1.91	0.09	(0.31)	0.00	(0.00)	0
downstream 10:100 AluY ² $\times$ downstream 0:2 LINE_L2 ¹	-1.9	0.39	(1.33)	0.01	(0.05)	0
downstream 10:100 Alu $\pm^1$	1.89	0.02	(0.58)	0.00	(0.55)	4.10×10^{-1}
upstream 5:0 AluY ² $\times$ upstream 6:5 PU1 ³	-1.88	1.03	(2.86)	0.00	(0.00)	0
upstream 100:10 FRAM ¹	1.87	1.09	(1.29)	0.88	(1.28)	1.56×10^{-1}
downstream 0:2 SINE_MIR ² $\times$ upstream 1:0 ATF ³	-1.86	1.08	(3.30)	0.00	(0.00)	0
upstream 3:2 TFIIID ¹	-1.85	1.14	(1.29)	0.85	(1.12)	5.99×10^{-2}
upstream 10:9 ICP4 ³	1.84	0.05	(0.21)	0.08	(0.27)	2.70×10^{-1}
upstream 5:0 L1PA ¹	1.83	0.09	(0.37)	0.10	(0.44)	4.59×10^{-1}
downstream 10:100 LIMC ²	-1.82	1.41	(1.55)	1.43	(1.64)	4.69×10^{-1}
upstream 9:8 TFIIID ³ $\times$ upstream 8:7 Sp1 ³	-1.81	0.10	(0.30)	0.00	(0.00)	0
intron L1PB ¹	1.8	0.26	(1.11)	0.45	(2.25)	2.98×10^{-1}
upstream 10:5 SINE_MIR ² $\times$ upstream 5:0 AluS ¹	-1.79	2.08	(4.66)	0.23	(0.63)	0
upstream 5:0 AluS ² $\times$ upstream 2:0 AP2 ³	-1.78	5.68	(9.31)	1.28	(2.82)	2.27×10^{-12}
exon LIME ²	1.77	0.23	(3.77)	3.17	(20.06)	1.83×10^{-1}
upstream 10:5 FAM ²	1.76	0.02	(0.20)	0.03	(0.22)	3.89×10^{-1}
upstream 1:0 API ¹ $\times$ upstream 10:9 NFue5 ³	-1.75	0.40	(0.94)	0.03	(0.16)	0
upstream 10:5 SINE_MIR $\pm^2$	1.74	63.22	(108.32)	53.71	(117.12)	3.08×10^{-1}
upstream 4:3 AP2 ³	1.73	0.26	(0.44)	0.38	(0.49)	8.00×10^{-2}
upstream 100:10 AluJ ² $\times$ upstream 70:60 CpGi ^{1,11}	-1.72	7.82	(11.89)	2.40	(3.04)	3.97×10^{-14}
upstream 100:10 AluY $\pm^1$	-1.71	0.29	(2.38)	0.09	(1.98)	2.70×10^{-1}
downstream 10:100 LINE_CRI ¹ $\times$ upstream 10:5 AluS $\pm^2$	-1.7	249.42	(708.04)	23.28	(81.55)	0
upstream 2:0 BPVE2 ¹ $\times$ upstream 5:0 NFue5 ¹	-1.69	1.57	(2.87)	0.28	(0.55)	0
upstream 5:0 DNA_Tc2 ¹	1.68	0.01	(0.13)	0.05	(0.32)	2.13×10^{-1}
upstream 2:0 ETFA ³ $\times$ downstream 0:100 MIR phase change ¹	-1.67	1.16	(3.68)	0.00	(0.00)	0
upstream 3:2 BPVE2 ¹	1.66	0.48	(0.71)	0.58	(0.84)	2.54×10^{-1}
downstream 0:5 DNA_Mariner $\pm^1$	1.65	0.00	(0.18)	0.00	(0.23)	4.81×10^{-1}
upstream 100:10 DNA_T2_type $\pm^2$	-1.64	12.81	(88.09)	0.00	(0.00)	0
downstream 0:1 LIME ¹	1.63	0.03	(0.21)	0.08	(0.35)	2.27×10^{-1}
upstream 100:10 DNA_Tip100 ²	-1.62	0.12	(0.30)	0.10	(0.35)	3.51×10^{-1}
upstream 5:0 Pit1 ¹ $\times$ downstream 0:100 MLT1C phase change ²	-1.61	0.43	(1.24)	0.04	(0.17)	0
upstream 10:5 AluJ ² $\times$ upstream 2:0 BPVE2 ³	-1.6	1.27	(2.41)	0.02	(0.13)	0
exon SINE_Alus $\pm^1$	-1.59	0.00	(0.43)	-0.05	(0.22)	7.73×10^{-2}
upstream 2:0 LIM2 ¹	-1.58	0.01	(0.11)	0.03	(0.16)	2.52×10^{-1}
intron DNA_MER2_type ²	-1.57	40.83	(121.55)	36.63	(89.65)	3.86×10^{-1}
upstream 5:0 NFue1 ³	1.56	0.20	(0.40)	0.25	(0.44)	2.55×10^{-1}
downstream 10:100 FLAM ²	1.55	0.34	(0.32)	0.22	(0.23)	1.57×10^{-3}
upstream 5:0 LIME ¹ $\times$ upstream 10:0 NF1 ¹	-1.54	0.38	(1.64)	0.00	(0.00)	0
upstream 5:0 AluY ¹ $\times$ upstream 100:0 MIR phase change ²	-1.53	0.14	(0.29)	0.01	(0.07)	7.22×10^{-15}
upstream 5:4 APF ³	1.52	0.84	(0.37)	0.80	(0.41)	2.95×10^{-1}
upstream 10:5 LTR_MaLR ¹ $\times$ upstream 2:0 BPVE2 ³	-1.51	0.31	(0.84)	0.00	(0.00)	0
intron MIR $\pm^2$ $\times$ upstream 5:0 AP2 ³	-1.5	33.71	(108.04)	0.77	(1.32)	0
upstream 2:1 COUP ³ $\times$ upstream 2:0 NFue4 ³	-1.49	0.07	(0.25)	0.00	(0.00)	0
intron MIR $\pm^2$ $\times$ upstream 7:6 NFIII ³	-1.48	34.33	(109.61)	0.78	(1.20)	0
downstream 0:5 AluJ ² $\times$ upstream 5:4 SIF ³	-1.47	0.88	(3.00)	0.00	(0.00)	0
upstream 2:0 AluS ² $\times$ upstream 1:0 Pit1 ³	-1.46	2.32	(7.10)	0.00	(0.00)	0

upstream 6:5 NFue3 ¹	1.45	0.08	(0.29)	0.13	(0.33)	1.87×10^{-1}
downstream 0:5 SINE _{Alu} ¹ × upstream 5:4 SIF ³	-1.44	0.78	(2.14)	0.05	(0.22)	0
upstream 5:0 AluY ¹ × upstream 2:0 PU1 ³	-1.43	0.28	(0.61)	0.03	(0.16)	8.00×10^{-13}
downstream 0:2 SINE _{MIR} ± ¹	-1.42	0.00	(0.64)	0.00	(0.51)	4.88×10^{-1}
upstream 10:5 LIMD ¹	-1.41	0.08	(0.48)	0.00	(0.00)	0
intron MIR± ² × upstream 9:04:8.99 nucleosome potential ^{sd}	-1.4	17.79	(52.21)	1.61	(8.15)	7.77×10^{-16}
upstream 100:10 AluS ² × upstream 10:9 NFue5 ³	-1.39	3.02	(6.15)	0.41	(1.13)	0
upstream 100:10 AluS ¹ × upstream 100:10 MIR3± ²	-1.38	2450.40	(5083.01)	449.61	(1068.36)	7.55×10^{-15}
downstream 0:1 AluS ² × upstream 4:3 PU1 ³	-1.37	3.83	(11.21)	0.00	(0.00)	0
upstream 5:0 CpGi ¹ × upstream 2:0 AluJ ¹	-1.36	0.12	(0.48)	0.00	(0.00)	0
upstream 2:0 AluJ ² × upstream 10:9 PU1 ³	-1.35	1.57	(4.94)	0.00	(0.00)	0
exon MIR3 ²	-1.34	0.20	(1.75)	0.00	(0.00)	0
downstream 0:5 AluJ± ² × upstream 10:0 NFue4 ³	-1.33	36.43	(116.04)	0.00	(0.00)	0
downstream 10:100 CpGi ¹	1.32	21.32	(16.93)	22.00	(14.76)	3.87×10^{-1}
downstream 10:100 DNA _{Mariner} ¹ × upstream 100:10 LTR _{ERV1} ¹	-1.31	2.71	(8.90)	0.00	(0.00)	0
downstream 0:5 AluJ ² × upstream 7:6 GTIIC ¹	-1.3	1.01	(3.61)	0.00	(0.00)	0
upstream 9:8 COUP ¹	1.29	1.97	(1.44)	1.90	(1.68)	3.94×10^{-1}
upstream 10:5 LIMD ²	-1.28	0.28	(1.95)	0.00	(0.00)	0
upstream 10:9 NFue5 ¹ × upstream 1:0 Oct1 ³	-1.27	0.11	(0.39)	0.00	(0.00)	0
upstream 2:1 NFkB ¹	-1.26	0.09	(0.30)	0.05	(0.22)	1.54×10^{-1}
upstream 100:10 MIR ¹ × upstream 100:10 SINE _{Alu} ²	-1.25	220.09	(225.99)	78.31	(77.03)	1.77×10^{-14}
upstream 10:5 AluS ² × upstream 2:1 BPVE2 ³	-1.24	2.29	(4.66)	0.15	(0.93)	0
upstream 5:0 CEBP ³	1.23	0.16	(0.37)	0.20	(0.41)	2.63×10^{-1}
downstream 10:100 LINE _{CR1} ² × upstream 10:0 AP1 ¹	-1.22	4.29	(6.65)	0.96	(1.61)	3.33×10^{-16}
upstream 100:10 AluS ¹ × upstream 3:2 COUP ³	-1.21	30.04	(26.21)	12.90	(11.02)	2.74×10^{-12}
upstream 10:9 NFue5 ¹	-1.2	0.34	(0.64)	0.20	(0.56)	6.81×10^{-2}
exon LTR _{ERV1} ²	-1.19	0.44	(5.96)	0.00	(0.00)	0
upstream 10:5 AluS ¹ × upstream 2:1 BPVE2 ³	-1.18	0.83	(1.71)	0.05	(0.32)	0
downstream 5:10 LIM3 ²	-1.17	0.03	(0.68)	0.00	(0.00)	2.10×10^{-12}
downstream 0:2 AluS ¹ × upstream 1:0 BPVE2 ¹	-1.16	0.27	(0.84)	0.00	(0.00)	0
upstream 2:0 LIMC ¹	1.15	0.07	(0.34)	0.08	(0.35)	4.45×10^{-1}
downstream 0:1 SINE _{MIR} ¹ × upstream 3:2 AP1 ¹	-1.14	0.29	(1.00)	0.00	(0.00)	0
upstream 10:5 SINE _{MIR} ² × upstream 2:0 AluS ²	-1.13	9.05	(25.90)	0.00	(0.00)	0
downstream 0:1 SINE _{Alu} ² × upstream 7:6 GTIIC ¹	-1.12	3.58	(13.55)	0.00	(0.00)	0
upstream 1:0 SINE _{Alu} ¹ × upstream 7:6 Oct1 ³	-1.11	0.16	(0.47)	0.00	(0.00)	0
upstream 5:0 SINE _{Alu} ² × upstream 8:7 GT2B ¹	-1.1	7.19	(17.39)	1.40	(3.55)	5.11×10^{-13}
downstream 0:5 LIMB ²	-1.09	0.94	(4.69)	0.45	(1.79)	4.94×10^{-2}
upstream 100:0 CpGi ^{2,10}	-1.08	0.18	(0.15)	0.17	(0.12)	3.12×10^{-1}
upstream 100:10 SINE _{MIR} ¹ × upstream 100:0 Alu phase change ¹	-1.07	447.93	(440.90)	157.03	(154.06)	8.10×10^{-15}
downstream 10:100 LINE _{CR1} ² × upstream 5:0 AluS ¹	-1.06	0.39	(0.90)	0.04	(0.13)	0
upstream 2:0 AluS ² × upstream 5:0 ETFA ³	-1.05	2.19	(7.07)	0.00	(0.00)	0
downstream 10:100 AluY ¹ × upstream 100:10 AluS ¹	-1.04	291.62	(389.69)	97.25	(119.91)	7.77×10^{-13}
downstream 10:100 LINE _{CR1} ² × upstream 3:2 TFIIID ¹	-1.03	0.27	(0.68)	0.01	(0.05)	0
upstream 5:0 AluS ² × m3upIndicator	-1.02	6.98	(10.28)	1.40	(3.52)	1.48×10^{-12}
upstream 6:5 GATA1 ¹	-1.01	0.68	(0.88)	0.58	(0.78)	2.13×10^{-1}
upstream 100:10 LIM3± ²	-1	50.39	(302.85)	96.83	(305.95)	1.75×10^{-1}
upstream 7:6 Sp1 ¹	-0.99	0.35	(1.14)	0.50	(0.96)	1.66×10^{-1}
upstream 5:0 SINE _{Alu} ² × upstream 5:0 BPVE2 ¹	0.98	43.86	(59.14)	12.93	(19.79)	2.28×10^{-12}
upstream 3:2 Pit1 ¹ × upstream 10:9 NFue5 ³	-0.97	0.17	(0.63)	0.00	(0.00)	0
upstream 4:3 AR ¹	-0.96	12.17	(4.69)	10.98	(4.59)	5.66×10^{-2}
upstream 2:0 AluS ² × upstream 10:9 COUP ¹	-0.95	17.48	(33.29)	0.30	(1.91)	0
downstream 10:100 LINE _{CR1} ² × upstream 5:0 SINE _{Alu} ²	-0.94	3.49	(7.39)	0.29	(0.78)	0
upstream 5:0 SINE _{Alu} ¹ × upstream 5:0 AP1 ¹	0.93	33.65	(40.19)	10.73	(15.01)	4.43×10^{-12}
upstream 2:0 AluS± ² × m1intronIndicator	-0.92	76.80	(162.84)	4.68	(29.57)	0
downstream 10:100 AluJ ²	0.91	3.43	(2.48)	2.20	(1.31)	3.56×10^{-7}
downstream 5:10 LIMA ²	-0.9	0.85	(4.96)	0.58	(2.57)	2.61×10^{-1}
upstream 8:7 BPVE2 ¹ × upstream 2:0 E4TF1 ³	-0.89	0.09	(0.36)	0.00	(0.00)	0
upstream 1:0 NFIII ³	0.88	0.70	(0.46)	0.65	(0.48)	2.43×10^{-1}
upstream 10:5 GC ² × upstream 100:10 AluS ¹	-0.87	1585.80	(1238.67)	795.33	(490.41)	9.69×10^{-13}
upstream 100:10 AluS ² × upstream 3:2 AP1 ³	-0.86	8.16	(7.16)	2.97	(3.15)	5.57×10^{-13}
upstream 5:0 LINE _{L1} ²	-0.85	7.68	(13.27)	5.61	(10.69)	1.17×10^{-1}
upstream 9:8 CP1 ¹	-0.84	0.05	(0.25)	0.00	(0.00)	0
upstream 10:5 LIMA± ¹	-0.83	0.00	(0.49)	-0.05	(0.45)	2.34×10^{-1}
downstream 10:100 AluS± ¹	-0.82	-0.08	(2.12)	0.46	(2.72)	1.10×10^{-1}
downstream 10:100 SINE _{Alu} ² × upstream 10:0 AP1 ¹	0.81	290.85	(240.38)	144.13	(86.25)	1.96×10^{-13}
upstream 10:5 FLAM ¹	0.8	0.17	(0.44)	0.10	(0.30)	8.06×10^{-2}
upstream 5:0 AluS ¹ × upstream 9:8 COUP ³	0.79	1.64	(1.98)	0.50	(0.75)	4.92×10^{-12}
downstream 10:100 AluJ ² × downstream 5:10 SINE _{Alu} ²	0.78	38.62	(53.95)	12.50	(15.75)	3.94×10^{-13}
upstream 5:0 SINE _{Alu} ² × upstream 2:0 Sp1 ³	0.77	11.27	(15.08)	3.61	(5.46)	4.35×10^{-11}
downstream 0:5 AluS ¹ × upstream 2:1 BPVE2 ³	-0.76	0.67	(1.46)	0.05	(0.22)	0
upstream 100:0 MIR phase change ²	-0.75	0.41	(0.16)	0.37	(0.26)	1.74×10^{-1}
upstream 2:0 SINE _{Alu} ² × upstream 2:1 AP2 ¹	-0.74	4.12	(13.16)	0.00	(0.00)	0
downstream 0:1 MIR ¹ × upstream 1:0 AP1 ³	-0.73	0.09	(0.33)	0.00	(0.00)	0
upstream 5:0 AluS ¹ × upstream 8:7 SIF ³	-0.72	0.53	(1.46)	0.03	(0.16)	0
upstream 10:5 SINE _{MIR} ¹ × upstream 2:0 SINE _{Alu} ²	-0.71	11.65	(29.39)	0.66	(2.91)	0
upstream 5:0 NFue3 ¹	0.7	0.36	(0.64)	0.43	(0.59)	2.40×10^{-1}
upstream 5:0 SINE _{Alu} ² × upstream 9:8 COUP ³	0.69	14.50	(15.32)	4.48	(5.56)	3.46×10^{-14}
intron MIR± ² × upstream 90:80 CpGi ^{1,11}	-0.68	81.39	(319.80)	1.38	(3.50)	0
downstream 0:5 AluJ ¹ × upstream 50:40 CpGi ^{1,11}	-0.67	1.58	(3.89)	0.20	(0.65)	1.11×10^{-16}
upstream 5:0 DNA _{MER1} type± ²	-0.66	48.94	(128.50)	31.56	(80.74)	9.38×10^{-2}

upstream 100:10 SINE _{Alu} ¹ × upstream 2:1 BPVE2 ¹	-0.65	31.40	(59.03)	2.78	(8.41)	0
downstream 5:10 AluS ¹ × upstream 100:10 SINE _{Alu} ¹	-0.64	151.46	(229.53)	24.95	(33.88)	0
upstream 9:8 AP1 ³	0.63	0.84	(0.37)	0.80	(0.41)	2.92 × 10 ⁻¹
upstream 5:0 SINE _{Alu} ² × upstream 10:0 COUP ¹	0.62	353.25	(372.57)	115.04	(152.24)	2.27 × 10 ⁻¹²
upstream 1:0 AluS _± ² × upstream 2:1 NFII ¹	-0.61	102.61	(315.31)	0.00	(0.00)	0
downstream 5:10 AluS ¹ × downstream 0:1 AluS _± ²	-0.6	180.97	(537.94)	0.00	(0.00)	0
downstream 10:100 AluS ² × upstream 5:0 AluY ²	-0.59	24.05	(57.00)	2.15	(7.83)	0
upstream 10:5 AluJ ² × upstream 10:5 MIR _± ²	-0.58	118.71	(369.97)	8.33	(51.58)	0
downstream 0:1 MIR ¹ × upstream 2:0 AP1 ¹	-0.57	0.41	(1.49)	0.00	(0.00)	0
downstream 10:100 MIR3 _± ² × upstream 2:0 SINE _{Alu} ²	-0.56	939.36	(2652.77)	66.28	(285.18)	0
upstream 100:10 AluS ¹ × upstream 6:5 ICSBP ³	-0.55	27.43	(26.55)	11.55	(10.88)	1.55 × 10 ⁻¹¹
upstream 10:5 CpGi ¹ × upstream 5:0 AluS ²	0.54	36.71	(59.08)	7.97	(12.59)	0
upstream 5:0 SINE _{Alu} ² × upstream 100:0 L2 phase change ¹	0.53	82.44	(101.53)	25.81	(35.89)	1.75 × 10 ⁻¹²
downstream 10:100 FRAM ¹ × upstream 2:0 AluJ _± ²	-0.52	73.35	(256.02)	0.00	(0.00)	0
upstream 1:0 IgPE2 ¹	-0.51	0.02	(0.15)	0.00	(0.00)	0
downstream 5:10 AluS ² × downstream 0:1 AluS ²	-0.5	55.81	(160.17)	0.00	(0.00)	0
downstream 0:5 FLAM _± ² × upstream 2:0 ICSBP ¹	-0.49	43.41	(149.18)	0.14	(0.89)	0
upstream 8:7 CP1 ³	0.48	0.04	(0.20)	0.03	(0.16)	2.51 × 10 ⁻¹
upstream 1:0 AluS _± ² × upstream 6:5 COUP ³	-0.47	46.39	(113.64)	0.00	(0.00)	0
intron SINE _{MIR} _± ² × upstream 90:80 CpGi ^{1,11}	-0.46	77.89	(320.76)	1.47	(3.81)	0
downstream 0:5 AluS ² × upstream 2:1 BPVE2 ¹	-0.45	4.77	(11.64)	0.31	(1.35)	0
downstream 0:1 SINE _{Alu} _± ¹	0.44	0.04	(0.82)	0.00	(0.55)	3.43 × 10 ⁻¹
upstream 5:0 CpGi ² × upstream 1:0 SINE _{Alu} _± ²	-0.43	7072.20	(19530.74)	465.95	(2091.10)	0
downstream 5:10 AluS ² × upstream 2:1 AR ¹	-0.42	57.25	(66.33)	18.73	(26.75)	2.23 × 10 ⁻¹¹
upstream 100:10 SINE _{Alu} ² × upstream 2:1 BPVE2 ³	-0.41	6.19	(10.16)	0.75	(2.32)	0
downstream 5:10 AluS ² × upstream 2:0 AluJ ²	-0.4	20.65	(63.27)	0.00	(0.00)	0
upstream 2:0 SINE _{Alu} ² × upstream 10:9 GT2B ¹	-0.39	5.98	(17.47)	0.26	(1.62)	0
downstream 10:100 FLAM ¹ × downstream 5:10 AluS ²	-0.38	19.73	(33.22)	3.74	(7.76)	3.33 × 10 ⁻¹⁶
upstream 5:0 AluY ² × upstream 2:0 BPVE2 ¹	-0.37	2.02	(5.93)	0.14	(0.91)	2.22 × 10 ⁻¹⁶
upstream 2:0 FAM ¹	-0.36	0.00	(0.06)	0.00	(0.00)	0
downstream 5:10 SINE _{Alu} ² × upstream 10:5 SINE _{Alu} ¹	0.35	41.12	(65.94)	10.41	(15.68)	2.00 × 10 ⁻¹⁵
upstream 100:10 AluJ ² × upstream 7:6 AP1 ¹	-0.34	7.16	(8.55)	2.49	(3.04)	3.46 × 10 ⁻¹²
upstream 2:0 SINE _{Alu} ¹ × upstream 2:0 BPVE2 ¹	0.33	1.16	(2.44)	0.18	(0.50)	1.55 × 10 ⁻¹⁵
upstream 10:5 LIMB ²	0.32	0.68	(2.83)	0.60	(1.84)	3.90 × 10 ⁻¹
downstream 10:100 FLAM ² × downstream 5:10 AluS ²	-0.31	2.38	(4.01)	0.47	(0.97)	1.55 × 10 ⁻¹⁵
upstream 100:10 AluS ¹ × upstream 5:0 BPVE2 ¹	-0.3	87.38	(100.91)	30.50	(29.91)	6.00 × 10 ⁻¹⁵
downstream 10:100 FAM ¹	-0.29	0.26	(0.56)	0.13	(0.33)	8.12 × 10 ⁻³
downstream 5:10 SINE _{Alu} ² × upstream 2:0 SINE _{Alu} ²	0.28	152.03	(285.85)	21.61	(74.28)	6.67 × 10 ⁻¹⁴
upstream 100:10 AluS ² × upstream 2:0 AluJ ¹	-0.27	3.39	(9.25)	0.19	(0.73)	0
upstream 2:0 ATF ¹ × upstream 2:0 E4TF1 ³	-0.26	0.30	(0.91)	0.03	(0.16)	5.10 × 10 ⁻¹⁴
upstream 1:0 AluS ¹ × upstream 2:0 Sp1 ³	-0.25	0.14	(0.41)	0.00	(0.00)	0
upstream 100:10 AluS ¹ × upstream 3:2 COUP ¹	-0.24	72.30	(84.53)	30.48	(26.66)	1.99 × 10 ⁻¹²
downstream 0:2 DNA _{MER2} type ¹	-0.23	0.05	(0.29)	0.03	(0.16)	1.75 × 10 ⁻¹
upstream 5:0 SINE _{Alu} ¹ × upstream 4:3 TFIID ³	-0.22	2.12	(2.97)	0.60	(1.08)	4.59 × 10 ⁻¹¹
upstream 2:0 AluS ² × upstream 8:7 SIF ³	-0.21	2.32	(7.64)	0.00	(0.00)	0
downstream 5:10 AluS ² × upstream 10:5 SINE _{Alu} ¹	-0.2	25.68	(43.78)	3.78	(6.36)	0
upstream 5:0 AluS ¹ × upstream 10:9 NFUE5 ³	-0.19	0.61	(1.49)	0.05	(0.22)	0
downstream 5:10 LTR _{ERV1} ¹	-0.18	0.21	(0.69)	0.18	(0.50)	3.42 × 10 ⁻¹
downstream 5:10 FLAM ¹	0.17	0.15	(0.41)	0.08	(0.27)	3.67 × 10 ⁻²
upstream 2:0 DNA _{AcHobo} ²	-0.16	0.11	(1.32)	0.00	(0.00)	0
downstream 10:100 AluJ ² × upstream 5:0 AluS ²	0.15	45.82	(68.17)	8.98	(17.67)	2.22 × 10 ⁻¹⁶
downstream 0:1 LIMB ²	0.14	0.48	(5.11)	0.22	(1.36)	1.16 × 10 ⁻¹
downstream 10:100 AluY ¹ × upstream 5:0 SINE _{Alu} ¹	0.13	28.15	(43.61)	5.80	(9.77)	0
downstream 0:2 SINE _{Alu} ¹ × upstream 2:1 BPVE2 ¹	-0.12	0.56	(1.50)	0.03	(0.16)	0
downstream 0:2 LIMB ¹	-0.11	0.04	(0.26)	0.05	(0.22)	3.94 × 10 ⁻¹
downstream 10:100 LINE _{CR1} ² × upstream 100:10 AluS ¹	0.1	7.26	(13.49)	1.45	(3.33)	7.67 × 10 ⁻¹⁴
downstream 5:10 AluS ¹ × upstream 1:0 AluS ²	-0.09	15.56	(49.12)	0.00	(0.00)	0
upstream 100:10 LIMB ¹ × upstream 5:0 AluY ¹	-0.08	1.46	(4.19)	0.15	(0.58)	0
upstream 1:0 AluS ² × upstream 10:0 NFUE5 ¹	-0.07	24.38	(66.70)	1.18	(7.46)	0
downstream 5:10 AluS ² × upstream 1:0 AluS ¹	-0.06	1.66	(5.16)	0.00	(0.00)	0
downstream 5:10 SINE _{Alu} ¹ × upstream 1:0 SINE _{Alu} ²	0.05	42.54	(106.75)	3.85	(16.09)	0
downstream 10:100 LTR _{ERV1} _± ²	0.04	292.21	(693.57)	450.10	(1064.61)	1.80 × 10 ⁻¹
intron DNA _{Tc2} _± ²	0.03	14.45	(81.71)	6.91	(30.34)	6.53 × 10 ⁻²
downstream 0:2 Other ²	-0.02	0.62	(6.75)	0.00	(0.00)	0
upstream 2:0 SINE _{Alu} ² × upstream 5:0 Sp1 ³	-0.01	10.60	(15.55)	2.05	(5.41)	1.71 × 10 ⁻¹²
upstream 5:0 SINE _{Alu} ² × upstream 2:1 COUP ¹	0.01	35.57	(48.80)	11.25	(14.45)	2.53 × 10 ⁻¹³

Unit is kilobases and it refers to the beginning of the first or the end of the last exon, respectively. Corresponding table for SMLR available upon request.

For example, "downstream 10:100" refers to the 90 kb window from 10 kb to 100 kb downstream of the last exon.

¹ Number of this feature within the sequence window.

_±¹ denotes the ratio of repeated elements in + versus - orientation with respect to the gene. It is the negative inverse if there are more elements in - orientation than in +.

² Percentage.

_±² Ratio of the percentage of the sequence window covered by repeated elements in ± orientation.

³ Indicator for presence of this feature within the sequence window.

⁴ Indicator for presence of upstream CTCF consensus-binding site.

⁵ Indicator for presence of TGTGTTCAG consensus site.

⁶ The phase change happened at one of the following LTR elements: MLT1A0, MLT1B, MSTA, MSTB1, MLT1D, MLT2B4, or MLT1G1.

⁷ Indicator for presence of CpG island overlapping the last exon.

⁸ Indicator for presence of CpG island overlapping the first exon.

⁹ Orientation of motif relative to gene.

¹⁰ Methylation prone.

¹¹ Methylation resistant.

× indicates pairwise interaction between two variables.

Table 5. Relevant features for prediction of parental preference by Equibits classifier.

Feature	Weight	Mean (Standard deviation)		<i>P</i>
		Maternally expressed	Paternally expressed	
downstream 10:100 AluJ $\pm^1$ $\times$ upstream 1:0 ATF ³	19.57	-0.71 (1.15)	1.06 (1.46)	8.49×10^{-5}
downstream 10:100 CpGi ³ $\times$ upstream 3:2 Oct1 ³	-18.86	0.47 (0.51)	0 (0)	3.97×10^{-4}
downstream 10:100 CpGi ¹ $\times$ upstream 10:0 GATA1 ³	-17.94	4.68 (3.37)	0.85 (0.99)	5.19×10^{-5}
upstream 7:6 APF ³ $\times$ upstream 5:4 BPVE2 ³	-17.75	0.47 (0.51)	0 (0)	3.97×10^{-4}
upstream 4:3 E4F1 ³	-16.86	0.37 (0.50)	0.05 (0.22)	8.41×10^{-3}
downstream 50:90 LTR_ERVL $\pm^1$	16.49	0.21 (0.54)	2.08 (2.97)	5.93×10^{-3}
upstream 10:9 MLTF ³ $\times$ upstream 7:6 AP1 ³	-16.42	0.68 (0.48)	0.10 (0.31)	4.42×10^{-5}
upstream 4:3 E4F1 ¹	-15.92	0.42 (0.61)	0.05 (0.22)	9.90×10^{-3}
downstream 10:100 AluS $\pm^2$	-15.45	337.17 (781.15)	1.84 (1.10)	3.88×10^{-2}
upstream 10:5 AluY ¹	-14.9	0.47 (0.61)	0.10 (0.31)	1.21×10^{-2}
upstream 100:90 CpGi ^{2,10}	-14.88	0.18 (0.35)	0.03 (0.11)	3.47×10^{-2}
upstream 10:5 AluY ²	-14.69	1.43 (1.86)	0.31 (0.95)	1.31×10^{-2}
downstream 10:100 CpGi ¹	-14.57	4.68 (3.37)	1.30 (1.45)	2.36×10^{-4}
downstream 10:100 SINE_MIR $\pm^1$	14	-1.31 (1.80)	0.38 (2.51)	1.02×10^{-2}
downstream 10:100 LTR_ERVL $\pm^1$	13.99	-0.22 (2.05)	1.65 (2.90)	1.29×10^{-2}
downstream 10:100 MIR $\pm^2$	13.86	2.28 (3.47)	70.32 (153.20)	3.08×10^{-2}
upstream 6:5 GTTC ¹	13.79	0.21 (0.42)	0.60 (0.68)	1.90×10^{-2}
downstream 10:100 MIR3 $\pm^2$	-13.7	67.91 (99.59)	12.00 (29.01)	1.42×10^{-2}
upstream 7:6 CP1 ¹	-13.32	0.16 (0.37)	0 (0)	4.14×10^{-2}
upstream 100:10 L1 ²	13.27	0.07 (0.21)	0.73 (1.28)	1.73×10^{-2}
upstream 2:0 AluS $\pm^1$	-13.02	0.11 (0.32)	-0.25 (0.55)	9.23×10^{-3}
exon 0.225:0.41 nucleosome potential ²	12.99	-0.42 (1.24)	0.26 (0.81)	2.62×10^{-2}
upstream 100:10 LIM ²	12.83	0 (0)	0.03 (0.08)	6.64×10^{-2}
upstream 100:10 LIM ¹	12.73	0 (0)	0.15 (0.37)	4.14×10^{-2}
downstream 10:100 LINE_L1 ² $\times$ upstream 5:4 APF ¹	12.66	17.90 (22.58)	61.57 (37.34)	5.10×10^{-5}
upstream 9:8 NFUE4 ¹	12.63	0 (0)	0.10 (0.31)	8.13×10^{-2}
upstream 100:10 LTR_ERV1 $\pm^1$	-12.58	0.49 (1.74)	-1.07 (2.53)	1.54×10^{-2}
upstream 100:10 LIM4 ²	12.3	0.32 (0.66)	1.52 (1.76)	4.67×10^{-3}
upstream 6:5 GTTC ³	12.29	0.21 (0.42)	0.50 (0.51)	3.05×10^{-2}
downstream 10:100 LINE_CR1 ²	12.21	0.03 (0.05)	0.11 (0.17)	3.29×10^{-2}

Unit is kilobases and it refers to the beginning of the first or the end of the last exon, respectively.

For example, "downstream 10:100" refers to the 90 kb window from 10 kb to 100 kb downstream of the last exon.

¹ Number of this feature within the sequence window.

$\pm^1$ denotes the ratio of repeated elements in + versus - orientation with respect to the gene. It is the negative inverse if there are more elements in - orientation than in +.

² Percentage of the sequence window covered by this feature.

$\pm^2$ Ratio of the percentage of the sequence window covered by repeated elements in $\pm$ orientation.

³ Indicator for presence of this feature within the sequence window.

¹⁰ Methylation prone.

$\times$ indicates pairwise interaction between two variables.

Table 6. Genes proved or predicted with high confidence to be imprinted map to loci linked to various human conditions.

Condition	Band	Locus	Coordinate	Allele	Linkage/Reference
Alcoholism	2p14	TSC0053926	66.5	<i>p</i>	Linkage to alcoholism (LOD=1.52) (Liu et al., 2005). Involved in brain development (Boyl et al., 2001).
		<i>OTX1</i>	63.2	M	
	12q24	D12S1045	128.8	<i>m</i>	Linkage to alcoholism (LOD=3.17; MOD=3.68) (Liu et al., 2005; Strauch et al., 2005).
		<i>Q9HCM7</i>	131.6	M	
	21q22	D21S1440	38.1	<i>m</i>	Linkage to alcoholism (MOD=3.86) (Strauch et al., 2005). Involved in brain development (Goshu et al., 2004).
		<i>SIM2</i>	37.0	P	
Alzheimer's	10q23	D10S583	94.4		Linkage to Alzheimer's disease (LOD=3.3) (Bertram et al., 2000; Ait-Ghezala et al., 2002).
		<i>Q9H6Z8</i>	92.4	P	
	10q24	D10S1710	102.8		Linkage to Alzheimer's disease (LOD=0.9) (Bertram et al., 2000).
		<i>LDB1</i>	103.8	M	
	12p13	D12S1623	6.8		Linkage to Alzheimer's disease (LOD=3.15) (Mayeux et al., 2002).
		<i>RBP5</i>	7.2	P	
	12p11	D12S1042	27.5		Linkage to Alzheimer's disease (LOD=1.43) (Mayeux et al., 2002).
		<i>ABCC9</i>	21.9	M	
	12q13	D12S398-D12S1632	51.5-54.7		Linkage to Alzheimer's disease (LOD=1.40) (Scott et al., 2000).
		<i>HOXC9</i>	52.7	M	
		<i>HOXC4</i>	52.7	M	
Asthma/Atopy	3q21	D3S3606	128.7	<i>m</i>	Linkage to allergic sensitization ($Z_{all}=4.31$) (Lee et al., 2000b). Mice deficient in this gene show decreased hepatic folate levels (Champion et al., 1994).
		<i>FTHFD</i>	128.3	M	
	14q24	D14S74	77.7	<i>p</i>	Suggestive linkage to atopy and indications for imprinting (MOD=2.88) (Strauch et al., 2001).
		<i>ENSG00000183992</i>	80.7	M	
Autism	1q25	D1S1677-D1S1589	156-172.5		Linkage to autism (Bartlett et al., 2005).
		<i>HSPA6</i>	159.8	M	
	7q32	D7S530-D7S640	128.9-132.3	<i>m</i>	Linkage to autism (MLS=2.31) (Lamb et al., 2005). Known human imprinted gene (Kayashima et al., 2003). Known human imprinted gene (Kobayashi et al., 1997).
		<i>CPA4</i>	129.7	M	
		<i>MEST</i>	129.9	P	
	9q34	D9S158-D9S905	136.3-137.2		Linkage to autism (MLS=1.67) (Lamb et al., 2005).
		<i>PHPT1</i>	137.0	M	
		<i>EGFL7</i>	136.8	P	
	10p14	D10S189	6.8		Linkage to autism (MLS=1.15) and schizophrenia (LOD=3.60) (Lamb et al., 2005; DeLisi et al., 2002). Regulates the development of serotonergic neurons (van Doorninck et al., 1999). In 30% of autistic people the most frequent dysfunction is the increase of serotonin (Baghdadi et al., 2002). Haploinsufficiency for <i>GATA3</i> was observed in a patient with autism and severe mental retardation (Verri et al., 2004).
		<i>GATA3</i>	8.1	P	
	17q11	D17S1800	26.7		Linkage to autism-spectrum disorders (MLS=2.83) (Yonan et al., 2003). Suggestive linkage to ASD and indications for imprinting (Bartlett et al., 2005).
		D17S1871,D17S1824	21.9,23.7	<i>p</i>	
		<i>PYY2</i>	23.6	P	

Bipolar disorder	1q41	D1S549	217.7	<i>m</i>	Linkage to bipolar disorder (MLS=1.43) (McInnis et al., 2003).
		<i>PTPN14</i>	212.6	M	
	2q36	D2S396-D2S206	230.4-233.4	<i>m</i>	Linkage to bipolar disorder (HLOD=2.20) (Cichon et al., 2001).
		<i>TIGD1</i>	233.1	P	
	8q24	D8S256	134.5	M†	Linkage to bipolar disorder (NPL=3.13) (McInnis et al., 2003). K ⁺ channel protein involved in neuron apoptosis and cell tumorigenesis (Patel and Lazdunski, 2004).
		<i>KCNK9</i>	140.7		
	14q32	D14S65-D14S78	96.7-99.5	<i>p</i>	Linkage to bipolar disorder (HLOD=2.47) (Cichon et al., 2001). Known human imprinted gene (Wylie et al., 2000; Kobayashi et al., 2000). Known human imprinted gene (Miyoshi et al., 2000). Imprinted in mouse (Seitz et al., 2003) and sheep (Charlier et al., 2001).
		<i>DLK1</i>	100.3	P	
		<i>MEG3</i>	100.4	M	
		<i>RTL1</i>	100.4	M	
Fetal malformation	14q12	D14S608	27.9	P†	Paternal UPD results in fetal malformations (Kurosawa et al., 2002). Shows haploinsufficiency in a patient with severe mental retardation, brain malformations and microcephaly (Shoichet et al., 2005). Mouse orthologue is essential for normal development of the telencephalon (Xuan et al., 1995).
		<i>FOXP1C</i>	28.3		
Male homosexuality	10q26	D10S217	129.4	<i>m</i>	Linkage to male sexual orientation (MLOD=1.81) (Mustanski et al., 2005).
		<i>C10orf91</i>	134.1	M	
		<i>NKX6-2</i>	134.4	M†	Predominantly expressed in the brain (Lee et al., 2001).
		<i>C10orf93</i>	134.6	M	
		<i>VENTX2</i>	134.9	M	
		<i>Q8N377</i>	135.0	M	
		<i>PAOX</i>	135.1	M	
Obesity/Diabetes	2q37	D2S2987	242.5		Linkage to type 2 diabetes (LOD=3.19) (Einarsdottir et al., 2006).
	2q37	GATA23A02-GATA178G09M	235.7-237.7	<i>m</i>	Linkage to body mass index (BMI) and percentage of fat mass (LOD=2.23/3.34) (Guo et al., 2006).
		<i>Q9Y419</i>	239.4	M	
		<i>MYEOV2</i>	240.7	P	
	3q24	AAT071	151.5	<i>m</i>	Linkage to BMI (LOD=1.97) (Guo et al., 2006).
		<i>ZIC1</i>	148.6	M	
	19q13	Mfd232	55.6	<i>m</i>	Linkage to BMI (LOD=1.81) (Guo et al., 2006).
		<i>LILRB4</i>	59.9	M	
Schizophrenia	1q42	D1S2709	228.3	P	Linkage to schizophrenia (LOD=2.71) (Ekelund et al., 2001).
		<i>OBSCN</i>	224.7		
		<i>HIST3H2BB</i>	225		
	8p11	D8S532	40.9	P	Linkage to schizophrenia (LOD=3.06) (Stefansson et al., 2002).
		<i>PURG</i>	31		
	9q21	D9S922	80	M	Linkage to schizophrenia (LOD=1.95) (Hovatta et al., 1999).
		<i>NP_001001670</i>	81.8		
	22q11	<i>PRODH2-DGCR6</i>	17.3	P	Linkage to schizophrenia (Liu et al., 2002). Expressed in the developing and adult mouse brain (Maynard et al., 2003).
		<i>DGCR6</i>	17.3		

The table lists loci that have previously been linked to various human conditions, and high-confidence imprinted gene candidates that map into or within 10 mb (or less) of that locus. If a locus has been observed to have a parent-of-origin effect, this is denoted by a lowercase *m* or *p*, for maternal or paternal effects, respectively. Genes predicted to be expressed from the maternal or paternal allele are denoted by **M** or **P**, respectively. Genes also predicted to be imprinted in the mouse are marked by †. Alleles that have been proved to be exclusively expressed are printed in bold face.

Supplementary Methods

We used a number of criteria to prioritize our 156 predictions for experimental validation: large posterior probabilities of being imprinted (in the case of SMLR), large signed hyperplane distances (in the case of SVM), potential involvement in an important condition (such as a cancer or one of the conditions listed in Table 2), and location in a chromosome not known to contain imprinted genes (many imprinted genes have to date been identified by searching near known imprinted genes, so finding some on a completely different chromosome would be compelling; also this would ensure we would not see confounding effects related to known imprinted genes nearby). We further decided that we wanted one candidate to have an orthologue predicted to be imprinted in the mouse but the other not, to emphasize that the two sets of predictions do not overlap significantly and that novel human imprinted genes can be discovered even without relying on any conservation of imprinting status between human and mouse. This resulted in a high-priority list of five genes. We then quickly screened the conceptuses we had available to determine for each gene, whether a sufficient number possessed an informative genotype that would permit us to experimentally detect monoallelic expression. After this, we narrowed our list to *DLGAP2* and *KCNK9*, and these were the only two genes for which we undertook a detailed validation of imprinting status.

DLGAP2 (Disks large-associated protein 2), also known as *DAP-2*, is annotated to have four splice variants (UCSC Genome Website, May 2004 assembly (Karolchik et al., 2003)). The four splice variants chr8.27.24, chr8.27.25, chr8.27.26, and chr8.27.27, are referred to as *DLGAP2*-24, -25, -26, and -27, respectively. Variants *DLGAP2*-24 and *DLGAP2*-27 lack exon 7 compared to isoforms *DLGAP2*-25 and *DLGAP2*-26. Conversely, isoforms *DLGAP2*-24 and *DLGAP2*-25 share common exons in the 3' end, which are absent from *DLGAP2*-26 and *DLGAP2*-27 and vice-versa. Thus, we were able to distinguish the four transcripts as follows (see Supplementary Fig. 2 for a schematic). Isoforms *DLGAP2*-24 and *DLGAP2*-25 were reverse transcribed using primer DLGAP2-RT1 (square), while DLGAP2-RT2 (diamond)

was used to reverse transcribe *DLGAP2-26* and *DLGAP2-27*. cDNA from *DLGAP2-24* and *DLGAP2-27* was specifically amplified using reverse primer DLGAP2-M1R (upward triangle), while DLGAP2-M2R (downward triangle) was used to amplify *DLGAP2-25* and *DLGAP2-26*. DLGAP2-M1F (circle) was used as a common forward primer to amplify cDNA. When amplifying cDNA, the primers bridged two long introns, ruling out any potential influence of undigested genomic DNA. Genomic DNA was amplified and sequenced using DLGAP2-1F and DLGAP2-1R.




Figure 2. Schematic representation of the four *DLGAP2* isoforms studied. Vertical lines represent exons. Exons colored in dark blue are shared in common among all isoforms, red exons are unique to *DLGAP2-24* and *DLGAP2-25*, the green exon is unique to *DLGAP2-25* and *DLGAP2-26*, and the orange exons are unique to *DLGAP2-26* and *DLGAP2-27*. The primers used for reverse transcription, *DLGAP2-RT1* and *DLGAP2-RT2*, are represented as a square and a diamond, respectively. The PCR primers *DLGAP2-M1R*, *DLGAP2-M2R*, and *DLGAP2-M1F* are depicted as an upward triangle, a downward triangle, and a circle, respectively. The cross symbolizes the polymorphic sites.

KCNK9 (potassium channel, subfamily K, member 9), also known as *TASK-3*, is annotated to have one isoform. We used primers *KCNK9-1F* and *-1R* for the amplification of genomic DNA. cDNA was amplified using *KCNK9-M1F* and *-M1R*, which bridge an 84kb intron.

Table 7. Primers used for expression analysis of *DLGAP2* and *KCNK9*.

Name	Sequence 5' -...-3'	Position
DLGAP2-1F	TAGGCTAGACGTCCAGGAACA	1603779-1603799
DLGAP2-1R	TATTGGCAGGACTGAGTGGAG	1604304-1604284
DLGAP2-RT1	ACATGAGAAGCTGGGCACTC	2585-2604†
DLGAP2-RT2	CGTCACCTCCATCGACTTCT	2651-2670‡
DLGAP2-M1F	CAGCTACCTTCGAGCCATTG	1605-1624†
DLGAP2-M1R	GGCCGTTTCCACCTGAATC	2048-2066†
DLGAP2-M2R	TGATGCTCTGGGAATTCAG	2059-2077‡
KCNK9-1F	CAAGGCCTTCTGCATGTTCT	53849487-53849468
KCNK9-1R	GTGAATGACCATGCTGTTGC	53848983-53849002
KCNK9-M1F	TCCTTCTACTTTGCGATCACG	53933168-53933148
KCNK9-M1R	CATGGTCAAGAACCTGAGGAC	53849058-53849078

Positions for *DLGAP2* primers refer to GI37552484, chr8.27.24 (†), and chr8.27.26 (‡).

Positions for *KCNK9* primers are given for GI51467074.





Figure 3. A receiver operator characteristic (ROC) curve illustrating the relationship between sensitivity and specificity for the SMLR classifier under the two different kernel functions, linear and RBF.




Figure 4. Flow-chart illustrating schematically the processes of cross-validation, training, testing, and prediction under two different kernels and employing both the Equibits and SMLR classifier learning strategies.

Table 8. Independent negative test genes.

Gene	Band	Expression	Reference
Stochastic monoallelic expression			
<i>IL2</i>	4q27	X	Monoallelically expressed (Hollander et al., 1998).
<i>IL4</i>	5q23	X	Monoallelically expressed (Bix and Locksley, 1998).
<i>IL5</i>	5q23	X	Monoallelically expressed (Kelly and Locksley, 2000).
<i>IL13</i>	5q23	X	Monoallelically expressed (Kelly and Locksley, 2000).
<i>OR2A1</i>	7q35	X	Monoallelically expressed (Singh et al., 2003).
<i>TLR4</i>	9q33	X	Monoallelically expressed (Pereira et al., 2003).
<i>SFTPD</i>	10q22	X	Heterogeneous allele-specific expression in extrapulmonary tissues (Lin and Floros, 2002).
<i>KLRC1</i>	12p13	X	Monoallelically expressed (Vance et al., 2002).
<i>KLRA1</i>	12p13	X	Monoallelically expressed (Tanamachi et al., 2001; Byun et al., 2003).
<i>NUBP2</i>	16p13	X	Monoallelically expressed (Sano et al., 2001).
<i>IGFALS</i>	16p13	X	Monoallelically expressed (Sano et al., 2001).
<i>JSAP1</i>	16p13	X	Monoallelically expressed (Sano et al., 2001).
<i>OR7A17</i>	19p13	X	Monoallelically expressed (Singh et al., 2003).
Presumed biallelic expression			
<i>CD2</i>	1p13	X	Synchronously replicated (Mostoslavsky et al., 2001).
<i>APOB</i>	2p24	X	Synchronously replicated (Kitsberg et al., 1993).
<i>GPD2</i>	2q24	X	No evidence of imprinting (Piras et al., 2000).
<i>IGFBP5</i>	2q35	X	No evidence of imprinting (Piras et al., 2000).
<i>RPL23</i>	2q36	X	Biallelically expressed (Greally et al., 1998).
<i>Gt(ROSA)26asSor</i>	3p25	X	Biallelically expressed (Singh et al., 2003).
<i>MSX1</i>	4p16	X	No evidence of imprinting (Blin-Wakkach et al., 2001).
<i>GHR</i>	5p12	X	Biallelically expressed (Buettner et al., 2004).
<i>OSMR</i>	5p13	X	Biallelically expressed (Buettner et al., 2004).
<i>PRLR</i>	5p13	X	Biallelically expressed (Buettner et al., 2004).
<i>IL7R</i>	5p13	X	Biallelically expressed (Buettner et al., 2004).
<i>NPR3</i>	5p13	X	Biallelically expressed (Buettner et al., 2004).
<i>SEMA5A</i>	5p15	X	Biallelically expressed (Buettner et al., 2004).
<i>CDH10</i>	5p14	X	Biallelically expressed (Buettner et al., 2004).
<i>GABRA6</i>	5q34	X	Biallelically expressed (Takahashi and Ko, 1993).
<i>SLC22A1</i>	6q25	X	Biallelically expressed (Schweifer et al., 1997).
<i>SOD2</i>	6q25	X	Biallelically expressed in mouse (Barlow et al., 1991).
<i>TCP1</i>	6q25	X	Biallelically expressed in mouse (Barlow et al., 1991).
<i>MAS1</i>	6q25	X	Biallelically expressed in mouse (Schweifer et al., 1997; Lyle et al., 2000).
<i>PLG</i>	6q26	X	Biallelically expressed in mouse (Barlow et al., 1991).
<i>COL1A2</i>	7q21	X	Biallelically expressed (Mizuno et al., 2002).
<i>ACTB</i>	7p22	X	Biallelically expressed (Zhang et al., 1994).
<i>ACHE</i>	7q22	X	Synchronously replicated (Kitsberg et al., 1993).
<i>UBE2H</i>	7q32	X	Biallelically expressed (Yamada et al., 2003).
<i>MKRN1</i>	7q34	X	No evidence of imprinting (Walter and Paulsen, 2003).
<i>SDC2</i>	8q22	X	Biallelically expressed (Buettner et al., 2004).
<i>FZD6</i>	8q22	X	Biallelically expressed (Buettner et al., 2004).
<i>NOV</i>	8q24	X	Biallelically expressed (Buettner et al., 2004).
<i>MYC</i>	8q24	X	Synchronously replicated (Chess et al., 1994).
<i>DOCK8</i>	9p24	X	Biallelically expressed (Lerer et al., 2005).
<i>TYRL</i>	11p11	X	Synchronously replicated (Singh et al., 2003).
<i>PAX6</i>	11p13	X	Biallelically expressed (van Raamsdonk and Tilghman, 2000).
<i>GAS2</i>	11p14	X	No evidence of imprinting (Piras et al., 2000).
<i>STIM1</i>	11p15	X	Biallelically expressed (Overall et al., 1998).
<i>TPH1</i>	11p15	X	Biallelically expressed (Buettner et al., 2004).
<i>CARS</i>	11p15	X	Biallelically expressed (Clark et al., 2002).
<i>RNH</i>	11p15	X	Biallelically expressed (Rachmilewitz et al., 1993).
<i>TH</i>	11p15	X	Biallelically expressed (Reik and Walter, 2001).
<i>ASCL2</i>	11p15	X	Imprinted in mouse but not in human (Monk et al., 2006).
<i>CTSD</i>	11p15	X	Biallelically expressed in human hydatidiform mole, mature teratoma, and normal placenta (Rachmilewitz et al., 1993).

<i>RRM1</i>	11p15	X	No evidence of imprinting (Byrne and Smith, 1993).
<i>DUSP8</i>	11p15	X	Biallelically expressed (Goldberg et al., 2003).
<i>NAP1L4</i>	11p15	X	Biallelic expression in multiple murine fetal and adult tissues (Hu et al., 1996; Paulsen et al., 1998; Umlauf et al., 2004), not imprinted in the human (Monk et al., 2006).
<i>PYGM</i>	11q13	X	Synchronously replicated (Kitsberg et al., 1993).
<i>CD3D</i>	11q23	X	Synchronously replicated (Kitsberg et al., 1993).
<i>GAPD</i>	12p13	X	Biallelically expressed (Paulsen et al., 1998).
<i>CD4</i>	12p13	X	Biallelically expressed (Williamson et al., 1995).
<i>DCN</i>	12q21	X	Imprinted in mouse but not in human (Monk et al., 2006).
<i>RB1</i>	13q14	X	Synchronously replicated (Amiel et al., 1999).
<i>YY1</i>	14q32	X	Biallelically expressed (Yevtdiyenko et al., 2002).
<i>WARS</i>	14q32	X	Biallelically expressed (Yevtdiyenko et al., 2002).
<i>PPP2R5C</i>	14q32	X	Biallelically expressed (Tierling et al., 2006).
<i>DNCHC1</i>	14q32	X	Biallelically expressed (Tierling et al., 2006).
<i>HERC2</i>	15q11	X	Biallelically expressed (Chai et al., 2003).
<i>NDNL2</i>	15q13	X	Biallelically expressed (Chibuk et al., 2001).
<i>DUOX1</i>	15q21	X	No evidence of imprinting (Sandell et al., 2003).
<i>SLC28A2</i>	15q21	X	No evidence of imprinting (Sandell et al., 2003).
<i>DUOX2</i>	15q21	X	No evidence of imprinting (Sandell et al., 2003).
<i>SLC30A4</i>	15q21	X	No evidence of imprinting (Sandell et al., 2003).
<i>GATM</i>	15q21	X	Imprinted in mouse but not in human (Monk et al., 2006).
<i>TP53</i>	17p13	X	Synchronously replicated (Kitsberg et al., 1993).
<i>RPL19</i>	17q12	X	Biallelically expressed (Piras et al., 2000).
<i>ERBB2</i>	17q12	X	Synchronously replicated (Amiel et al., 1999).
<i>APLP1</i>	19q13	X	Biallelically expressed (Buettner et al., 2004).
<i>MAG</i>	19q13	X	Biallelically expressed (Buettner et al., 2004).
<i>SCN1B</i>	19q13	X	Biallelically expressed (Buettner et al., 2004).
<i>GRIK5</i>	19q13	X	Biallelically expressed (Buettner et al., 2004).
<i>APOE</i>	19q13	X	Biallelically expressed (Buettner et al., 2004).
<i>KCNA7</i>	19q13	X	Biallelically expressed (Buettner et al., 2004).
<i>SYT3</i>	19q13	X	Biallelically expressed (Buettner et al., 2004).
<i>GRIN2D</i>	19q13	X	Biallelically expressed (Buettner et al., 2004).
<i>HRC</i>	19q13	X	Biallelically expressed (Buettner et al., 2004).
<i>KCNC3</i>	19q13	X	Biallelically expressed (Buettner et al., 2004).
<i>RRAS</i>	19q13	X	Synchronously replicated (Kitsberg et al., 1993).
<i>E2F1</i>	20q11	X	Biallelically expressed (Williamson et al., 1995).
<i>BC10, BLCAP</i>	20q11	X	Biallelically expressed (Evans et al., 2001; John et al., 2001).
<i>PLCG1</i>	20q12	X	Biallelically expressed (Williamson et al., 1995).
<i>PPGB</i>	20q13	X	Biallelically expressed (Williamson et al., 1994).
<i>TNFRSF5</i>	20q13	X	Biallelically expressed (Williamson et al., 1995).
<i>KCNB1</i>	20q13	X	Biallelically expressed (Williamson et al., 1995).
<i>CYP24A1</i>	20q13	X	Biallelically expressed (Williamson et al., 1995).
<i>EDN3</i>	20q13	X	Biallelically expressed (Williamson et al., 1995).
<i>PCK1</i>	20q13	X	Biallelically expressed (Williamson et al., 1995).
<i>NTSR1</i>	20q13	X	Biallelically expressed (Williamson et al., 1995).
<i>BMP7</i>	20q13	X	No evidence of imprinting (Marker et al., 1995).
<i>CDH4</i>	20q13	X	Synchronously replicated (Williamson et al., 1995).
<i>RUNX1</i>	21q22	X	Synchronously replicated (Dotan et al., 2000).
<i>PFKL</i>	21q22	X	Synchronously replicated (Kitsberg et al., 1993).

Expression can be one of the following: P (Imprinted and paternally expressed), M (Imprinted and maternally expressed), or X (Not imprinted). All 101 genes were correctly predicted not to be imprinted by the combined classifier. The experimental results cited here may relate to either mouse or human.

Table 9. Training genes of known imprint status.

Gene	Band	Expression	Reference
<u>Imprinted</u>			
<i>ARHI</i>	1p31	P	Yu et al. (1999); Luo et al. (2001)
<i>TP73</i>	1p36	M	Kaghad et al. (1997); Mai et al. (1998); Cai et al. (2000)
<i>HYMAI</i>	6q24	P	Arima et al. (2000)
<i>PLAGL1</i>	6q24	P	Kamiya et al. (2000)
<i>GRB10</i>	7p12	I	Blagitko et al. (2000); Yoshihashi et al. (2000)
<i>DLX5</i>	7q21	M	Okita et al. (2003)
<i>PPP1R9A</i>	7q21	M	Nakabayashi et al. (2004)
<i>SGCE</i>	7q21	P	Zimprich et al. (2001)
<i>PEG10</i>	7q21	P	Ono et al. (2001)
<i>CPA4</i>	7q32	M	Kayashima et al. (2003)
<i>MEST</i>	7q32	P	Kobayashi et al. (1997)
<i>WT1</i>	11p13	P	Dallosso et al. (2004)
<i>IGF2</i>	11p15	P	Ogawa et al. (1993a); Ohlsson et al. (1993); Rainier et al. (1993)
<i>OSBPL5</i>	11p15	M	Higashimoto et al. (2002)
<i>SLC22A1L</i>	11p15	M	Dao et al. (1998); Cooper et al. (1998a)
<i>CDKN1C</i>	11p15	M	Matsuoka et al. (1996); Chung et al. (1996); Taniguchi et al. (1997)
<i>ZNF215</i>	11p15	M	Alders et al. (2000)
<i>KCNQ1DN</i>	11p15	M	Xin et al. (2000)
<i>PHLDA2</i>	11p15	M	Qian et al. (1997)
<i>SLC22A1LS</i>	11p15	M	Cooper et al. (1998b); Bajaj et al. (2004)
<i>KCNQ1</i>	11p15	M	Lee et al. (1997)
<i>H19</i>	11p15	M	Zhang and Tycko (1992); Rachmilewitz et al. (1992); Rainier et al. (1993)
<i>IGF2AS</i>	11p15	P	Okutsu et al. (2000)
<i>INS</i>	11p15	P	Moore et al. (2001)
<i>SMPD1</i>	11p15	M	Simonaro et al. (2006)
<i>MEG3</i>	14q32	M	Miyoshi et al. (2000)
<i>DLK1</i>	14q32	P	Wyllie et al. (2000); Kobayashi et al. (2000)
<i>SNURF</i>	15q11	P	Gray et al. (1999)
<i>MKRN3</i>	15q11	P	Driscoll et al. (1992); Glenn et al. (1993, 1997); Jong et al. (1999)
<i>NDN</i>	15q11	P	MacDonald and Wevrick (1997); Jay et al. (1997)
<i>MAGEL2</i>	15q11	P	Boccaccio et al. (1999); Lee et al. (2000a)
<i>IPW</i>	15q11	P	Wevrick et al. (1994)
<i>UBE3A</i>	15q12	M	Rougeulle et al. (1997); Vu and Hoffman (1997)
<i>ATP10A</i>	15q12	M	Meguro et al. (2001); Herzing et al. (2001)
<i>TCEB3C</i>	18q21	M	Strichman-Almashanu et al. (2001)
<i>ZIM2</i>	19q13	P	Murphy et al. (2001); Van den Veyver et al. (2001)
<i>NNAT</i>	20q11	P	Evans et al. (2001)
<i>NESP55</i>	20q13	M	Hayward et al. (1998)
<i>L3MBTL</i>	20q13	P	Li et al. (2004)
<i>GNAS1</i>	20q13	P	Liu et al. (2000)
<u>Non-imprinted</u>			
<i>NGFB</i>	1p13	X	P. Luedi (unpublished)
<i>CDKN2C</i>	1p32	X	Cost et al. (1997)
<i>COMMD1</i>	2p15	X	Nabetani et al. (1997)
<i>CDKN1A</i>	6p21	X	Cost et al. (1997)
<i>SERPINB6</i>	6p25	X	P. P. Luedi (unpublished)
<i>IGF2R</i>	6q25	X	Kalscheuer et al. (1993); Ogawa et al. (1993b); Killian et al. (2001)
<i>EGFR</i>	7p11	X	Wakeling et al. (1998)
<i>COBL</i>	7p12	X	Hitchins et al. (2002)
<i>DDC</i>	7p12	X	Hitchins et al. (2002)
<i>IGFBP3</i>	7p13	X	Eggermann et al. (1999); Wakeling et al. (2000)
<i>IGFBP1</i>	7p13	X	Eggermann et al. (1999); Wakeling et al. (2000)
<i>CPA1</i>	7q32	X	Bentley et al. (2003)
<i>HSPC216</i>	7q32	X	Yamada et al. (2003)
<i>NRF1</i>	7q32	X	Yamada et al. (2003)

<i>TSGA14</i>	7q32	X	Yamada et al. (2002)
<i>KIAA0265</i>	7q32	X	Yamada et al. (2003)
<i>Flj14803</i>	7q32	X	Yamada et al. (2003)
<i>CPA2</i>	7q32	X	Bentley et al. (2003)
<i>UBE2H</i>	7q32	X	Yamada et al. (2003)
<i>CNTNAP2</i>	7q36	X	P. P. Luedi (unpublished)
<i>EN2</i>	7q36	X	P. P. Luedi (unpublished)
<i>C9ORF39</i>	9p22	X	P. P. Luedi (unpublished)
<i>NOR1/NR4A3</i>	9q22	X	P. P. Luedi (unpublished)
<i>SAMD6</i>	9q22	X	K. S. Kucera (unpublished)
<i>C10orf9</i>	10p11	X	P. P. Luedi (unpublished)
<i>SFMBT2</i>	10p14	X	P. P. Luedi (unpublished)
<i>C10ORF28</i>	10q24	X	P. P. Luedi (unpublished)
<i>PHEM1</i>	11p15	X	Paulsen et al. (2000); Monk et al. (2006)
<i>DRD4</i>	11p15	X	Cichon et al. (1996)
<i>MUCDHL</i>	11p15	X	Goldberg et al. (2003)
<i>MRPL23</i>	11p15	X	Ishihara et al. (1998); Paulsen et al. (2000)
<i>CD81</i>	11p15	X	Maecker et al. (1998); Gabriel et al. (1998); Monk et al. (2006)
<i>TNNT3</i>	11p15	X	Yuan et al. (1996)
<i>HRAS</i>	11p15	X	Goldberg et al. (2003)
<i>TSSC4</i>	11p15	X	Paulsen et al. (2000)
<i>C11ORF2</i>	11q13	X	Zhu et al. (2000)
<i>NEU3</i>	11q13	X	P. P. Luedi (unpublished)
<i>CDKN1B</i>	12p13	X	Cost et al. (1997)
<i>NOVA1</i>	14q12	X	K. S. Kucera, P. P. Luedi (unpublished)
<i>CYFIP1</i>	15q11	X	Chai et al. (2003)
<i>NIPA2</i>	15q11	X	Chai et al. (2003)
<i>TUBGCP5</i>	15q11	X	Chai et al. (2003)
<i>NIPA1</i>	15q11	X	Chai et al. (2003)
<i>C15ORF2</i>	15q11	X	Farber et al. (2000)
<i>OCA2</i>	15q12	X	Chai et al. (2003)
<i>GABRB3</i>	15q12	X	Chai et al. (2003)
<i>GABRG3</i>	15q12	X	Chai et al. (2003)
<i>CABLES</i>	18q11	X	P. P. Luedi (unpublished)
<i>IMPACT</i>	18q11	X	Morison et al. (2001)
<i>JAG1</i>	20p12	X	P. P. Luedi (unpublished)
<i>TH1L</i>	20q13	X	Bonthron et al. (2000)
<i>CTSZ</i>	20q13	X	Bonthron et al. (2000)

Expression can be one of the following: P (Imprinted and paternally expressed), M (Imprinted and maternally expressed), or X (Not imprinted). The *GRB10* locus encodes oppositely imprinted transcripts and was excluded from the maternal/paternal model (denoted by I). The experimental results cited here may relate to either mouse or human.

References

- Ait-Ghezala, G., Abdullah, L., Crescentini, R., Crawford, F., Town, T., Singh, S., Richards, D., Duara, R., and Mullan, M. 2002. Confirmation of association between D10S583 and Alzheimer's disease in a case-control sample. *Neurosci Lett* **325**:87–90.
- Alders, M., Ryan, A., Hodges, M., Blik, J., Feinberg, A. P., Privitera, O., Westerveld, A., Little, P. F., and Mannens, M. 2000. Disruption of a novel imprinted zinc-finger gene, ZNF215, in Beckwith-Wiedemann syndrome. *Am. J. Hum. Genet.* **66**:1473–1484.
- Amiel, A., Korenstein, A., Gaber, E., and Avivi, L. 1999. Asynchronous replication of alleles in genomes carrying an extra autosome. *Eur. J. Hum. Genet.* **7**:223–230.
- Arima, T., Drewell, R. A., Oshimura, M., Wake, N., and Surani, M. A. 2000. A novel imprinted gene, HYMAI, is located within an imprinted domain on human chromosome 6 containing ZAC. *Genomics* **67**:248–255.
- Baghdadli, A., Gonnier, V., and Aussilloux, C. 2002. Review of psychopharmacological treatments in adolescents and adults with autistic disorders. *Encephale* **28**:248–254.
- Bajaj, V., Markandaya, M., Krishna, L., and Kumar, A. 2004. Paternal imprinting of the SLC22A1LS gene located in the human chromosome segment 11p15.5. *BMC Genet.* **5**:13.
- Barlow, D. P., Stoger, R., Herrmann, B. G., Saito, K., Schweifer, N. B., Stoger, R., Herrmann, B. G., Saito, K., and Schweifer, N. 1991. The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. *Nature* **349**:84–87.
- Bartlett, C. W., Goedken, R., and Vieland, V. J. 2005. Effects of Updating Linkage Evidence across Subsets of Data: Reanalysis of the Autism Genetic Resource Exchange Data Set. *Am. J. Hum. Genet.* **76**:688–695.
- Bentley, L., Nakabayashi, K., Monk, D., Beechey, C., Peters, J., Birjandi, Z., Khayat, F. E., Patel, M., Preece, M. A., Stanier, P., Scherer, S. W., and Moore, G. E. 2003. The imprinted region on human chromosome 7q32 extends to the carboxypeptidase A gene cluster: an imprinted candidate for Silver-Russell syndrome. *J. Med. Genet.* **40**:249–256.
- Bertram, L., Blacker, D., Mullin, K., Keeney, D., Jones, J., Basu, S., Yhu, S., McInnis, M. G., Go, R. C., Vekrellis, K., Selkoe, D. J., Saunders, A. J., and Tanzi, R. E. 2000. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. *Science* **290**:2302–2303.
- Bix, M. and Locksley, R. M. 1998. Independent and epigenetic regulation of the interleukin-4 alleles in CD4+ T cells. *Science* **281**:1352–1354.
- Blagitko, N., Mergenthaler, S., Schulz, U., Wollmann, H. A., Craigen, W., Eggermann, T., Ropers, H. H., and Kalscheuer, V. M. 2000. Human GRB10 is imprinted and expressed from the paternal and maternal allele in a highly tissue- and isoform-specific fashion. *Hum. Mol. Genet.* **9**:1587–1595.
- Blin-Wakkach, C., Lezot, F., Ghoul-Mazgar, S., Hotton, D., Monteiro, S., Teillaud, C., Pibouin, L., Orestes-Cardoso, S., Papagerakis, P., Macdougall, M., Robert, B., and Berdal, A. 2001. Endogenous Msx1 antisense transcript: in vivo and in vitro evidences, structure, and potential involvement in skeleton development in mammals. *Proc. Natl. Acad. Sci.* **98**:7336–7341.
- Boccaccio, I., Glatt-Deeley, H., Watrin, F., Roeckel, N., Lalande, M., and Muscatelli, F. 1999. The human MAGEL2 gene and its mouse homologue are paternally expressed and mapped to the Prader-Willi region. *Hum. Mol. Genet.* **8**:2497–2505.
- Bonthron, D. T., Hayward, B. E., Moran, V., and Strain, L. 2000. Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13. *Hum. Genet.* **107**:165–175.
- Boyl, P. P., Signore, M., Annino, A., Barbera, J. P., Acampora, D., and Simeone, A. 2001. Otx genes in the development and evolution of the vertebrate brain. *Int. J. Dev. Neurosci.* **19**:353–363.
- Brakenhoff, R. H., Stroomer, J. G., ten Brink, C., de Bree, R., Weima, S. M., Snow, G. B., and van Dongen, G. A. 1999. Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction. *Clin. Cancer Res.* **5**:725–732.
- Buettner, V. L., Longmate, J. A., Barish, M. E., Mann, J. R., and Singer-Sam, J. 2004. Analysis of imprinting in mice with uniparental duplication of proximal chromosomes 7 and 15 by use of a custom oligonucleotide microarray. *Mamm. Genome* **15**:199–209.
- Byrne, J. A. and Smith, P. J. 1993. The 11p15.5 ribonucleotide reductase M1 subunit locus is not imprinted in Wilms' tumour and hepatoblastoma. *Hum. Genet.* **93**:275–277.
- Byun, D. S., Cho, K., Ryu, B. K., Lee, M. G., Park, J. I., Chae, K. S., Kim, H. J., and Chi, S. G. 2003. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. *Int. J. Cancer* **104**:318–327.

- Cai, Y. C., Yang, G. Y., Nie, Y., Wang, L. D., Zhao, X., Song, Y. L., Seril, D. N., Liao, J., Xing, E. P., and Yang, C. S. 2000. Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. *Carcinogenesis* **21**:683–689.
- Chai, J. H., Locke, D. P., Greally, J. M., Knoll, J. H., Ohta, T., Dunai, J., Yavor, A., Eichler, E. E., and Nicholls, R. D. 2003. Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons. *Am. J. Hum. Genet.* **73**:898–925.
- Champion, K. M., Cook, R. J., Tollaksen, S. L., and Giometti, C. S. 1994. Identification of a heritable deficiency of the folate-dependent enzyme 10-formyltetrahydrofolate dehydrogenase in mice. *Proc. Natl. Acad. Sci.* **91**:11338–11342.
- Charlier, C., Segers, K., Wagenaar, D., Karim, L., Berghmans, S., Jaillon, O., Shay, T., Weissenbach, J., Cockett, N., Gyapay, G., and Georges, M. 2001. Human-ovine comparative sequencing of a 250-kb imprinted domain encompassing the callipyge (clpg) locus and identification of six imprinted transcripts: DLK1, DAT, GTL2, PEG11, antiPEG11, and MEG8. *Genome Res.* **11**:850–862.
- Chess, A., Simon, I., Cedar, H., and Axel, R. 1994. Allelic inactivation regulates olfactory receptor gene expression. *Cell* **78**:823–834.
- Chibuk, T. K., Bischof, J. M., and Wevrick, R. 2001. A necdin/MAGE-like gene in the chromosome 15 autism. *BMC Genet.* **2**.
- Chung, W. Y., Yuan, L., Feng, L., Hensle, T., and Tycko, B. 1996. Chromosome 11p15.5 regional imprinting: comparative analysis of KIP2 and H19 in human tissues and Wilms' tumors. *Hum. Mol. Genet.* **5**:1101–1108.
- Cichon, S., Nothen, M., Wolf, H., and Propping, P. 1996. Lack of imprinting of the human dopamine D4 receptor (DRD4) gene. *Am. J. Med. Genet.* **67**:229–231.
- Cichon, S., Schumacher, J., Muller, D. J., Hurter, M., Windemuth, C., Strauch, K., Hemmer, S., Schulze, T. G., Schmidt-Wolf, G., Albus, M., Borrmann-Hassenbach, M., Franzek, E., Lanczik, M., Fritze, J., Kreiner, R., Reuner, U., Weigelt, B., Minges, J., Lichtermann, D., Lerer, B., Kanyas, K., Baur, M. P., Wienker, T. F., Maier, W., Rietschel, M., Propping, P., and Nothen, M. M. 2001. A genome screen for genes predisposing to bipolar affective disorder detects a new susceptibility locus on 8q. *Hum. Mol. Genet.* **10**:2933–2944.
- Clark, L., Wei, M., Cattoretti, G., Mendelsohn, C., and Tycko, B. 2002. The Tnfrh1 (Tnfrsf23) gene is weakly imprinted in several organs and expressed at the trophoblast-decidua interface. *BMC Genet.* **11**.
- Cooper, P. R., Smilnich, N. J., Day, C. D., Nowak, N. J., Reid, L. H., Pearsall, R. S., Reece, M., Prawitt, D., Landers, J., Housman, D. E., Winterpacht, A., Zabel, B. U., Pelletier, J., Weissman, B. E., Shows, T. B., and Higgins, M. J. 1998a. Divergently transcribed overlapping genes expressed in liver and kidney and located in the 11p15.5 imprinted domain. *Genomics* **49**:38–51.
- Cooper, P. R., Smilnich, N. J., Day, C. D., Nowak, N. J., Reid, L. H., Pearsall, R. S., Reece, M., Prawitt, D., Landers, J., Housman, D. E., Winterpacht, B. B. R. C. A., Zabel, B. U., Pelletier, J., Weissman, B. E., Shows, T. B., and Higgins, M. J. 1998b. Divergently transcribed overlapping genes expressed in liver and kidney and located in the 11p15.5 imprinted domain. *Genomics* **49**:38–51.
- Cost, G. J., Thompson, J. S., Reichard, B. A., Lee, J. Y., and Feinberg, A. P. 1997. Lack of imprinting of three human cyclin-dependent kinase inhibitor genes. *Cancer Res.* **57**:926–929.
- Dallosso, A. R., Hancock, A. L., Brown, K. W., Williams, A. C., Jackson, S., and Malik, K. 2004. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours. *Hum. Mol. Genet.* **13**:405–415.
- Dao, D., Frank, D., Qian, N., O'Keefe, D., Vosatka, R. J., Walsh, C. P., and Tycko, B. 1998. IMPT1, an imprinted gene similar to polyspecific transporter and multi-drug resistance genes. *Hum. Mol. Genet.* **7**:597–608.
- DeLisi, L. E., Shaw, S. H., Crow, T. J., Shields, G., Smith, A. B., Larach, V. W., Wellman, N., Loftus, J., Nanthakumar, B., Razi, K., Stewart, J., Comazzi, M., Vita, A., Heffner, T., and Sherrington, R. 2002. A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. *Am. J. Psychiatry* **159**:803–812.
- Dotan, Z. A., Dotan, A., Litmanovitch, T., Ravia, Y., Oniashvili, N., Leibovitch, I., Ramon, J., and Avivi, L. 2000. Modification in the inherent mode of allelic replication in lymphocytes of patients suffering from renal cell carcinoma: a novel genetic alteration associated with malignancy. *Genes Chromosomes Cancer* **27**:270–277.
- Driscoll, D. J., Waters, M. F., Williams, C. A., Zori, R. T., Glenn, C. C., Avidano, K. M., and Nicholls, R. D. 1992. A DNA methylation imprint, determined by the sex of the parent, distinguishes the Angelman and Prader-Willi syndromes. *Genomics* **13**:917–924.
- Du, Y., Jenkins, N. A., and Copeland, N. G. 2005. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. *Blood* **106**:3932–3939.

- Eggermann, K., Wollmann, H. A., Binder, G., Kaiser, P., Ranke, M. B., and Eggermann, T. 1999. Biparental expression of IGFBP1 and IGFBP3 renders their involvement in the etiology of Silver-Russell syndrome unlikely. *Ann. Genet.* **42**:117–121.
- Einarsdottir, E., Mayans, S., Ruikka, K., Escher, S. A., Lindgren, P., Agren, A., Eliasson, M., and Holmberg, D. 2006. Linkage but not association of calpain-10 to type 2 diabetes replicated in northern Sweden. *Diabetes* **55**:1879–1883.
- Ekelund, J., Hovatta, I., Parker, A., Paunio, T., Varilo, T., Martin, R., Suhonen, J., Ellonen, P., Chan, G., Sinsheimer, J. S., Sobel, E., Juvonen, H., Arajärvi, R., Partonen, T., Suvisaari, J., Lonnqvist, J., Meyer, J., and Peltonen, L. 2001. Chromosome 1 loci in Finnish schizophrenia families. *Hum. Mol. Genet.* **10**:1611–1617.
- Evans, H. K., Wylie, A. A., Murphy, S. K., and Jirtle, R. L. 2001. The neuronatin gene resides in a “micro-imprinted domain” on human chromosome 20q11.2. *Genomics* **77**:99–104.
- Farber, C., Gross, S., Neesen, J., Buiting, K., and Horsthemke, B. 2000. Identification of a testis-specific gene (C15orf2) in the Prader-Willi syndrome region on chromosome 15. *Genomics* **65**:174–183.
- Furukawa, C., Daigo, Y., Ishikawa, N., Kato, T., Ito, T., Tsuchiya, E., Sone, S., and Nakamura, Y. 2005. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. *Cancer Res.* **65**:7102–7110.
- Gabriel, J. M., Higgins, M. J., Gebuhr, T. C., Shows, T. B., Saitoh, S., and Nicholls, R. D. 1998. A model system to study genomic imprinting of human genes. *Proc. Natl. Acad. Sci.* **95**:14857–14862.
- Gilks, C. B., Bear, S. E., Grimes, H. L., and Tschlis, P. N. 1993. Progression of interleukin-2 (IL-2)-dependent rat T cell lymphoma lines to IL-2-independent growth following activation of a gene (Gfi-1) encoding a novel zinc finger protein. *Mol. Cell Biol.* **13**:1759–1768.
- Glenn, C. C., Driscoll, D. J., Yang, T. P., and Nicholls, R. D. 1997. Genomic imprinting: potential function and mechanisms revealed by the Prader-Willi and Angelman syndromes. *Mol. Hum. Reprod.* **3**:321–332.
- Glenn, C. C., Porter, K. A., Jong, M. T., Nicholls, R. D., and Driscoll, D. J. 1993. Functional imprinting and epigenetic modification of the human SNRPN gene. *Hum. Mol. Genet.* **2**:2001–2005.
- Goldberg, M., Wei, M., Yuan, L., Murty, V., and Tycko, B. 2003. Biallelic expression of HRAS and MUCDHL in human and mouse. *Hum. Genet.* **112**:334–342.
- Goshu, E., Jin, H., Lovejoy, J., Marion, J. F., Michaud, J. L., and Fan, C. M. 2004. Sim2 contributes to neuroendocrine hormone gene expression in the anterior hypothalamus. *Mol. Endocrinol.* **18**:1251–1262.
- Gray, T. A., Saitoh, S., and Nicholls, R. D. 1999. An imprinted, mammalian bicistronic transcript encodes two independent proteins. *Proc. Natl. Acad. Sci.* **96**:5616–5621.
- Greally, J. M., Starr, D. J., Hwang, S., Song, L., Jaarola, M., and Zemel, S. 1998. The mouse H19 locus mediates a transition between imprinted and non-imprinted DNA replication patterns. *Hum. Mol. Genet.* **7**:91–95.
- Guo, Y. F., Shen, H., Liu, Y. J., Wang, W., Xiong, D. H., Xiao, P., Liu, Y. Z., Zhao, L. J., Recker, R. R., and Deng, H. W. 2006. Assessment of Genetic Linkage and Parent-of-origin Effects on Obesity. *J. Clin. Endocrinol. Metab.* .
- Hayward, B. E., Moran, V., Strain, L., and Bonthron, D. T. 1998. Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally, and biallelically derived proteins. *Proc. Natl. Acad. Sci.* **95**:15475–15480.
- Herzing, L. B., Kim, S. J., Cook, E. H., and Ledbetter, D. H. 2001. The human aminophospholipid-transporting ATPase gene ATP10C maps adjacent to UBE3A and exhibits similar imprinted expression. *Am. J. Hum. Genet.* **68**:1501–1505.
- Higashimoto, K., Soejima, H., Yatsuki, H., Joh, K., Uchiyama, M., Obata, Y., Ono, R., Wang, Y., Xin, Z., Zhu, X., Masuko, S., Ishino, F., Hatada, I., Jinno, Y., Iwasaka, T., Katsuki, T., and Mukai, T. 2002. Characterization and imprinting status of OBPH1/Obph1 gene: implications for an extended imprinting domain in human and mouse. *Genomics* **80**:575–584.
- Hitchins, M. P., Bentley, L., Monk, D., Beechey, C., Peters, J., Kelsey, G., Ishino, F., Preece, M. A., Stanier, P., and Moore, G. E. 2002. DDC and COBL, flanking the imprinted GRB10 gene on 7p12, are biallelically expressed. *Mamm. Genome* **13**:686–691.
- Hollander, G. A., Zuklys, S., Morel, C., Mizoguchi, E., Mobisson, K., Simpson, S., Terhorst, C., Wishart, W., Golan, D. E., Bhan, A. K., and Burakoff, S. J. 1998. Monoallelic expression of the interleukin-2 locus. *Science* **279**:2118–2121.
- Hovatta, I., Varilo, T., Suvisaari, J., Terwilliger, J. D., Ollikainen, V., Arajärvi, R., Juvonen, H., Kokko-Sahin, M. L., Vaisanen, L., Mannila, H., Lonnqvist, J., and Peltonen, L. 1999. A genomewide screen for schizophrenia genes in an isolated Finnish subpopulation, suggesting multiple susceptibility loci. *Am. J. Hum. Genet.* **65**:1114–1124.

- Hu, R. J., Lee, M. P., Johnson, L. A., and Feinberg, A. P. 1996. A novel human homologue of yeast nucleosome assembly protein, 65 kb centromeric to the p57kip2 gene, is biallelically expressed in fetal and adult tissues. *Hum. Mol. Genet.* **5**:1743–1748.
- Ishihara, K., Kato, R., Furuumi, H., Zubair, M., and Sasaki, H. 1998. Sequence of a 42-kb mouse region containing the imprinted H19 locus: identification of a novel muscle-specific transcription unit showing biallelic expression. *Mamm. Genome* **9**:775–777.
- Jay, P., Rougeulle, C., Massacrier, A., Moncla, A., Mattei, M. G., Malzac, P., Roeckel, N., Taviaux, S., Lefranc, J. L., Cau, P., Berta, P., Lalande, M., and Muscatelli, F. 1997. The human necdin gene, NDN, is maternally imprinted and located in the Prader-Willi syndrome chromosomal region. *Nat. Genet.* **17**:357–361.
- John, R. M., Aparicio, S. A., Ainscough, J. F., Arney, K. L., Khosla, S., Hawker, K., Hilton, K. J., Barton, S. C., and Surani, M. A. 2001. Imprinted expression of neuronatin from modified BAC transgenes reveals regulation by distinct and distant enhancers. *Dev. Biol.* **236**:387–399.
- Jong, M. T., Gray, T. A., Ji, Y., Glenn, C. C., Saitoh, S., Driscoll, D. J., and Nicholls, R. D. 1999. A novel imprinted gene, encoding a RING zinc-finger protein, and overlapping antisense transcript in the Prader-Willi syndrome critical region. *Hum. Mol. Genet.* **8**:783–793.
- Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. C., Valent, A., Minty, A., Chalon, P., Lelias, J. M., Dumont, X., Ferrara, P., McKeon, F., and Caput, D. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. *Cell* **90**:809–819.
- Kalscheuer, V. M., Mariman, E. C., Schepens, M. T., Rehder, H., and Ropers, H. H. 1993. The insulin-like growth factor type-2 receptor gene is imprinted in the mouse but not in humans. *Nat. Genet.* **5**:74–78.
- Kamiya, M., Judson, H., Okazaki, Y., Kusakabe, M., Muramatsu, M., Takada, S., Takagi, N., Arima, T., Wake, N., Kamimura, K., Satomura, K., Hermann, R., Bonthron, D. T., and Hayashizaki, Y. 2000. The cell cycle control gene ZAC/PLAGL1 is imprinted—a strong candidate gene for transient neonatal diabetes. *Hum. Mol. Genet.* **9**:453–460.
- Karolchik, D., Baertsch, R., Diekhans, M., Furey, T. S., Hinrichs, A., Lu, Y. T., Roskin, K. M., Schwartz, M., Sugnet, C. W., Thomas, D. J., Weber, R. J., Haussler, D., and Kent, W. J. 2003. The UCSC Genome Browser Database. *Nucleic Acids Res.* **31**:51–54.
- Kato, M. V., Ikawa, Y., Hayashizaki, Y., and Shibata, H. 1998. Paternal imprinting of mouse serotonin receptor 2A gene Htr2 in embryonic eye: a conserved imprinting regulation on the RB/Rb locus. *Genomics* **47**:146–148.
- Kayashima, T., Yamasaki, K., Yamada, T., Sakai, H., Miwa, N., Ohta, T., Yoshiura, K., Matsumoto, N., Nakane, Y., Kanetake, H., Ishino, F., Niikawa, N., and Kishino, T. 2003. The novel imprinted carboxypeptidase A4 gene (CPA4) in the 7q32 imprinting domain. *Hum. Genet.* **112**:220–226.
- Kelly, B. and Locksley, R. 2000. Coordinate regulation of the IL-4, IL-13, and IL-5 cytokine cluster in Th2 clones revealed by allelic expression patterns. *J. Immunol.* **165**:2982–2986.
- Killian, J. K., Nolan, C. M., Wylie, A. A., Li, T., Vu, T. H., Hoffman, A. R., and Jirtle, R. L. 2001. Divergent evolution in M6P/IGF2R imprinting from the Jurassic to the Quaternary. *Hum. Mol. Genet.* **10**:1721–1728.
- Kitsberg, D., Selig, S., Brandeis, M., Simon, I., Keshet, I., Driscoll, D. J., Nicholls, R. D., and Cedar, H. 1993. Allele-specific replication timing of imprinted gene regions. *Nature* **364**:459–463.
- Kobayashi, S., Kohda, T., Miyoshi, N., Kuroiwa, Y., Aisaka, K., Tsutsumi, O., Kaneko-Ishino, T., and Ishino, F. 1997. Human PEG1/MEST, an imprinted gene on chromosome 7. *Hum. Mol. Genet.* **6**:781–786.
- Kobayashi, S., Wagatsuma, H., Ono, R., Ichikawa, H., Yamazaki, M., Tashiro, H., Aisaka, K., Miyoshi, N., Kohda, T., Ogura, A., Ohki, M., Kaneko-Ishino, T., and Ishino, F. 2000. Mouse Peg9/Dlk1 and human PEG9/DLK1 are paternally expressed imprinted genes closely located to the maternally expressed imprinted genes: mouse Meg3/Gtl2 and human MEG3. *Genes Cells* **5**:1029–1037.
- Koide, R., Ikeuchi, T., Onodera, O., Tanaka, H., Igarashi, S., Endo, K., Takahashi, H., Kondo, R., Ishikawa, A., Hayashi, T., and et al. 1994. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidolulysian atrophy (DRPLA). *Nat. Genet.* **6**:9–13.
- Kurosawa, K., Sasaki, H., Sato, Y., Yamanaka, M., Shimizu, M., Ito, Y., Okuyama, T., Matsuo, M., Imaizumi, K., Kuroki, Y., and Nishimura, G. 2002. Paternal UPD14 is responsible for a distinctive malformation complex. *Am. J. Med. Genet.* **110**:268–272.
- Lamb, J. A., Barnby, G., Bonora, E., Sykes, N., Bacchelli, E., Blasi, F., Maestrini, E., Broxholme, J., Tzenova, J., Weeks, D., Bailey, A. J., and Monaco, A. P. 2005. Analysis of IMGSAC autism susceptibility loci: evidence for sex limited and parent of origin specific effects. *J. Med. Genet.* **42**:132–137.

- Lee, M. P., Hu, R. J., Johnson, L. A., and Feinberg, A. P. 1997. Human KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements. *Nat. Genet.* **15**:181–185.
- Lee, S., Kozlov, S., Hernandez, L., Chamberlain, S. J., Brannan, C. I., Stewart, C. L., and Wevrick. 2000a. Expression and imprinting of MAGEL2 suggest a role in Prader-willi syndrome and the homologous murine imprinting phenotype. *Hum. Mol. Genet.* **9**:1813–1819.
- Lee, S. H., Davison, J. A., Vidal, S. M., and Belouchi, A. 2001. Cloning, expression and chromosomal location of NKX6B TO 10Q26, a region frequently deleted in brain tumors. *Mamm. Genome* **12**:157–162.
- Lee, Y. A., Wahn, U., Kehrt, R., Tarani, L., Businco, L., Gustafsson, D., Andersson, F., Oranje, A. P., Wolkertstorfer, A., v Berg, A., Hoffmann, U., Kuster, W., Wienker, T., Ruschendorf, F., and Reis, A. 2000b. A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. *Nat. Genet.* **26**:470–473.
- Lerer, I., Sagi, M., Meiner, V., Cohen, T., Zlotogora, J., and Abeliovich, D. 2005. Deletion of the ANKRD15 gene at 9p24.3 causes parent-of-origin-dependent inheritance of familial cerebral palsy. *Hum. Mol. Genet.* **14**:3911–3920.
- Li, J., Bench, A. J., Vassiliou, G. S., Fourouclas, N., Ferguson-Smith, A. C., and Green, A. R. 2004. Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. *Proc. Natl. Acad. Sci.* **101**:7341–7346.
- Li, S. H., McInnis, M. G., Margolis, R. L., Antonarakis, S. E., and Ross, C. A. 1993. Novel triplet repeat containing genes in human brain: cloning, expression, and length polymorphisms. *Genomics* **16**:572–579.
- Lin, Z. and Floros, J. 2002. Heterogeneous allele expression of pulmonary SP-D gene in rat large intestine and other tissues. *Physiol. Genomics* **11**:235–243.
- Liu, H., Heath, S. C., Sobin, C., Roos, J. L., Galke, B. L., Blundell, M. L., Lenane, M., Robertson, B., Wijsman, E. M., Rapoport, J. L., Gogos, J. A., and Karayiorgou, M. 2002. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. *Proc. Natl. Acad. Sci.* **99**:3717–3722.
- Liu, J., Litman, D., Rosenberg, M. J., Yu, S., Biesecker, L. G., and Weinstein, L. S. 2000. A GNAS1 imprinting defect in pseudohypoparathyroidism type IB. *J. Clin. Invest.* **106**:1167–1174.
- Liu, X. Q., Greenwood, C. M., Wang, K. S., and Paterson, A. D. 2005. A genome scan for parent-of-origin linkage effects in alcoholism. *BMC Genet.* **6 Suppl 1**:S160.
- Luedi, P. P., Hartemink, A. J., and Jirtle, R. L. 2005. Genome-wide prediction of imprinted murine genes. *Genome Res.* **15**:875–884.
- Luo, R. Z., Peng, H., Xu, F., Bao, J., Pang, Y., Pershad, R., Issa, J. P., Liao, W. S., Bast, J., R. C., and Yu, Y. 2001. Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. *Biochim. Biophys. Acta* **1519**:216–222.
- Lyle, R., Watanabe, D., te Vrugte, D., Lerchner, W., Smrzka, O. W., Wutz, A., Schageman, J., Hahner, L., Davies, C., and Barlow, D. P. 2000. The imprinted antisense RNA at the Igf2r locus overlaps but does not imprint Mas1. *Nat. Genet.* **25**:19–21.
- MacDonald, H. R. and Wevrick, R. 1997. The necdin gene is deleted in prader-willi syndrome and is imprinted in human and mouse. *Hum. Mol. Genet.* **6**:1873–1878.
- Maecker, H. T., Do, M. S., and Levy, S. 1998. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. *Proc. Natl. Acad. Sci.* **95**:2458–2462.
- Mai, M., Qian, C., Yokomizo, A., Tindall, D. J., Bostwick, D., Polychronakos, C., Smith, D. I., and Liu, W. 1998. Loss of imprinting and allele switching of p73 in renal cell carcinoma. *Oncogene* **17**:1739–1741.
- Marker, P. C., King, J. A., Copeland, N. G., Jenkins, N. A., and Kingsley, D. M. 1995. Chromosomal localization, embryonic expression, and imprinting tests for bmp7 on distal mouse chromosome 2. *Genomics* **28**:576–580.
- Matsuoka, S., Thompson, J. S., Edwards, M. C., Bartletta, J. M., Grundy, P., Kalikin, L. M., Harper, J. W., Elledge, S. J., and Feinberg, A. P. 1996. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. *Proc. Natl. Acad. Sci.* **93**:3026–3030.
- Mayeux, R., Lee, J. H., Romas, S. N., Mayo, D., Santana, V., Williamson, J., Ciappa, A., Rondon, H. Z., Estevez, P., Lantigua, R., Medrano, M., Torres, M., Stern, Y., Tycko, B., and Knowles, J. A. 2002. Chromosome-12 mapping of late-onset Alzheimer disease among Caribbean Hispanics. *Am J Hum Genet* **70**:237–243.

- Maynard, T. M., Haskell, G. T., Peters, A. Z., Sikich, L., Lieberman, J. A., and LaMantia, A. S. 2003. A comprehensive analysis of 22q11 gene expression in the developing and adult brain. *Proc. Natl. Acad. Sci.* **100**:14433–14438.
- McInnis, M. G., Lan, T. H., Willour, V. L., McMahon, F. J., Simpson, S. G., Addington, A. M., MacKinnon, D. F., Potash, J. B., Mahoney, A. T., Chellis, J., Huo, Y., Swift-Scanlan, T., Chen, H., Koskela, R., Stine, O. C., Jamison, K. R., Holmans, P., Folstein, S. E., Ranade, K., Friddle, C., Botstein, D., Marr, T., Beaty, T. H., Zandi, P., and DePaulo, J. R. 2003. Genome-wide scan of bipolar disorder in 65 pedigrees: supportive evidence for linkage at 8q24, 18q22, 4q32, 2p12, and 13q12. *Mol. Psychiatry* **8**:288–298.
- Meguro, M., Kashiwagi, A., Mitsuya, K., Nakao, M., Kondo, I., Saitoh, S., and Oshimura, M. 2001. A novel maternally expressed gene, ATP10C, encodes a putative aminophospholipid translocase associated with Angelman syndrome. *Nat. Genet.* **28**:19–20.
- Miyoshi, N., Wagatsuma, H., Wakana, S., Shiroishi, T., Nomura, M., Aisaka, K., Kohda, T., Surani, M. A., Kaneko-Ishino, T., and Ishino, F. 2000. Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. *Genes Cells* **5**:211–220.
- Mizuno, Y., Sotomaru, Y., Katsuzawa, Y., Kono, T., Meguro, M., Oshimura, M., Kawai, J., Tomaru, Y., Kiyosawa, H., Nikaido, I., Amanuma, H., Hayashizaki, Y., and Okazaki, Y. 2002. Asb4, Ata3, and Dcn are novel imprinted genes identified by high-throughput screening using RIKEN cDNA microarray. *Biochem. Biophys. Res. Commun.* **290**:1499–1505.
- Monk, D., Arnaud, P., Apostolidou, S., Hills, F. A., Kelsey, G., Stanier, P., Feil, R., and Moore, G. E. 2006. Limited evolutionary conservation of imprinting in the human placenta. *Proc. Natl. Acad. Sci.* **103**:6623–6628.
- Moore, G. E., Abu-Amero, S. N., Bell, G., Wakeling, E. L., Kingsnorth, A., Stanier, P., Jauniaux, E., and Bennett, S. T. 2001. Evidence that insulin is imprinted in the human yolk sac. *Diabetes* **50**:199–203.
- Morison, I., Paton, C., and Cleverley, S. 2001. The imprinted gene and parent-of-origin effect database. *Nucleic Acids Res.* **29**:275–276.
- Moroy, T. 2005. The zinc finger transcription factor Growth factor independence 1 (Gfi1). *Int. J. Biochem. Cell Biol.* **37**:541–546.
- Mostoslavsky, R., Singh, N., Tenzen, T., Goldmit, M., Gabay, C., Elizur, S., Qi, P., Reubinoff, B. E., Chess, A., Cedar, H., and Bergman, Y. 2001. Asynchronous replication and allelic exclusion in the immune system. *Nature* **414**:221–225.
- Murphy, S. K., Wylie, A. A., and Jirtle, R. L. 2001. Imprinting of PEG3, the human homologue of a mouse gene involved in nurturing behavior. *Genomics* **71**:110–117.
- Mustanski, B. S., Dupree, M. G., Nievergelt, C. M., Bocklandt, S., Schork, N. J., and Hamer, D. H. 2005. A genomewide scan of male sexual orientation. *Hum. Genet.* **116**:272–278.
- Nabetani, A., Hatada, I., Morisaki, H., Oshimura, M., and Mukai, T. 1997. Mouse U2af1-rs1 is a neomorphic imprinted gene. *Mol. Cell Biol.* **17**:789–798.
- Nagafuchi, S., Yanagisawa, H., Ohsaki, E., Shirayama, T., Tadokoro, K., Inoue, T., and Yamada, M. 1994. Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidolysian atrophy (DRPLA). *Nat. Genet.* **8**:177–182.
- Nakabayashi, K., Makino, S., Minagawa, S., Smith, A. C., Bamforth, J. S., Stanier, P., Preece, M., Parker-Katirae, L., Paton, T., Oshimura, M., Mill, P., Yoshikawa, Y., Hui, C. C., Monk, D., Moore, G. E., and Scherer, S. W. 2004. Genomic imprinting of PPP1R9A encoding neurabin I in skeletal muscle and extra-embryonic tissues. *J. Med. Genet.* **41**:601–608.
- Ogawa, O., Eccles, M. R., Szeto, J., McNoe, L. A., Yun, K., Maw, M. A., Smith, P. J., and Reeve, A. E. 1993a. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. *Nature* **362**:749–751.
- Ogawa, O., McNoe, L. A., Eccles, M. R., Morison, I. M., and Reeve, A. E. 1993b. Human insulin-like growth factor type I and type II receptors are not imprinted. *Hum. Mol. Genet.* **2**:2163–2165.
- Ohlsson, R., Nystrom, A., Pfeifer-Ohlsson, S., Tohonen, V., Hedborg, F., Schofield, P., Flam, F., and Ekstrom, T. J. 1993. IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. *Nat. Genet.* **4**:94–97.
- Okita, C., Meguro, M., Hoshiya, H., Haruta, M., Sakamoto, Y., and Oshimura, M. 2003. A new imprinted cluster on the human chromosome 7q21-q31, identified by human-mouse monochromosomal hybrids. *Genomics* **81**:556–559.
- Okutsu, T., Kuroiwa, Y., Kagitani, F., Kai, M., Aisaka, K., Tsutsumi, O., Kaneko, Y., Yokomori, K., Surani, M. A., Kohda, T., Kaneko-Ishino, T., and Ishino, F. 2000. Expression and imprinting status of human PEG8/IGF2AS, a paternally expressed antisense transcript from the IGF2 locus, in Wilms' tumors. *J. Biochem.* **127**:475–483.

- Ono, R., Kobayashi, S., Wagatsuma, H., Aisaka, K., Kohda, T., Kaneko-Ishino, T., and Ishino, F. 2001. A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. *Genomics* **73**:232–237.
- Overall, M. L., Parker, N. J., Scarcella, D. L., Smith, P. J., and Dziadek, M. 1998. Murine Stim1 maps to distal chromosome 7 and is not imprinted. *Mamm. Genome* **9**:657–659.
- Patel, A. J. and Lazdunski, M. 2004. The 2P-domain K⁺ channels: role in apoptosis and tumorigenesis. *Pflugers Arch.* **448**:261–273.
- Paulsen, M., Davies, K. R., Bowden, L. M., Villar, A. J., Franck, O., Fuermann, M., Dean, W. L., Moore, T. F., Rodrigues, N., Davies, K. E., Hu, R. J., Feinberg, A. P., Maher, E. R., Reik, W., and Walter, J. 1998. Syntenic organization of the mouse distal chromosome 7 imprinting cluster and the Beckwith-Wiedemann syndrome region in chromosome 11p15.5. *Hum. Mol. Genet.* **7**:1149–1159.
- Paulsen, M., El-Maarri, O., Engemann, S., Strodicke, M., Franck, O., Davies, K., Reinhardt, R., Reik, W., and Walter, J. 2000. Sequence conservation and variability of imprinting in the Beckwith-Wiedemann syndrome gene cluster in human and mouse. *Hum. Mol. Genet.* **9**:1829–1841.
- Pereira, J. P., Girard, R., Chaby, R., Cumano, A., and Vieira, P. 2003. Monoallelic expression of the murine gene encoding Toll-like receptor 4. *Nat. Immunol.* **4**:464–470.
- Piras, G., El, K. h., Kozlov, S., Escalante-Alcalde, D., Hernandez, L., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and Stewart, C. L. 2000. Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilon-sarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast lines. *Mol. Cell. Biol.* **20**:3308–3315.
- Qian, N., Frank, D., O'Keefe, D., Dao, D., Zhao, L., Yuan, L., Wang, Q., Keating, M., Walsh, C., and Tycko, B. 1997. The IPL gene on chromosome 11p15.5 is imprinted in humans and mice and is similar to TDAG51, implicated in Fas expression and apoptosis. *Hum. Mol. Genet.* **6**:2021–2029.
- Rachmilewitz, J., Gonik, B., Goshen, R., Ariel, I., Schneider, T., de Groot, N., and Hochberg, A. 1993. Use of a novel system for defining a gene imprinting region. *Biochem. Biophys. Res. Commun.* **196**:659–664.
- Rachmilewitz, J., Goshen, R., Ariel, I., Schneider, T., de Groot, N., and Hochberg, A. 1992. Parental imprinting of the human H19 gene. *FEBS Lett.* **309**:25–28.
- Rainier, S., Johnson, L. A., Dobry, C. J., Ping, A. J., Grundy, P. E., and Feinberg, A. P. 1993. Relaxation of imprinted genes in human cancer. *Nature* **362**:747–749.
- Reik, W. and Walter, J. 2001. Genomic imprinting: parental influence on the genome. *Nat. Rev. Genet.* **2**:21–32.
- Rougeulle, C., Glatt, H., and Lalande, M. 1997. The Angelman syndrome candidate gene, UBE3A/E6-AP, is imprinted in brain. *Nat. Genet.* **17**:14–15.
- Sandell, L. L., Guan, X. J., Ingram, R., and Tilghman, S. M. 2003. Gattm, a creatine synthesis enzyme, is imprinted in mouse placenta. *Proc. Natl. Acad. Sci.* **100**:4622–4627.
- Sano, Y., Shimada, T., Nakashima, H., Nicholson, R. H., Eliason, J. F., Kocarek, T. A., and Ko, M. S. 2001. Random monoallelic expression of three genes clustered within 60 kb of mouse t complex genomic DNA. *Genome Res.* **11**:1833–1841.
- Schweifer, N., Valk, P. J., Delwel, R., Cox, R., Francis, F., Meier-Ewert, S., Lehrach, H., and Barlow, D. P. 1997. Characterization of the C3 YAC contig from proximal mouse chromosome 17 and analysis of allelic expression of genes flanking the imprinted Igf2r gene. *Genomics* **43**:285–297.
- Scott, W. K., Grubber, J. M., Conneally, P. M., Small, G. W., Hulette, C. M., Rosenberg, C. K., Saunders, A. M., Roses, A. D., Haines, J. L., and Pericak-Vance, M. A. 2000. Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. *Am. J. Hum. Genet.* **66**:922–932.
- Seitz, H., Youngson, N., Lin, S. P., Dalbert, S., Paulsen, M., Bachellerie, J. P., Ferguson-Smith, A. C., and Cavaille, J. 2003. Imprinted microRNA genes transcribed antisense to a reciprocally imprinted retrotransposon-like gene. *Nat. Genet.* **34**:261–262.
- Shoichet, S. A., Kunde, S. A., Viertel, P., Schell-Apacik, C., von Voss, H., Tommerup, N., Ropers, H. H., and Kalscheuer, V. M. 2005. Haploinsufficiency of novel FOXG1B variants in a patient with severe mental retardation, brain malformations and microcephaly. *Hum. Genet.* **117**:536–544.
- Simonaro, C. M., Park, J. H., Eliyahu, E., Shtraizent, N., McGovern, M. M., and Schuchman, E. H. 2006. Imprinting at the SMPD1 Locus: Implications for Acid Sphingomyelinase- Deficient Niemann-Pick Disease. *Am. J. Hum. Genet.* **78**:865–870.

- Singh, N., Ebrahimi, F. A., Gimelbrant, A. A., Ensminger, A. W., Tackett, M. R., Qi, P., Gribnau, J., and Chess, A. 2003. Coordination of the random asynchronous replication of autosomal loci. *Nat. Genet.* **33**:339–341.
- Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., Chou, T. T., Hjaltason, O., Birgisdottir, B., Jonsson, H., Gudnadottir, V. G., Gudmundsdottir, E., Bjornsson, A., Ingvarsson, B., Ingason, A., Sigfusson, S., Hardardottir, H., Harvey, R. P., Lai, D., Zhou, M., Brunner, D., Mutel, V., Gonzalo, A., Lemke, G., Sainz, J., Johannesson, G., Andresson, T., Gudbjartsson, D., Manolescu, A., Frigge, M. L., Gurney, M. E., Kong, A., Gulcher, J. R., Petursson, H., and Stefansson, K. 2002. Neuregulin 1 and susceptibility to schizophrenia. *Am. J. Hum. Genet.* **71**:877–892.
- Strauch, K., Bogdanow, M., Fimmers, R., Baur, M. P., and Wienker, T. F. 2001. Linkage analysis of asthma and atopy including models with genomic imprinting. *Genet. Epidemiol.* **21 Suppl 1**:S204–209.
- Strauch, K., Furst, R., Ruschendorf, F., Windemuth, C., Dietter, J., Flaquer, A., Baur, M. P., and Wienker, T. F. 2005. Linkage analysis of alcohol dependence using MOD scores. *BMC Genet.* **6 Suppl 1**:S162.
- Strichman-Almashanu, L. Z., Lee, R. S., Onyango, P. O., Perlman, E., Flam, F., Frieman, M. B., and Feinberg, A. P. 2001. A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes. *Genome Res.* **12**:543–554.
- Strichman-Almashanu, L. Z., Lee, R. S., Onyango, P. O., Perlman, E., Flam, F., Frieman, M. B., and Feinberg, A. P. 2002. A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes. *Genome Res.* **12**:543–554.
- Takahashi, N. and Ko, M. 1993. The short 3'-end region of complementary DNAs as PCR-based polymorphic markers for an expression map of the mouse genome. *Genomics* **16**:161–168.
- Tanamachi, D. M., Hanke, T., Takizawa, H., Jamieson, A. M., and Raulet, D. R. 2001. Expression of natural killer receptor alleles at different Ly49 loci occurs independently and is regulated by major histocompatibility complex class I molecules. *J. Exp. Med.* **193**:307–315.
- Taniguchi, T., Okamoto, K., and Reeve, A. E. 1997. Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour. *Oncogene* **14**:1201–1206.
- Tierling, S., Dalbert, S., Schoppenhorst, S., Tsai, C. E., Oligier, S., Ferguson-Smith, A. C., Paulsen, M., and Walter, J. 2006. High-resolution map and imprinting analysis of the Gtl2-Dnch1 domain on mouse chromosome 12. *Genomics* **87**:225–235.
- Umlauf, D., Goto, Y., Cao, R., Cerqueira, F., Wagschal, A., Zhang, Y., and Feil, R. 2004. Imprinting along the Kcnq1 domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexes. *Nat. Genet.* **36**:1296–1300.
- Van den Veyver, I. B., Norman, B., Tran, C. Q., Bourjac, J., and Slim, R. 2001. The human homologue (PEG3) of the mouse paternally expressed gene 3 (Peg3) is maternally imprinted but not mutated in women with familial recurrent hydatidiform molar pregnancies. *J. Soc. Gynecol. Investig.* **8**:305–313.
- van Doorninck, J. H., van Der Wees, J., Karis, A., Goedknecht, E., Engel, J. D., Coesmans, M., Rutteman, M., Grosveld, F., and De Zeeuw, C. I. 1999. GATA-3 is involved in the development of serotonergic neurons in the caudal raphe nuclei. *J. Neurosci.* **19**:RC12.
- van Raamsdonk, C. and Tilghman, S. 2000. Dosage requirement and allelic expression of PAX6 during lens placode formation. *Development* **127**:5439–5448.
- Vance, R. E., Jamieson, A. M., Cado, D., and Raulet, D. H. 2002. Implications of CD94 deficiency and monoallelic NKG2A expression for natural killer cell development and repertoire formation. *Proc. Natl. Acad. Sci.* **99**:868–873.
- Verri, A., Maraschio, P., Devriendt, K., Uggetti, C., Spadoni, E., Haeusler, E., and Federico, A. 2004. Chromosome 10p deletion in a patient with hypoparathyroidism, severe mental retardation, autism and basal ganglia calcifications. *Ann. Genet.* **47**:281–287.
- Vu, T. H. and Hoffman, A. R. 1997. Imprinting of the Angelman syndrome gene, UBE3A, is restricted to brain. *Nat. Genet.* **17**:12–13.
- Wakeling, E. L., Abu-Amero, S. N., Stanier, P., Preece, M. A., and Moore, G. E. 1998. Human EGFR, a candidate gene for the Silver-Russell syndrome, is biallelically expressed in a wide range of fetal tissues. *Eur. J. Hum. Genet.* **6**:158–164.
- Wakeling, E. L., Hitchins, M. P., Abu-Amero, S. N., Stanier, P., Moore, G. E., and Preece, M. A. 2000. Biallelic expression of IGFBP1 and IGFBP3, two candidate genes for the Silver-Russell syndrome. *J. Med. Genet.* **37**:65–67.
- Walter, J. and Paulsen, M. 2003. The potential role of gene duplications in the evolution of imprinting mechanisms. *Hum. Mol. Genet.* **12**:215–220.
- Wevrick, R., Kerns, J. A., and Francke, U. 1994. Identification of a novel paternally expressed gene in the Prader-Willi syndrome region. *Hum. Mol. Genet.* **3**:1877–1882.

- Williamson, C. M., Dutton, E. R., Abbott, C. M., Beechey, C. V., Ball, S. T., and Peters, J. 1995. Thirteen genes (Cebpb, E2f1, Tcf4, Cyp24, Pck1, Acra4, Edn3, Kcnb1, Mc3r, Ntsr, Cd40, Plcg1 and Rcad) that probably lie in the distal imprinting region of mouse chromosome 2 are not monoallelically expressed. *Genet. Res.* **65**:83–93.
- Williamson, C. M., Dutton, E. R., Beechey, C. V., and Peters, J. 1994. Protective protein for beta-galactosidase, Ppgb, maps to the distal imprinting region of mouse chromosome 2 but is not imprinted. *Genomics* **22**:240–242.
- Wood, J. D., Yuan, J., Margolis, R. L., Colomer, V., Duan, K., Kushi, J., Kaminsky, Z., Kleiderlein, J. J., Sharp, A. H., and Ross, C. A. 1998. Atrophin-1, the DRPLA gene product, interacts with two families of WW domain-containing proteins. *Mol. Cell. Neurosci.* **11**:149–160.
- Wright, G. J., Leslie, J. D., Ariza-McNaughton, L., and Lewis, J. 2004. Delta proteins and MAGI proteins: an interaction of Notch ligands with intracellular scaffolding molecules and its significance for zebrafish development. *Development* **131**:5659–5669.
- Wylie, A. A., Murphy, S. K., Orton, T. C., and Jirtle, R. L. 2000. Novel imprinted DLK1/GTL2 domain on human chromosome 14 contains motifs that mimic those implicated in IGF2/H19 regulation. *Genome Res.* **10**:1711–1718.
- Xin, Z., Soejima, H., Higashimoto, K., Yatsuki, H., Zhu, X., Satoh, Y., Masaki, Z., Kaneko, Y., Jinno, Y., Fukuzawa, R., Hata, J., and Mukai, T. 2000. A novel imprinted gene, KCNQ1DN, within the WT2 critical region of human chromosome 11p15.5 and its reduced expression in Wilms' tumors. *J. Biochem.* **128**:847–853.
- Xuan, S., Baptista, C. A., Balas, G., Tao, W., Soares, V. C., and Lai, E. 1995. Winged helix transcription factor BF-1 is essential for the development of the cerebral hemispheres. *Neuron* **14**:1141–1152.
- Yamada, T., Kayashima, T., Yamasaki, K., Ohta, T., Yoshiura, K., Matsumoto, N., Fujimoto, S., Niikawa, N., and Kishino, T. 2002. The gene TSGA14, adjacent to the imprinted gene MEST, escapes genomic imprinting. *Gene* **288**:57–63.
- Yamada, T., Mitsuya, K., Kayashima, T., Yamasaki, K., Ohta, T., Yoshiura, K., Matsumoto, N., Yamada, H., Minakami, H., Oshimura, M., Niikawa, N., and Kishino, T. 2003. Imprinting analysis of 10 genes and/or transcripts in a 1.5-mb mest-flanking region at human chromosome 7q32. *Genomics* **83**:402–412.
- Yevtodiyenko, A., Carr, M. S., Patel, N., and Schmidt, J. V. 2002. Analysis of candidate imprinted genes linked to Dlk1-Gtl2 using a congenic mouse line. *Mamm. Genome* **13**:633–638.
- Yonan, A. L., Alarcon, M., Cheng, R., Magnusson, P. K., Spence, S. J., Palmer, A. A., Grunn, A., Juo, S. H., Terwilliger, J. D., Liu, J., Cantor, R. M., Geschwind, D. H., and Gilliam, T. C. 2003. A genomewide screen of 345 families for autism-susceptibility loci. *Am. J. Hum. Genet.* **73**:886–897.
- Yoshihashi, H., Maeyama, K., Kosaki, R., Ogata, T., Tsukahara, M., Goto, Y., Hata, J., Matsuo, N., Smith, R. J., and Kosaki, K. 2000. Imprinting of human GRB10 and its mutations in two patients with Russell-Silver syndrome. *Am. J. Hum. Genet.* **67**:476–482.
- Yu, Y., Xu, F., Peng, H., Fang, X., Zhao, S., Li, Y., Cuevas, B., Kuo, W. L., Gray, J. W., Siciliano, M., Mills, G. B., and Bast, R. C. 1999. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. *Proc. Natl. Acad. Sci.* **96**:214–219.
- Yuan, L., Qian, N., and Tycko, B. 1996. An extended region of biallelic gene expression and rodent-human synteny downstream of the imprinted H19 gene on chromosome 11p15.5. *Hum. Mol. Genet.* **5**:1931–1937.
- Zhang, G., Taneja, K. L., Singer, R. H., and Green, M. R. 1994. Localization of pre-mRNA splicing in mammalian nuclei. *Nature* **372**:809–812.
- Zhang, Y. and Tycko, B. 1992. Monoallelic expression of the human H19 gene. *Nat. Genet.* **1**:40–44.
- Zhu, X., Higashimoto, K., Soejima, H., Yatsuki, H., Sugihara, H., Mukai, T., and Joh, K. 2000. C11orf21, a novel gene within the Beckwith-Wiedemann syndrome region in human chromosome 11p15.5. *Gene* **256**:311–317.
- Zimprich, A., Grabowski, M., Asmus, F., Naumann, M., Berg, D., Bertram, M., Scheidtmann, K., Kern, P., Winkelmann, J., Muller-Myhsok, B., Riedel, L., Bauer, M., Muller, T., Castro, M., Meitinger, T., Strom, T. M., and Gasser, T. 2001. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. *Nat. Genet.* **29**:66–69.